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Development of protective immunity against maiiy pathogens requires fine 
orchestration of both humoral as well as cell mediated immunity. While, circulating 
antibodies play crucial role in the elimination of extra cellular infections, majority of 
intracellular infections (e.g. malaria, leishmaniasis, candidiasis etc.) require 
generation of CDS"^  cytotoxic T- cells (CTL) in conjunction to strong CD4* T - helper 
cells (Th) because such pathogens adapt intracellular parasitism as a strategy to avoid 
recognition by antibodies. Besides, some pathogens (e.g. Palsmodium sp, Chiamydia 
5/7, HIV) introduce substantial antigenic variations, which further complicate the 
process of vaccine designing. Ironically, a typical protocol followed in immimization 
with soluble antigens leads to the induction of humoral immune response mainly. In 
contrast activation of the cell mediated immune response, upon administration of 
soluble antigens has remained an uphill task. This requires strategies to expose 
antigens to the proteasome machinery, a multifiinctiorial protease complex in the 
cytosolic proteolytic system forms the cardinal step involved in the induction of 
cytotoxic T lymphocytes (CTLs). Therefore to generate a CD8"^  T- lymphocyte 
response, this is a prerequisite to delivery antigens into the cytosol of the APCs, 
which is further followed by its processing and presentation along with class I major 
histocompatibility complex (MHC I) molecules. The present study has been planned 
to fulfill the requirement of eliciting desired immune responses against \'arious 
intracellular infections and has been presented in two parts. 
In the first part of the study we have developed novel fusogenic liposomes made up of 
lipids from X cerevsiae (saccharosomes). These liposomes have been shown to 
undergo membrane membrane fusion with cytoplasmic membrane of target cell 
including professional antigen presenting cells. The study demonstrates that antigen 
encapsulated in saccharosome could be successfully delivered simultaneously as well 
as endosomal processing pathways of antigen presenting cells, leading to the 
generation of both CD4^ T- helper and CD8* cytotoxic T cell response. In contrast, 
encapsulation of same antigen I egg PC liposomes, just like Antigen- Incomplete 
Freund,s Adjuvant (IFA) complex, has in efficient access to the cytosolic pathway of 
MHC I dependent antigen presentation and failed to generate antigen specific CD8"^  
cytotoxic T cell response. However, both egg PC liposomes as well as saccharosomes 
encapsulated antigen elicited strong humoral immune response in immunized animals 
but antibody titre was significantly higher in the group of animals immunized with 
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saccharosomes encapsulated antigen. Furthermore, antigen, antigen entrapped in 
saccharosomes stimulates antigen specific CD4* T cell proliferation and also 
enhances tfie level of IL-2, IFN- y and IL-4 in the immunized animals, these results 
imply usage of liposome based adjuvant as potential candidate vaccine capable of 
eliciting both cell mediated as well as humoral immmue responses. 
In the second part, we evaluated the (A) saccharosomes and (B) niosome as an 
antigen delivery system in the inmiunization studies against blood stage infection of 
lethal Plasmodiul yoelii (MDR) in BALB/c mice. Today, malaria is considered one of 
the most devastating and deadly disease that claim about 1.4 to 2.7 million deaths 
annually. Furthermore, the recent development of resistance of Plasmodium sp. to the 
chemotherapeutic agents and of its vector to DDT, alarm us to opt for alternative 
weapons for its control. This has led to choose prophylactic measures as 
complementary tools for controlling this dreadful disease, which in turn requires 
understanding of the basic immunological complexities involved in the resolution of 
the disease. However, in spite of the numerous efforts made for developing malaria 
vaccine, no effective malaria vaccine is available today. 
It has been shown that elimination of liver stage Plasmodium infection require 
involvement of CD8* CTL response, while immunity against blood stages of malaria 
is dependent on IFN-y secreting CD4* Th - cells and IgG2a isotype of antibodies. In 
the study, soluble blood stage antigens of P.yoelii (sAg) were encapsulated in 
saccharosome and niosome or EPC/chol liposomes and BALB/c mice were 
inmiunized at various days for performing protection as well as immunological 
studies. Result from the study revealed that immunization with saccharosome and 
niosome entrapped sAg induced strong protective immune responses that successfully 
suppressed drug resistant P. yoelii infection, whereas other formulation of sAg such as 
EPC/ chol liposome entrapped sAg, or sAg with incomplete Freund, s Adjuvant (IFA) 
failed to impart significant levels of protection. Among all the sAg formulations used 
in the study, saccharosomes and niosomes based vaccine elicited strongest humoral as 
well as cell mediated immune responses in immunized BALB/c mice. 
Saccharosome - sAg and nio-sAg mediated protection was found to be associated 
with enhanced antigen specific CD4'^  and CDS"^  T cell populations. Furthermore, 
activation of Th- cells requires not only TCR occupancy by presented by presented 
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MHC- antigen complex, but also a set of other co- stimulatory signals provided by 
APCs. In this concern, co-stimulatory molecules (CD80 and CD86) provide mutation 
signals to T- lymphocytes, leading to their proliferation cytokine production and 
development of effector function. Higher expression of CD80 and CD86 on the 
macrophages incubated with saccharosome- sAg or nio-sAg again supports the data 
representing the expansion of Th cells. Analysis of cytokine profiles in immunized 
animals revealed that the saccharosome mediated delivery of sAg was associated with 
the induction of a mixed Thl/Th2 (IFN-y and IL-4) cytokine response. Moreover, 
vaccination with saccharosome and niosome entrapped sAg elicited high IgGl and 
IgG2a isotype responses that played important role in imparting protection against 
blood stage infection of Plasmodium yoelii (MDR) in BALB/c mice. 
In the final part of study we have evaluated potential of combination therapy 
comprising immunomodulator picroliv and antimalarial chloroquine z^ainst 
experimental Plasmodium yoelii infection in BALBb/c mice. The immunomodulatory 
potential of picroliv was established by immunizing animals with model antigen along 
with picroliv. Immune response was assessed using T-cell proliferation assay and also 
by determining the antibody isotype- profile developed in the immunized mice. 
In the next set of experiment, co-administration of picroliv in combination with 
chloroquine was used against treatment oi P.yoelii (MDR) infection in BALB/c mice. 
The development of fiill blown malaria suggests non effectiveness of parasite specific 
antibodies and T-cells develop by the host during the course of establishment of 
infection. This in turn suggests that the use of immunomodulator picroliv in 
combination with CHQ could be a useful choice in revoking immune system of the 
host ensuing in successful elimination of pathogen. The immunomodulatory role of 
picroliv was established by its potential to induce humoral (antibody production) as 
well as cell mediated immunity (T cell proliferation) in the host. As evident from data 
of the present study pretreatment with picroliv helps in induction of strong immune 
response in the animals upon their exposure to OVA. Interestingly, picroliv was found 
to help in induction of IgG2a isotype of antibody. This indirectly suggests that the 
immunomodulator helps in skewing of immune response in favor of Thl subtype of 
T- helper cells. Co-administration of picroliv enhances efficacy of CHQ against 
experimental murine infection. The combination therapy resists the establishment of 
infection and helps in maintaining low multiplication rate. 
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Abstract 
Development of protective immunity against many pathogens requires fine 
orchestration of both humoral as well as cell mediated immunity. While, circulating 
antibodies play crucial role in the elimination of extra cellular infections, majority of 
intracellular infections (e.g. malaria, leishmaniasis, candidiasis etc.) require 
generation of CD8"^  cytotoxic T- cells (CTL) in conjunction to strong CD4"^  T - helper 
cells (Th) because such pathogens adapt intracellular parasitism as a strategy to avoid 
recognition by antibodies. Besides, some pathogens (e.g. Palsmodium sp, Chlamydia 
5p,HIV) introduce substantial antigenic variations, which further complicate the 
process of vaccine designing. Ironically, a typical protocol followed in immunization 
with soluble antigens leads to the induction of humoral immune response mainly. In 
contrast activation of the cell mediated immune response, upon administration of 
soluble antigens has remained an uphill task. This requires strategies to expose 
antigens to the proteasome machinery, a multifunctional protease complex in the 
cytosolic proteolytic system forms the cardinal step involved in the induction of 
cytotoxic T lymphocytes (CTLs). Therefore to generate a CD8^ T- lymphocyte 
response, this is a prerequisite to delivery antigens into the cytosol of the APCs, 
which is further followed by its processing and presentation along with class I major 
histocompatibility complex (MHC I) molecules. The present study has been planned 
to ftilfill the requirement of eliciting desired immune responses against various 
intracellular infections and has been presented in two parts. 
In the first part of the study we have developed novel fusogenic liposomes made up of 
lipids from S. cerevsiae (saccharosomes). These liposomes have been shown to 
undergo membrane membrane fusion with cytoplasmic membrane of target cell 
including professional antigen presenting cells. The study demonstrates that antigen 
encapsulated in saccharosome could be successfully delivered simultaneously as well 
as endosomal processing pathways of antigen presenting cells, leading to the 
generation of both CD4* T- helper and CD8^ cytotoxic T cell response. In contrast, 
encapsulation of same antigen I egg PC liposomes, just like Antigen- Incomplete 
Freund,s Adjuvant (IFA) complex, has in efficient access to the cytosolic pathway of 
MHC I dependent antigen presentation and failed to generate antigen specific CD8^ 
cytotoxic T cell response. However, both egg PC liposomes as well as saccharosomes 
encapsulated antigen elicited strong humoral immune response in immunized animals 
but antibody titre was significantly higher in the group of animals immunized with 
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saccharosomes encapsulated antigen. Furthermore, antigen, antigen entrapped in 
saccharosomes stimulates antigen specific CD4^ T cell proliferation and also 
enhances the level of IL-2, IFN- y and IL-4 in the immunized animals, these results 
imply usage of liposome based adjuvant as potential candidate vaccine capable of 
eliciting both cell mediated as well as humoral immmue responses. 
In the second part, we evaluated the (A) saccharosomes and (B) niosome as an 
antigen delivery system in the immunization studies against blood stage infection of 
lethal Plasmodiul yoelii (MDR) in BALB/c mice. Today, malaria is considered one of 
the most devastating and deadly disease that claim about 1.4 to 2.7 million deaths 
annually. Furthermore, the recent development of resistance of Plasmodium sp. to the 
chemotherapeutic agents and of its vector to DDT, alarm us to opt for alternative 
weapons for its control. This has led to choose prophylactic measures as 
complementary tools for controlling this dreadful disease, which in turn requires 
understanding of the basic immunological complexities involved in the resolution of 
the disease. However, in spite of the numerous efforts made for developing malaria 
vaccine, no effective malaria vaccine is available today. 
It has been shown that elimination of liver stage Plasmodium infection require 
involvement of CD8^ CTL response, while immunity against blood stages of malaria 
is dependent on IFN-y secreting CD4^ Th - cells and IgG2a isotype of antibodies. In 
the study, soluble blood stage antigens of P.yoelii (sAg) were encapsulated in 
saccharosome and niosome or EPC/chol liposomes and BALB/c mice were 
immunized at various days for performing protection as well as immunological 
studies. Result from the study revealed that immunization with saccharosome and 
niosome entrapped sAg induced strong protective immune responses that successfully 
suppressed drug resistant P. yoelii infection, whereas other formulation of sAg such as 
EPC/ chol liposome entrapped sAg, or sAg with incomplete Freund, s Adjuvant (IFA) 
failed to impart significant levels of protection. Among all the sAg formulations used 
in the study, saccharosomes and niosomes based vaccine elicited strongest humoral as 
well as cell mediated immune responses in immunized BALB/c mice. 
Saccharosome - sAg and nio-sAg mediated protection was found to be associated 
with enhanced antigen specific CD4"^  and CD8^ T cell populations. Furthermore, 
activation of Th- cells requires not only TCR occupancy by presented by presented 
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MHC- antigen complex, but also a set of other co- stimulatory signals provided by 
APCs. In this concern, co-stimulatory molecules (CD80 and CD86) provide mutation 
signals to T- lymphocytes, leading to their proliferation cytokine production and 
development of effector function. Higher expression of CD80 and CD86 on the 
macrophages incubated with saccharosome- sAg or nio-sAg again supports the data 
representing the expansion of Th cells. Analysis of cytokine profiles in immunized 
animals revealed that the saccharosome mediated delivery of sAg was associated with 
the induction of a mixed Thl/Th2 (IFN-7 and IL-4) cytokine response. Moreover, 
vaccination with saccharosome and niosome entrapped sAg elicited high IgGl and 
IgG2a isotype responses that played important role in imparting protection against 
blood stage infection of Plasmodium yoelii (MDR) in BALB/c mice. 
In the final part of study we have evaluated potential of combination therapy 
comprising immunomodulator picroliv and antimalarial chloroquine against 
experimental Plasmodium yoelii infection in BALBb/c mice. The immunomodulatory 
potential of picroliv was established by immunizing animals with model antigen along 
with picroliv. Immune response was assessed using T-cell proliferation assay and also 
by determining the antibody isotype- profile developed in the immunized mice. 
In the next set of experiment, co-administration of picroliv in combination with 
chloroquine was used against treatment of P.yoelii (MDR) infection in BALB/c mice. 
The development of full blown malaria suggests non effectiveness of parasite specific 
antibodies and T-cells develop by the host during the course of establishment of 
infection. This in turn suggests that the use of immunomodulator picroliv in 
combination with CHQ could be a usefiil choice in revoking immune system of the 
host ensuing in successful elimination of pathogen. The immunomodulatory role of 
picroliv was established by its potential to induce himioral (antibody production) as 
well as cell mediated immunity (T cell proliferation) in the host. As evident from data 
of the present study pretreatment with picroliv helps in induction of strong immune 
response in the animals upon their exposure to OVA. Interestingly, picroliv was found 
to help in induction of IgG2a isotype of antibody. This indirectly suggests that the 
immunomodulator helps in skewing of immune response in favor of Thl subtype of 
T- helper cells. Co-administration of picroliv enhances efficacy of CHQ against 
experimental murine infection. The combination therapy resists the establishment of 
infection and helps in maintaining low multiplication rate. 
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1. Vaccines and Vaccination: 
1.1. Vaccination: a prophylactic measure to control infectious diseases. 
Development of vaccine constitutes the greatest achievement in the field of modem 
medical sciences. It is perhaps one of the most cost effective and economic 
therapeutic interventions available today. Conventional vaccines consisted of live 
attenuated pathogens, whole inactivated organisms, or inactivated toxins. Although 
such forms of vaccine have proved successful in past, several drawbacks limited their 
use against more challenging diseases such as hepatitis C and AIDS etc. first, certain 
live- attenuated vaccines can cause disease in immunosuppresed individuals by 
reverting to a more virulent phenotype. Second, whole inactivated vaccines (e. g. 
Bordetella pertusis) contain reactogenic components that can cause undesirable side 
effects. Third, some pathogens are difficuh or even impossible to grow in culture (e. 
g. hepatitis B, hepatitis C, and human papilloma virus etc.) making preparation of a 
vaccine problematic. During recent past, several approaches in vaccine development 
have emerged that may have significant advantages over traditional approaches. 
These new stretagies include recombinant protein subunits, synthetic peptides and 
plasmid DNA. Although they offer advantaged such as reduced toxicity, they are poor 
immunogenic when administered alone.f This is particularly true for the vaccines 
based on recombinant proteins and f)eptides. Further, traditionzil vaccines are 
heterogeneous and contain maiiy epitopes, some of which can provide additional T-
cell help or function as adjuvants (e. g. bacterial DNA in whole cell vaccines). 
Therefore, a great need exists for immunological adjuvants that are potent, safe, and 
compatible with new generation vaccine, including DNA vaccine. 
Vaccines can be broadly classified into four major groups: live, killed/ inactivated, 
subunit and DNA based vaccine. Each of these groups can be fiirther divided into 
various subclasses, which include recombinant derived antigens as well as native 
microorganisms and their components. In addition, there are new enabling 
technologies such as delivery systems and vectors, which can be exploited as potential 
adjuvant to achieve coveted goals. Most pathogens targets, whether infectious or 
noninfectious in origin, can be approached by the application of several different 
vaccine technologies and can be tested during the discovery phase of vaccine 
development. 
1~ 
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Table: 1 
Comparative properties of active vaccines 
Type of vaccine 
Live vaccine 
Subunit vaccines 
(killed inactivated) 
Genetic vaccines 
(DNA- based) 
Salient features 
Able to replicate in the host 
Attenuated devoid of 
pathogenicity 
Unable to replicate in the host 
Stimulate synthesis of antigens 
only upon administration in the 
cells 
Advantages 
May elicit broader 
immune responses 
May require fewer does 
Generally longer and 
lasting protection 
Cannot multiply or 
revert to pathogenicity 
Generally less 
reactogenic 
Non transmissible to 
another person 
Usually more feasible 
technically 
Elicit cellular immune 
responses 
Standardized method of 
production 
1.2. Live vaccines: 
Conventional live viral and bacterial vaccines are produced by selecting avirulent 
mutants, which can establish themselves in host, however fail to invoke full blovwi 
disease. The mutations are generally induced by treatment of organisms with 
mutagens, chemicals, heat or passage in vitro. Following induction of mutational 
events, a virulent mutant is selected and tested in vivo. In most cases, multiple 
mutations led to the development of attenuated form of pathogen although it is often 
^ ^ ^ ^ ' 
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unknown what constellation of genes are altered to achieve attenuation. Using this 
approach, it is difficult to modulate the degree of attenuation and if the attenuation 
happens to be due to single- point mutation, there is high probability of reversion to 
the virulence upon administration to the host (Minor et al 1986). This reversion can 
result into fiiU blown disease, especially to the underlying immunosuppressive 
conditions. Secondly, some of the viral vaccines shed virulent virus into the 
environment, which can infect non-vaccinated contacts. 
Nevertheless, some live vaccine come very close to meeting the criteria for an ideal 
vaccine and elicits life long protection with minimal reactogenicity. Such vaccines 
consist of microorganisms (usually viruses) that replicate similarly to the natural 
microorganism in vivo, thereby eliciting an immune response similar to that of natural 
infection. The live vaccine is attenuated by technical or biological manipulations for 
eliminating its disease causing capacity. The live vaccine should be neither over 
attenuated, such that it no longer replicates sufficiently to function as a vaccine, nor 
imder attenuated, whereby it retains even limited pathogenicity or ability to revert to 
pathogenicity. 
1.3. Subunit vaccine: 
Subunit vaccines are defined as those containing one or more pure or semi- pure 
antigens. In order to develop subunit vaccines, it is critical to identify the individual 
components out of myriad of proteins and glycol- proteins of the pathogen, that are 
involved in inducing protection. Indeed, some of the proteins present in pathogens are 
immimosuppressive, whereas immune responses to certain other proteins may actually 
enhance disease. Thus, it is crucial to identify antigenic proteins that are important for 
imparting protection and help in elimination of pathogens. The potential advantages 
associated with the subunit vaccines are increased safety, less antigenic competition. 
Although, subunit vaccines can be produced by conventional technologies, the 
purification is generally not economic due to low quantities of protective antigens 
produced by most of the infectious agent. For example, Pasteurella haemolytica 
produces low level of extra cellular toxin (leukotoxin), which is involved in 
pathogenesis and tissue damage in the lungs of cattle {Lo et al 1987, Shewen and 
Wilkins, 1982). This makes the development of neutralizing antibodies a very costly 
affair. In addition, some bacterial proteins required for scavenging nutrients such as 
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iron are not expressed at sufficient level to allow purification of protective 
component. By identifying the proteins involved in inducing protective immunity, or 
the genes coding for these proteins, it is impossible to use recombinant DNA 
technology or synthetic peptide technology to produce sufficient quantities of these 
protective epitopes for incorporation into vaccines. 
In addition to identifying potential targets of pathogens, it is also possible to develop 
subunit vaccines, which reduce vector transmission of some pathogens by 
immunization against the vector. For example, many infectious agents are transmitted 
by blood feeding vectors. Studies have shown that immunization of animals against 
antigens present in the gut of the vector resuhs in the disruption of their intestinal cell 
function when exposed to antibodies rich blood meal directed against these intestinal 
antigens. Relying on the recombinant DNA technology to express protective antigen 
and its use in development oCpathogen specific vaccine is demand of the ordeal. The 
identification and subsequent expression of such antigen is likely to shorten the time 
required to develop subunit vaccines for a large number of pathogens. 
1.4. Genetic Vaccines: 
A recent novel approach for successful immunization exploits usage of DNA that 
encodes specific protective antigen. The in vitro paradigm for this approach lay in the 
transformation of mammalian cells in the culture with a plasmid that directs the 
expression of a vaccine antigen from the cells that take up the plasmid DNA. 
Subsequent to its uptake the administered DNA encodes antigen (s) that can be 
secreted or be associated with the cell surface in a way that would trigger a humoral 
or cellular immune component of the host. The uptake of DNA can be facilitated by 
chemical formulation or delivery by a virus or bacteria. Several strategies have been 
exploited for immunization with genetic vaccine. 
1.4.1. Purified DNA: 
In the early nineties, intramuscular administration of solution of uncoated or naked 
DNA encoding a vaccine was found to induce desirable immune response (Wolfe/ al 
1990). Cells take up the DNA, transcribe it to induce desirable antigen, which may be 
processed in a similar way to that of administration of DNA subsequent to viral 
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attack. Both humoral and cellular immune responses to the encoded antigen were 
elicited. The advantages of using DNA based vaccine involve relatively technically 
easy way of preparation and ability to direct the synthesis of multiple copies of 
mRNA that eventually results in amplification of both antigen synthesis and immune 
responses. Such vaccine has been shovm to be effective in many animal models. DNA 
vaccines are particularly proficient at eliciting cellular immune responses. One 
strategy has been the presentation of DNA on gold micro projectiles that are shot 
directly into cells that eventually results in expression of antigen to stimulate an 
immune response (Williams et al 1991). DNA also has been coated with cationic 
lipids, lipospermines or other molecules, which neutralize its charge, while surplus 
cationic lipid moieties facilitate cellular uptake (Remy et al 1994). 
1.4.2. Virus mediated DNA delivery: 
For delivery of DNA by fowl pox or canary pox virus, the expression cassette for the 
recombinant protein is integrated into the viral genome. Although able to infect avian 
species to produce disease, these poxviruses can infect mammalian (human) cells 
without inflicting any infection; hence can be considered as a safe genetic approach 
for immunization (Kent et al 1994). This single round of self- limiting infection may 
be sufficient to elicit broad immunity against pathogen whose recombinant 
polypeptide is expressed by these avian poxviruses in infected cells. The approach has 
some basic advantages over Vaccinia virus as these viruses have considerably less 
reactogenicity mostly because of their inability to spread with in host. 
1.4.3. Bacterial delivery: 
The intracellular bacteria can be engineered to deliver plasmid DNA into host cells 
for the expression of recombinant proteins. S. flexneri has been attenuated by making 
a deletion mutation in the essential asd gene (Sizemore et al 1996). The attenuated 
strain can be prolonged in vitro in the presence of diaminopimelic acid (DAP) and 
retains its potential to invade ells (as long as it maintains a plasmid encoding invasion 
- associated polypeptides). However, it cannot replicate in- vivo because of the 
absence of DAP. A plasmid harboring a prokaryotic promoter and recombinant gene 
can be transformed into this strain. The resultant recombinant S. flexneri strain was 
shown to be able to invade mammalian cells in-vitro and to express the plasmid-
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encoded protein as a potential vaccine antigen. Since, iS. flexneri replicates in the 
intestine and stimulate mucosal immunity; its oral administration can effectively 
deliver DNA to the cells to evoke mucosal immunity. 
1.5. Combination vaccines: 
In this strategy, combination of more than one vaccine can be administered to the 
hosts. There are two general categories of combination vaccines. 
Multi Disease combination vaccines include individual vaccines for several 
diseases. A muhi disease combination is usually developed after each individual 
vaccine in the combination has been developed and licensed separately, so that this 
becomes a combination of licensed components. 
Multivalent combination vaccines are directed against more than one type 
(serotypes or serogroups) of viral or bacterial pathogen. A multivalent combination is 
developed as sue from the outset rather than developing and licensing each individual 
serotype vaccine separately. While muhivalent combinations invariably are mixed 
during the manufacturing process. Multi disease combinations may be mixed at one of 
three stages; (i) during the manufacturing process such that the combination is filled 
into vials or syringes, (ii) At the time of administration by prior mixing of different 
vaccines in a vial then using the mixture for injection or (iii) mixing of individual 
vaccine preparation at the time of administration using dual chambered syringe. While 
the first alternative is clearly preferred for ease of use, it is not always possible in 
cases where the combination is not compatible giving giving rise to fully unstable 
preparation. 
Till date only three different types of combination vaccine are available. Live 
attenuated vaccines consisting of viruses or bacteria, which have been cultivated in 
vitro in a way which attenuates their infectivity and pathogenicity. Such strains of 
viruses or bacteria are able to infect and replicate in vivo to some limited extent but do 
not cause disease. The second type of combination vaccine is referred to as non live 
(inactivated, killed or subunit vaccine). Such vaccines may be chemically inactivated 
viruses or bacteria (inactivated or killed vaccine), individual antigens purified from 
viruses or bacteria or expressed by recombinant host cells (subunit), or synthetic 
components such as peptides (subunit). Vaccines may be combinations of live or non-
live components, but there are not yet any examples of successfiil combination of live 
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and non live components together. The third type of vaccine has been categorized as 
genetic or DNA based, however as this type of vaccines have entered clinical trials in 
recent past only, there are not yet examples of combinations of such vaccines. There 
are six combination vaccines, both multi disease and multivalent, which have been 
available for periods of 2 to 6 decades for routine immunization as discussed below. 
Some of these have been mixed with other vaccines and further developed into 
combination vaccine. 
1.5.1. DTP (Diptheria- Tetanus- Pertussis) vaccine: 
This multi - disease non- live combination vaccine is available for over last fifty years 
and required as pediatric vaccine in most major countries worldwide. It is typically 
being given three to four times in first two years of life with subsequent boosters. 
(Ramon 1923, Plotkin and Cadoz 1997). 
1.5.2. Influenza vaccine: 
The trivalent inactivated combination vaccine has been available for over last forty 
years (Kilboume 1994). It is widely used, especially in older adults, for the prevention 
of acute disease through annual immunization. The vaccine consists of two HA 
antigen serotypes of influenza virus; one of serogroup A and serogroup B. 
1.5.3. Polio vaccine: 
This multivalent combination vaccine has been available in two different forms. The 
inactivated vaccine (IPV; Salk vaccine) is a combination of three serotypes of 
poliovirus, each is purified and inactivated prior to mixing. The vaccine is indicated 
for immunization up to four times in first two years of life (Salk and Gori 1960). The 
live attenuated oral polio vaccine (OPV; Sabin vaccine) is trivalent, consisting of a 
combination of three serotype viruses, each of which has been attenuated through in 
vitro passage (Sabin 1957). The vaccine is indicated for immunization three to four 
times in first two years of life, or is given in a mixed regimen with the first two doses 
as IPV and next two doses as OPV (Plotkin et al 1968). 
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1.5.4. MMR (measles, mumps, rubella) vaccine: 
This multi disease live combination has been available for more than 30 years 
(Weibel et al \ 980). Each of the three components of the vaccines was attenuated 
through in vitro passage and developed as an individual vaccine prior to the 
combination being made and developed. In areas where trivalent vaccine has been 
widely utilized, there has been a >99% reduction in the incidence of each of three 
diseases (Paunio et al 1991). 
1.5.5. Pneumococcal vaccines: 
This multivalent combination has been available for over last two decades (Austrian 
et al 1989). Even though there are > 80 known serotypes of Streptococcus 
pneumoniae (Pn), it was recognized that only limited population is responsible for 
most cases of disease in susceptible adults as well as children. 
1.5.6. Meningococcal vaccine: 
This multivalent vaccine has been available for more than two decades. Among the 
multiple serotypes of Neisseria meninitidis, five serotypes were recognized as 
responsible for infliction of disease in children and adults. The serotype specificity is 
carried on polysaccharide (Ps). Among them type B, is non immunogenic. Therefore, 
the vaccine was developed as a mixture of remains four capsular Ps (types A, C W-
135, Y) for the immunization of children and adults (Armand et al 1982). 
1.6. Marker vaccine: 
A marker vaccine can be either a subunit or a gene- deleted vaccine and is defined as 
one which can be used in conjunction with a diagnostic test to differentiate a 
vaccinated animal versus a carrier animal. These vaccines are gaining popularity in 
veterinary medicine where eradication of specific diseases is of national interest. The 
technology for developing marker vaccines has been used most extensively for 
eradication of Herpes- virus in pigs and cattle. The basis of marker vaccine is that 
animals develop immune responses to the antigens present in the vaccine but not to 
antigens of the pathogen origin that have been excluded from the vaccine, since these 
vaccines reduce shedding from latently infected animals, it is possible to immunize a 
herd for a number of years and eventually reduce the shedding to such a level that 
only the older animals are latently infected (Bosch et al 1998). One important 
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criterion for choosing a marker protein is that it must be one that induces a rapid and 
long lived antibody response in infected animals but not in vaccinated animals even 
after repeated immunization. 
2. Attributes of the successful vaccination: 
The requirement of eliciting a protective immune response against pathogens requires 
involvement of specific components of immune system for their successful clearance 
from systemic circulation. In general, pathogens may simply be eliminated by specific 
antibodies, however, certain classes of pathogens adapt intracellular shelter to avoid 
antibody on slaught. The elimination of intracellular pathogens e.g. Mycobacterium, 
Leishmania, Candida sps is executed with the help of CD8* T-cells of the host 
immune system (Flynn et al 1993, Muller et al 1991). Interestingly, requirement of 
vaccination to evoke characteristic immune responses against some pathogens may 
even vary against different stages of their life cycle. For example, taken example of 
malaria parasite Plasmodium sps, it has been seen that the protective immunity 
required against sporozoites and liver stages of parasite may be generated by specific 
CD8^ CTL responses (Suss and Pink 1992), while the require CD4* Thl type immune 
response successfully suppress blood stages of the parasite without involving CD8^ T-
cells (Vander-Heyde et al 1993). Thus before designing a vaccine, one should keep 
into consideration not only the type of pathogen but the specific immuno-protective 
mechanism also that is involved in eliminating the pathogen. As suggested by Ada 
and Ramsay (1997) the general attributes of successful vaccination include: 
I. The vaccine must be able to activate antigen presenting cells (APCs) for the 
processing and presentation of antigen by the lysosomal/cytoplasmic 
pathways, the expression of co-stimulatory factors and chemokine receptors at 
the cell surface, and the secretion of certain other important cytokines. 
II. The vaccine formulation should enhance the replication and differentiation of 
T and B lymphocytes that leads to the generation of large pools of memory 
cells of desirable phenotypes. 
III. Vaccine preparation should include both sufficient B-ccU epitopes to generate 
strong neutralizing antibody responses as well as T-cell determinants that bind 
with high affinity to at least the major regional HLA haplotypes to be 
recognized by the T-cell receptor. 
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IV. The long term persistence of conformationally intact antigen is desirable, 
preferably as aggregates complexed with antibodies and held at the surface of 
FDCs (Follicular Dendritic Cells) in lymphoid tissues. This allows the 
continuing production of cells those secret antibody with increasing higher 
affinity, and memory B-cells responses. 
3. Immunological adjuvant: 
Immimological adjuvants were originally described by Ramon as substance used in 
combination with a specific antigen that produce more inununity than the antigen 
alone (Ramon 1924). This broad definition encompasses a very wide range of 
materials that can adjuvenate immune system of the host upon their administration 
(Vogel and Powell 1995). However, despite extensive evaluation over many years, the 
only adjuvants currently approved by US Food & Drug Administration (Rockville, 
MD) are aluminium- based mineral salts [generically called alum (Gupta 1998). The 
most important issue in adjuvant development is its safety, which has restricted the 
development of newer adjuvant (Eldman 1997). Many experimental adjuvant have 
advanced to clinical trials and some have demonstrated high potency, but most have 
proved too toxic for routine clinical use. For standard prophylactic immunization in 
healthy individuals, the adjuvant that induce minimal side effect is likely to be 
acceptable. In contrast, for adjuvant that are designed to be used in life threatening 
situations (e.g. cancer), the acceptable level of adverse events is likely to be higher. 
Additional issues that are important for adjuvant development include 
biodegradability, stability, ease of manufacture, cost and applicability to a wide range 
of vaccines. Ideally, for ease of administration and patient compliance, an adjuvant 
should allow a vaccine to be given by a mucosal route. Some of the adjuvant that has 
been evaluated in clinical trials are enlisted in (Table 2), Although the mechanisms of 
action of most of the adjuvant are often poorly imderstood, they can be broadly 
classified on the basis of their basic principal of action. Hence, the most convenient 
way to classify the wide range of adjuvant includes their mode of action as mentioned 
below (Ada and Ramsay 1997) 
I. Some adjuvant (e.g. Freund's adjuvant) forms a depot of antigen for its long 
persistence at the site of the application primarily and ft-om where the antigen 
is released over a period of time. 
1 0 -
Chapter 1 Review of Literature 
II. The activation and maturation of APCs, particularly DCs and macrophages, 
may be influenced by some adjuvant {e.g. liposomes) resulting in expression 
of different co- stimulatory molecules chemokines receptors. 
III. Many adjuvant are shown to increase the synthesis and secretion of enhancing 
factors, such as cytokines and chemokines that act principally for evoking 
immune response, but not only on cells of the immune system, especially T 
and B lymphocytes. 
3.1. Mineral salts: 
The mineral salts, which have been used as adjuvant, include aluminum hydroxide/ 
phosphate (alum adjuvant) and calciimi phosphate. Alum has historically served as 
immuno-potentiater in vaccine development and continued to be the most widely used 
adjuvant (Lindblad 1995). Alum has a good safety record, but comparative studies 
show that it's a weak adjuvant for antibody induction against protein subunits and a 
poor adjuvant for cell mediated immunity. Not to be on very positive side, alum 
adjuvants can induce immunoglobulin E (IgE) antibody responses and have been 
associated with some allergic reactions in human subjects (Gupta 1998, Relyveld et al 
1998). 
3.2. Microbial components: 
3.2.1. Muramyl dipeptide: 
N- acetyl muramyl-1 alanyl - D isoglutamine is smallest subunit of the mycobacterial 
cell wall that retains immunoadjuvant activity and referred as Muramyl di peptide 
(MDP). MDP solution administered in saline induces humoral immune responses 
mainly, while water in oil emulsion (e.g. Syntax, emulsion of threonyl MDP and 
squaline) increases antibody and cell mediated immunity (EUouz et al 1974, Warren 
e/a/1986). 
3.2.2. Monophosphoryl Lipid A: 
Monophosphoryl lipid A (MLA) is a less toxic but active derivative of 
lipopolysaccharide (Ribi et al 1984). The adjuvant promotes IFN-gamma production 
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by T-cells and thus indirectly helps in the production of antibodies (Tomai and 
Jhonson 1989). MLA preferentially triggers Th-1 cells and direct secretion of IgG2a 
isotype (Takayama et al 1991). Because of its safety and 
Table 2 
Selected examples of vaccine adjuvants 
Adjuvant type 
Mineral salts 
Microbial 
Particulate 
Oil emulsion and surfactant- based 
Synthetic 
Cytokines 
Genetic 
General examples 
Aluminium hydroxide/phosphate, 
Calcium phosphate 
Muramyl dipeptide, bacterial exotoxins 
(e.g. cholera toxin, heat labile 
enterotoxin)/ endotoxins (e.g. 
monophosphoryl lipid A, bacterial 
DNA) 
Microspheres, ISCOMS, Liposomes, 
niosome, virosomes. 
Freunds adjuvant, MF 59, SAF 
Saponins (e.g. QS 21), Muramyl peptide 
derivatives, non- ionic block co-
polymers, synthetic polynucleotides 
IL-2, IL-12, GM- CSF, IFN-y 
Cytokine genes or genes encoding 
costimulatory molecules delivered as 
plasmid DNA 
extensive clinical evaluation, MPL is strong candidate for human preventive and 
therapeutic vaccines against infectious and neoplastic diseases. 
3.2.3. Bacterial DNA: 
One of the most promising classes of new adjuvant is the imunostimulatory sequence 
in bacterial DNA. These are short nucleotides of DNA containing un methylated 
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guanine and cytosine dinucieotides, so called CpG motifs. They trigger B cell 
activation and induce cytokine response leading to Th-1 response. CpG 
oligodeoxynucleotide work for both systemic and mucosally administered antigens 
(McCluskie and Davis 2000, Weeratna et al 2000). 
3.3. Cytokines: 
Several cytokines have been used as experimental vaccine adjuvants, including IL-2 
and IFN-Y (Nohira and Rubin 1994). Recently IL-12 and IL- 18 have also been 
incorporated in various newly developed vaccines (Schott and Trinchieri 1997). 
Cytokine mixtures, including GM- CSF, TNF-alphaand IL-12 emulsified in IFA have 
also been employed to steer the immune response in desired direction (Ahlers et al 
1997). 
3.4. Oil emulsion and surfactant based vaccine: 
3.4.1. Freunds Adjuvant: 
The powerful immunologic adjuvant is composed of water- in- mineral oil emulsion 
and containing killed mycobacterium as an additional immunomodualtor (Freund et al 
1937). This adjuvant is known as Freund' s complete adjuvant (FCA). Although FCA 
is one of the most effective adjuvants known, is highly reactogenic and cannot be 
used in human vaccines. However, Freund, s incomplete adjuvant (FIA), which does 
not contain mycobacteria was employed in an influenza vaccine licensed in the United 
Kingdom and is^sed in several HIV vaccines that are under clinical evaluation 
(Jancene/a/1998). 
3.4.2. MF59 Adjuvant: 
MF59 is oil in water microfluidised emulsion composed of stable droplets (250nm) of 
the metabolizable oil squaline (4.3 %w/v) and two surfactant polyoxyethylene 
sorbitan monooleate (Tween 80; 0.5 % w/v) and sorbitan trioleate (Span 85; 0.5 % 
w/v). MF59 is safe, practical and potent adjuvant for use with human vaccines, with 
more than five million doses distributed. The adjuvant has been shown both in animal 
models and in humans to be a potent stimulator of cellular responses to subunit 
antigens. Toxicology studies in animal models and phase I through IV studies in 
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humans have demonstrated the safety of MF 59 with HSV, HIV, and influenza 
vaccines (Podda 2001, Ott et al 1995). 
4. Immunological perspective of controired antigen delivery: 
The response to various vaccine antigens is routinely optimized by assessing a variety 
of delivery methods that include variation of the adjuvant and delivery systems used 
or manipulation in the dose and number of injections as well as the route of vaccine 
delivery etc. The recent advances in the antigen delivery have resulted in the 
development of controlled delivery systems (such as liposomes) that can offer a 
further parameter for vaccine assessment and may provide means of enhancing and 
manipulating the host immune response to a significant extent. Nevertheless, 
application of such delivery systems for vaccination would allow effective utilization 
of vaccine antigens that have previously not been able to induce adequate or 
appropriate immune responses thus, improving the responses to existing vaccines. 
4.1. Induction of affinity maturation and isotype switching 
The maturational changes in the immune response include antibody shift from IgM to 
a predominant IgG isotypes, development of a high affinity antibody response as well 
as presence of memory lymphocytes that will mount a rapid response following 
further antigenic challenge. This process is generally described as occurring after at 
least two doses of antigen administration. Furthermore, prolonged antigen exposure 
assisted by controlled delivery system can also allow immune maturation to occur and 
may even enhance this process many folds. This property of the delivery systems is 
desirable as most of the controlled release mechanisms result in delivery of low levels 
of antigen over time, which will first stimulate high affinity B-cell clones to 
proliferate. For example, induction of higher affinity antibody responses by low doses 
of antigen has been demonstrated (Gonzalez-Fernandez and Milstein 1998). 
4.2. Induction of immune memory 
Research on controlled antigen delivery has facilitated the memory immune 
responses, which is the aim of most of the vaccine formulations. For example, 
delivery of Yersinia pestis V antigen through PLA microspheres as well as BSA by 
archaeosomes has resulted in generating significant memory immune responses in 
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mice (Eyles et al 2001). Apart from such type of antigen delivery systems, injectable 
silicone implants that delivered avidin and IL-ip as adjuvant were useful in 
generating a strong memory antibody responses as well (Kemp et al 2002). 
Interestingly, in these studies, the effectors response induced a mixture of IgGl and 
IgG2 isotypes of antibodies, in contrast to the memory response generated by soluble 
antigen alone that showed predominance of IgGl isotype. 
Besides activating effectors arms of immunity, the persistence of an antigen for longer 
duration may contribute in maintaining immune memory as well, although its exact 
role is yet to be resolved. This condition may arise due to differential antigen 
requirements of different cell types for the formation of memory cell repertoires 
(Eyles et al 2001, Marumaya et al 2000). Thus, controlled antigen delivery facilitates 
the low level of antigen and continuous drainage of the antigenic materials to the 
FDCs present in the lymph nodes that eventually helps in maintaining immune 
memory. 
4.3. Manipulation of Thl/Th2 responses: 
Recently, it has been demonstrated that a difference in antigen exposure in vivo may 
direct different precursors to produce IL-4 secreting CD4^ T-cells (Foucras et al 2000 
and 2002). In contrast, some other studies performed using a range of different 
antigen delivery mechanisms have shown preponderance of both Thl and Th2 
responses depending on the type of antigen and more importantly upon the type of 
delivery system used. For example, Moore et al (1995) induced strong CTL responses 
following vaccination of mice with a soluble recombinant HIV protein by 
encapsulating the antigen in polymer microspheres. Similar responses were induced 
by delivery of ovalbumin releasing microspheres (Newman et al 1998). More 
importantly, delivery of various antigens encapsulated in different types of liposomes 
has resulted in the induction of diversity in immune responses. These include a Thl 
dominant response following liposome encapsulation of various allergens (Sehra et al 
1998), and a Th2 dominant response using Leishmania antigens, characterized by 
poor DTH responses and predominant IgGl antibody responses that resulted in 
limited protection (Afrin et al 2000). In absence of polarization the simultaneous 
induction of both Thl and Th2 responses has also been reported from different kinds 
of liposomes (Krishnan et al 2000b; Babai et al 1999). Hence, the rational 
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manipulation of delivery systems, in combination with variation of other parameters 
such as dose, route of administration as well as use of adjuvant or delivery systems is 
likely to result in significant improvement in the effectiveness of many existing 
vaccines. 
Liposomes, also known for their potential and actual applications in targeted drug and 
gene delivery, appear to satisfy many of these criteria and therefore have potential for 
their future use in vaccine delivery (Gregoriadis 1990, Allison and Gregoriadis 1974). 
Delivery of antigens using liposome may therefore be used to rationally manipulate 
the type of immune response where liposome may be tailored to obtain a desired 
immune response (Owais and Gupta, 2000). Nevertheless, various other factors 
including intrinsic properties of an antigen, booster doses etc. may play important role 
during elicitation of immune responses. Therefore, a case-by-case basis in 
combination with variations in dose, routes of administration and schedule of delivery 
may be desired to develop effective vaccines. The structural versatility of liposomes, 
their ability to incorporate a wide variety of antigens regardless of size and solubility 
and a favorable bio-distribution profile have rendered the system an effective mean 
for the immunopotentiation and delivery of peptides and microbial vaccines alone or 
in conjunction with other co-adjuvants such as cytokines. The promise of the system 
as a vaccine carrier has recently been substantiated v^th the first liposome based 
vaccine (against hepatitis A) (Epaxal-Bema) licensed for use in humans (GUick 1994) 
and by the encouraging results of phase I and phase II clinical trials with a variety of 
other liposomal vaccines {e.g. trivalent influenza, hepatitis B, diphtheria, and tetanus 
toxoid vaccines) (Gregoriadis 1995). 
5. Particulate antigen delivery system: 
5.1. Liposomes: 
Liposomes were originally introduced in 1965 as models of lipid bilayer membrane 
(Bangham 1968). Since then, they have been widely applied as models for studying 
effectors phases of immune responses (Alving and Richards 1983). In 1974, 
liposomes were proposed as carriers of antigens to augment antibody responses in 
vivo (Allison and Gregoriadis 1974). In recent years, use of liposomes as potential 
carriers for vaccines has been extensively explored (Alving 1987, Gregoriadis 1990, 
Alving 1991, Alving et al, 1995) and applications of liposomes in immunology, and 
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particularly those relating to vaccines, have demonstrated that liposomes may have 
considerable practical utility as carriers of antigens. Besides antigen delivery, 
liposomes have ailso been shown to serve as carriers of a variety of adjuvants and 
mediators, including lipid A, muramyl dipeptide and its derivatives (Alving 1991). 
Among the various factors involved e.g. location of an antigen either on the surface or 
encapsulation within liposomes, fluidity of the lipid bilayers, number of lamellae (uni-
vs. multilamellar), size and surface charge of liposomes have proven most imperative 
in imparting variety in immune responses in vivo (Latif and Bachhawat 1984, Alving 
1987, Gregoriadisera/, 1989). 
5.2. Suitability of liposomes as vaccine carriers: 
Many studies have demonstrated that liposomes cein serve as effective vehicles for 
inducing humoral immunity to a wide range of liposomal antigens (Alving 1987, 
Gregoriadis 1990). The most common reason for using liposomes has been to convert 
a poorly immunogenic or even non-immunogenic protein into a highly immunogenic 
one. Some investigations have suggested that for certain antigens or under certain 
circumstances liposomes can be stronger adjuvants than CFA (Gregoriadis and 
Manesis 1980, Gregoriadis and Panagiotidi 1989, Brynestad et al 1990). Liposomes 
have also been shown to induce antibody having conformational specificities (Orgert 
et al 1990). e.g. an unconjugated synthetic peptide containing 25 amino acid residues 
was encapsulated in liposomes containing lipid A, and the liposomes were 
successfully used to produce MAbs that recognized widely separated sequences of 
amino acid epitopes (Geysen et al 1984). It may be presumed from the study that this 
type of specificity was caused by the conformation of the peptide as it interacted with 
the liposome bilayer. 
As mentioned earlier, a considerable amount of in vitro research has demonstrated 
that interaction of certain types of liposomes containing antigens with APCs can result 
in the generation of antigen specific MHC-restricted CTLs, and the similar results 
have also been obtained in vivo. Furthermore following immunization of mice with 
the liposomised-antigen, CTL response was induced that blocked the formation of 
tumor mass from Hantaan NP transfected B16 melanoma cells in C57BL/6 mice and 
delayed the growth of pre-inoculated melanoma cells (Chang et al 2001). 
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5.3. Strategies for optimization of liposomal adjuvanticity 
Approaches to further improve the immuno-adjuvant action of Uposomes include 
receptor-mediated targeting to macrophages (Garqon et al 1988), use of a variety of 
co-adjuvants (Alving 1991), modification of the structural characteristics of vesicles 
(Davis and Gregoriadis 1987) and the use of cytokines (Mbawiuke et al 1990, 
Abraham and Shah 1991). Importantly, liposomes have also been modified to target 
antigens to the desired APCs such as macrophages and DCs. For instance, liposomes 
coated with a marmose-terminating ligand promoted greater IgG responses in mice 
against entrapped tetanus toxoid than ligand-free liposomes (Nair et al., 1992), 
presumably because of improved targeting of vesicles to the dendritic cells which are 
known to express mannose receptors on their surface. Recently, the effect of targeting 
strategies for improving the interaction of liposomal PorA (a major antigen of 
Neisseria meningitidis) with DCs was investigated (Arigita et al 2003). In this study, 
purified PorA was reconstituted in different types of targeted liposomes i.e. by using 
mannose or phosphatidylserine as targeting moieties and such targeted liposomes 
were found to enhance maturation of murine DCs. Moreover, presentation of 
encapsulated proteins in sterically stabilized liposomes to the human DCs has been 
demonstrated to initiate CD8^ T-cell responses (Ignatius et al 2000). Administration 
of antigens into the liposomes together with interleukin-2 (IL-2) has been proved to 
be an effective way to augment immune responses against a variety of antigens. These 
include tetanus toxoid, bacterial polysaccharide (Abraham and Shah 1991), influenza 
A virus (Mbawiuke et a/., 1990), inactivated influenza virus and HSV-recombinant 
glycoprotein D vaccines. 
Structural characteristics of liposomes play a decisive role (both qualitatively and 
quantitatively) in the expression of immuno-adjuvant activity (Gregoriadis, 1988). 
There are for instance, numerous studies on the extent to which membrane fluidity 
(Kinsky 1978, Gamier etal \99\, Davis et al 1987), number of bilayers (Shek 1982), 
vesicle size (Francis 1985), surface charge (Kraaijeveld 1984), and location of antigen 
(Shek 1982) can affect adjuvanticity of liposome based delivery systems. 
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6. Fusogenic liposomes derived from microbial lipids: 
Since the inception of the concept of using liposomes as antigen carriers, numerous 
attempts have been made to develop liposome based particulate delivery systems. 
Among various strategies employed to improve liposome mediated antigen delivery, 
the fusogenic-liposome based vaccines remained more convincing approach to deliver 
antigens to the proteasome machinery through fusion of liposome with membrane of 
the target cells (Owais and Gupta 2000, Reddy et a/1991 Straubinger et al 1985), that 
eventually leads to MHC class I mediated presentation of the antigen ensuing specific 
CTLs generation. One method for imparting fusogenicity to liposomes is to 
incorporate charged phospholipids, for example in their preparation; thereby 
positively charged liposomes are capable of delivering encapsulated soluble antigens 
to the cytosol for class I MHC presentation unlike neutral lipid liposomes (Nakanishi 
et al 1997). Moreover, apart from intrinsic fusogenic property of the lipids, various 
glycoproteins such as hemagglutinin (HA) of influenza virus and fusion protein (F-
protein) from Sendai virus, which are responsible for the entry of virus into the host 
cells, have also been used for imparting fusogenicity to the conventional liposomes 
(Kunisawa era/2001). 
Recently, it has been demonstrated that liposomes made up of polar lipids extracted 
from Saccharomyces cerevisiae imdergo membrane-membrane fusion with the APCs 
to elicit antigen specific CTL responses (Owais and Gupta 2000). Some other groups 
have also reported the fusogenicity of total polar lipids unique to Archaea to prepare 
archaeosomes that can deliver entrapped solutes to the cytosol of the target cells. This 
eventually led to the elicitation of antigen specific Thl/Th2 cytokine as well as CD8"^  
CTL response against entrapped soluble antigens (Krishnan et ah, 2000a & 2000b; 
Sprotte/fl/1997 & 2003). 
Various strategies that have exploited microorganisms to impart fusogenicity to the 
antigen delivery vehicles are as follows. 
6.1. Virosomes: 
The interest to analyze the adjuvant effect of liposomes on one hand, and curiosity to 
know morphological and immunological aspects of influenza virus, on the other, led 
to the creation of the first so-called virosomes (Almeida et al 1975). The name itself 
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reflects the structural similarities between the viral liposomes and the actual influenza 
virus particles. The fusion potential of influenza virosome is based on the major viral 
envelop glycoprotein hemagglutinin (HA) and neuraminidase (NA) in which HA acts 
as a targeting device as it binds to sialic acid residues present on APCs and directs a 
passage for viral entry into the host cells (Skehel and Wiley 2000, Matlin et al 1981). 
After endocytic uptake, the acidic environment in the endosome induces a 
conformational change in the HA component of the virosomes that leads to the ftision 
of the virosomes with the endocytic membrane. Keeping in view the significance of 
HA conformation in the fusion mechanism, the protocols for influenza virosome 
preparation have been modified to conserve the properties of HA (Stegmarm et al 
1987). The virosomes thus produced retain the receptor binding and membrane fusion 
activity of the native virus, by preserving the conformational integrity of the viral HA. 
These functionally reconstituted influenza virosomes have the capacity to deliver 
encapsulated macromolecules to the cytosol of the target cells (Bron et al 1994, 
Schoen et al 1993). An additional advantage of influenza derived virosomes is that 
HA may also activate immune system of the host thereby acting as a potential 
adjuvant (Watts 1997). 
The detailed in vitro studies suggests that virosomes efficiently deliver their entrapped 
material to DCs for MHC class I and class II presentation (Bungener et al 2002). In 
these studies, influenza virosomes have been shown to induce DC maturation as 
measured by up-regulation of CD40, ICAM-1, B7.1 and B7.2. Moreover, insertion of 
HA as well as NA from influenza virus into immunostimulating complexes 
(ISCOMS) (Morein et al 1979, Coulter et al 2003), conventional liposomes (Almeida 
et al 1975), liposomes containing immunomodulators (Nerome et al 1990, linuma et 
al 1995) or liposomes having cationic lipids (Glqck and Zurbriggen, 2003), supports 
the notion that both HA and NA contribute significantly to the fusogenic properties of 
virosomes rather than envelop lipids. 
The earlier studies with influenza virosomes focused on enhancing its 
immunogenicity in vivo by using antigens from various sources. For instance, 
immunization of mice with virosomes containing a peptide derived from the influenza 
nucleoprotein (NP) resulted in successful priming of NP-specific CTL activity 
(Arkema et al 2000). Recently, immunopotentiating reconstituted influenza virosomes 
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(IRIV) as vehicles have been evaluated to deliver HLA-A*0201-restricted hepatitis C 
virus (HCV) peptides (core 35-44 and 131-140) into the cytoplasm of at least three 
different target cell types [including T2, a transporter associated with antigen 
processing (TAP)-deficient cell line] resulting in class I MHC presentation of the 
antigen and lysis by peptide-specific CTL lines (Hunziker et al 2002). Virosomes 
containing influenza matrix peptide 58-66 can efficiently restimulate in vivo primed 
CTL and importantly, IRIV containing HCV core peptides can even prime CTL from 
peripheral blood mononuclear cells of HCV~ healthy blood donors in vitro. In another 
study in vivo induction of cellular immime responses was demonstrated against 
influenza virosome-encapsulated ovalbumin (OVA) in mice (Bungener et al 2005). It 
was demonstrated that a small amount of OVA (0.75 ng) delivered by fusion-active 
virosomes was sufficient to induce strong class I MHC restricted CTL response. 
Because of their success rates, influenza virosome based vaccines have also been 
evaluated in clinical studies (Gluck 1999). In addition to the observed CTL responses 
elicited by influenza virosomes, incorporation of hepatitis A virons (HAV) in 
influenza-derived virosomes strongly stimulated HAV-specific antibody responses 
(Nerome et al 1990), in fact a virosomal HAV vaccine (Epaxal) is currently in the 
market as well. 
Apart from influenza, virosomes from Sendai virus have been generated by 
reconstitution of the Sendai fusion protein (F-protein), with or without the 
hemagglutinin-neuraminidase protein (HN-protein) in viral lipids (Bagai and Sarkar, 
1993 & 1994). Unlike HA & NA proteins of influenza virus, the F proteins of sendai 
virus are responsible for direct fusion with lipid layer of the cell membrane to induce 
cell fusion (Mizuguchi et al 1999). It was found in earlier studies that such virosomes 
can efficiently fuse with conventional liposomes as well as cell membranes at 37 C 
(Nakanishi et al 1985). Furthermore, the fact that the Sendai virus receptors (sialic 
acid residues) do not exist on the conventional liposome surface suggests that in the 
fusion process of Sendai virosomes this receptor is not mandatory. In addition to this 
unique fusion mechanism between the Sendai virus and liposomes, the Sendai virus-
liposome fusion vehicle has been shown to fuse with mammalian cells (Nakanishi et 
a/1985). The cytoplasmic delivery of macromolecules by these vehicles was 
established in vitro using 'diphtheria toxin A' subunit (DTA) as a probe. Sendai virus 
virosomes carrying DTA suppressed protein synthesis in cultured cells indicating its 
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cytoplasmic delivery by these virosomes (Nakanishi et al 2000, Mizuguchi et al 
1996a). Beside their use as antigen delivery systems, Sendai virosome mediated 
delivery of anti-tumor drugs facilitated total disappearance of S-180 tumors from the 
abdominal cavity without any side effects (Mizuguchi et al 1996a & 1996b). 
Further studies demonstrated that Sendai virosomes may potentially induce CTL 
response even better than complete Freund's adjuvant (CFA) (Nakanishi et al 2000) 
in conjunction to MHC class II response for enhanced antibody production (Hayashi 
et al 1999). Moreover, in a recent study nasal administration of model antigen (OVA) 
using fusion glycoproteins of Sendai virus on the surface of liposome membranes was 
found to efficiently deliver antigen to antigen-sampling macrophages in 
nasopharyngeal-associated lymphoreticular tissue and elicited strong immunological 
responses as well (Kunisawa et al 2001). Additionally, these vesicles also facilitated 
an adjuvant activity against mucosal epithelial cells to enhance MHC class II 
expression as demonstrated by induction of OVA-specific CD4* Thl and Th2 cell 
responses. Furthermore, antigen-specific CTL and humoral response were also 
elicited at both mucosal and systemic sites by nasal immunization with these OVA-
encapsulated fusogenic liposomes (Kunisawa et al 2001). However in another study, 
primary human B and T lymphocytes (CD4'^  or CD8^) and the human B cell line were 
not permissive to this kind of fusogenic liposome-mediated delivery (Watabe et al 
1999). 
Apart from these two extensively explored virosomes, reports are available where 
other viruses have been exploited to prepare fusogenic liposomes e.g. Rubella virus 
based virosomes were prepared by incorporating El and E2 envelope glycoproteins 
into liposomes (Orellana et al 1999) and vesicular stomatitis virus (VSV) virosomes 
were generated by adding the G-protein of VSV to preformed liposomes (Lx)h et al 
1979 Shoji et al 2004). In addition, virosomes have also been generated using 
Epstein-Barr virus (Grimaldi et al, 1995), human immunodeficiency virus (Comet et 
al 1990), Semliki Forest virus (Helenius et al 1977), Friend murine leukemia virus 
(Schneider et al 1983), herpes simplex virus (Johnson et al 1984) and Newcastle 
disease virus (Kapczynski and Tumpey 2003) etc. However, fusion activity of these 
virosomes was not always determined and the main emphasis of using such vehicles 
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remained restricted to study induction of humoral responses against the specific 
viruses from which they have been derived. 
6.2. Archaeosomes: 
Liposomes prepared from polar archaebacterial glycerolipids (archaeosomes) have 
been shown to induce strong adjuvant action in mammals. Membranes of 
archaebacteria are reported to contain lipids that are chemically distinct from that of 
eukaryotic or other prokaryotic organisms. The saturated, branched C-20, C-25 and C-
40 phytanyl chains form liposomes with unique properties in context to physical and 
chemical stability and uptake by APCs (Patel and Sprott, 1999) and it was speculated 
that such properties of lipids are the possible factor for observed adjuvanticity to 
occur (Sprott et al 2004). Immune responses comparable to immunization with CFA 
and superior to conventional liposomes have been reported after immunization with 
archaeosomes (Krishnan et al 2000b, Conlan et al 2001). Authors have shown the 
potential of liposomes composed of archaebacterial lipids of various archaebacteria in 
evoking CTL as well as antibody responses to their entrapped antigens (Krishnan et al 
2000a, 2001 & 2003). In these studies, ether glycerolipids extracted from various 
archaebacteria were formulated into liposomes and mice of varying genetic 
backgrounds, immunized via various parenteral routes with archaeosomes containing 
BSA demonstrated markedly enhanced serum anti-BSA antibody titers. These titers 
were often comparable to those achieved with CFA and considerably more than those 
with alum or conventional liposomes (PC/PG/chol, 1.8:0.2:1.5 molar ratio). 
Furthermore, antigen-specific IgGl, IgG2a, and IgG2b isotype antibodies were all 
induced. Apart from BSA, encapsulation of OVA or hen egg lysozyme within 
archaeosomes showed similar immune responses (Krishnan et al, 2000b). Moreover, 
antigen-archaeosome immunizations induced strong cell-mediated immune response 
as evident fi-om antigen-dependent proliferation and substantial production of both 
Thl (IFN-y) as well as Th2 (IL-4) cytokine responses. In contrast, conventional 
liposomes induced little cell-mediated immunity, whereas alum stimulated IL-4 
response only. Furtlier, in contrast to alum and CFA, archaeosomes composed of 
Thermoplasma acidophilum lipids evoked memory antibody responses to the 
encapsulated antigen as observed at =300 days after two initial immunizations (days 
0 and 14). The observed response was shown to be correlated with increased antigen-
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specific cell cycling of CD4* T cells as revealed by flow cytometry. In further studies, 
a comparison between liposomes prepared fix)m the lipids extracted from 
archaebacteria Haloferax volcanii, Planococcus sp. and a eubacterium Bacillus 
firmus was made on their ability to influence immune system to evoke effective 
immune responses (Sprott et al 2004). It was hypothesized that occurrence of 
isoprenoid neutral lipids was the possible factor for the adjuvanticity of B. firmus 
crude lipid-SDS micelles. On the other hand, due to similarities of lipid head groups 
(predominantly PG lipids, sulfoglycolipids and cardiolipin) between H. volcanii and 
Planococcus spp., either kind of vesicles delivered their encapsulated antigens in vivo 
to both MHC class I and class II compartments of APCs. Interestingly, out of these 
three liposome formulations, archaeosomes promoted a greater memory recall 
antibody responses in immunized mice that were found to be highly significant as 
compared to Planococcus liposomes. Surprisingly, CTL response generated by 
Planococcus liposomes were of short term, while liposomes made up of lipids from 
H. volcanii consisting of almost same lipid composition, elicited stronger CTL 
response. Moreover, Planococcus liposomes led to the activation of DCs to secrete 
inflammatory cytokines (IL-12 and IL-6) that may be the possible reason for observed 
short-term CTL responses (Dudani et al 2002). In other set of experiments, liposomes 
made up of archaeal lipids from M. smithi enhanced costimulation on DCs to facilitate 
T-cell activation (Krishnan et a/ 2001). However, the response was independent of IL-
12 production (Krishnan et al 2003), which supports the adjuvant activity of archeal 
lipid liposomes by providing both signals required to activate T-cells: efficient 
antigen delivery as well as co-stimulation (Zinkemagel 2002). Furthermore, 
archaeosome-entrapped listeria antigen elicited rapid and prolonged specific 
immunity against L. monocytogenes in the mice model (Conlan et al 2001). In this 
regard, superiority of tested archaeosomes to conventional liposomes (made up of 
PC/PG/chol) further emphasizes significant contribution of unique features of 
archaeosomes in antigen delivery. 
In the context of the lipid vesicles, possible routes of their entry into the cell include 
either direct fusion with the plasma membrane or phagocytosis by APCs (Owais and 
Gupta 2000). Alternatively, some other routes like endocytosis mediated by mannose 
receptor, FcRs, and those recognizing apoptotic cells, like PS-specific receptors, may 
be responsible for their uptake (Somersan and Bhardwaj 2001, Li et al 2003). In spite 
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of several reports available on archaeosome mediated antigen delivery, no 
intercession has been developed towards the fiisogenicity of these liposomes. 
Information deciphering the exact mechanism of archaeosome uptake by APCs was 
behind the screen until recently; an article demonstrating role of PS in uptake of such 
liposomes by APCs suggests that the whole process is dependent on 
phosphatidylserine receptor present on macrophages and DCs (Gumani et al 2004). 
Archaeosomes from M smithii have been fully characterized and found to comprise of 
30 mol % of the archaetidyl, which is equivalent of PS. These types of liposomes are 
striking in forming archaeosomes with surface-exposed PS head groups (Sprott et al 
2003). Hence, antigen presentation results corroborate PS-specific recognition as 
triggering archaeosome entry into the phagosomal compartment, leading to antigen 
delivery for MHC class I (Gumani et al 2004). 
6.3. Yeast lipid liposomes: 
An interesting correlation between the plasma membrane lipid composition of the 
living organisms and their generation time can be made. For example, bacteria such as 
Escherichia coli. Bacillus megaterium and Bacillus subtilis have preponderance of 
anionic lipids viz. PG and DPG (in combination of PE) in their plasma membranes 
and have very short generation time of the order of 20-25 minutes (Rattray 1988; Jain 
1988). On the other hand, membranes of relatively more evolved Saccharomyces 
cerevisiae or Candida albicans have greater variety of phospholipids with lower 
percentage of anionic lipids (e.g. PG, PI, PS, DPG) and the organisms have a 
generation time of approximately two hours. Since both the classes of organisms 
multiply by binary fission, it can be presumed that the presence of anionic lipids 
facilitates the fusion of the membranes essential for high duplication rates (Owais and 
Gupta, 2000). Unlike the lower organisms, the more evolved eukaryotes have neutral 
phospholipids as major membrane components and have generation times of the order 
of days {cf. -22 hrs). The plasma membrane of lower organisms is mainly composed 
of amino phospholipids along with cardiolipin and PG. The eukaryotic plasma 
membrane lipid composition is different from that of lower organisms and earlier 
work revealed the composition and distribution of phospholipids in eukaryotic cells 
(Kumar and Gupta, 1983). They contain all classes of phospholipids, distributed in a 
set fashion in the two leaflets of the bilayer. The amino-phospholipids are mainly 
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confined to the inner leaflet and play a major role in exocytosis, which involves 
membrane-membrane fusion. 
In the earlier studies, it was demonstrated that asymmetric distribution of 
phospholipids is also maintained in yeast cells (Balasubramanian and Gupta, 1996; 
Dixit and Gupta, 1998). However, similar to other lower organisms the baker's yeast 
{Saccharomyces cerevisiae) undergoes rapid cell duplication, in which the two 
opposite sites of the plasma membrane inner leaflet come close to each other and fuse 
under physiological conditions. TTierefore, the fusogenic properties of the vesicles 
formed from yeast lipids were evaluated to deliver antigen to APCs (Owais and Gupta 
2000). In this study, the fusion efficiencies of various types of membrane vesicles 
were compared using epifluorescence as well as other conventional membrane-
membrane fusion assay methods. In the content mixing assay, marked decrease in 
fluorescence results when ANTS containing fusogenic vesicles (yeast lipid liposomes) 
fuse with the excess of DPX containing vesicles of same lipid composition. Among 
various types of vesicles used in this study, quenching of fluorescence was highest in 
yeast lipid liposomes indicating their strong fusogenic potential. 
The membrane lipid composition of yeast exhibits a great majority of anionic 
phospholipids (PC 48.1; PE 23.1%; PI 16.1%; PS 6.0%; PG 3.9%; and cardiolipin 
1.6%) that play pivotal role in membrane-membrane fusion. Like yeast, Bacillus 
subtilis contains majority of anionic lipids in their plasma membrane (mainly PG & 
PE) and have a short generation period (Rattray 1988). Recently, membrane lipids 
from B. subtilis were extracted to demonstrate their fusogenic potential (Deba et al 
2005) that were found to posses greater fusogenicity than erythrocyte vesicles (RSO 
and ISO) or conventional egg PC/chol vesicles as revealed by conventional fusion 
assays. Moreover, to reconfirm that such vesicles interact via membrane-membrane 
fusion as a major mode of interaction with the target cells {illA A.l cells), the toxic 
effect of 'ricin A' was observed by incubating J774 Al cells with 'ricin A' loaded 
vesicles. It was shown that effect of 'ricin A' is more remarkable in case of 
subtilosomes followed by ISO and RSO erythroc>'te vesicles (Deba et al 2005). 
Therefore, both yeast lipid liposomes as well as subtilosomes (liposomes made up of 
Bacillus subtilis lipids) offer a novel approach to deliver the entrapped antigen into 
the cytosol of the APCs. 
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6.4. Niosomes: 
Apart from these fusogenic liposomes used as antigen delivery vehicles, few reports 
are available on fusogenic vesicles that belong to other classes of vesicle family (e.g. 
niosomes, transferosomes, proteosomes etc.). Niosomes are small unilamellar vesicles 
made from non-ionic surfactants. Hence, they are also called non-ionic surfactant 
vesicles (NISV) (Brev r^er and Alexander 1994) or Novasomes (Gupta et al 1996). 
BSA entrapped within niosomes was reported to be as immunogenic as BSA with 
CFA (Brewer and Alexander 1992) and the chemical stability of niosomes is higher 
than the stability of conventional phospholipid liposomes. Transfersomes are 'ultra 
deformable' liposomes with enhanced skin penetrating properties. These vesicles 
consist of PC/cholate (9:2 molar ratios). Studies with model antigen have shown that 
transfersomes have an upper heind than conventional liposomes when administered 
epicutaneously (Paul and Cevc 1995). Cochleates are non-vesicular bilayer sheets 
consisting of PE/PS/chol. Calcium ions are added which intercalate with the bilayers. 
This results in a rolled up bilayer sheet without internal volume. Results obtained with 
protein- and DNA-cochleates have been reviewed elsewhere (Gould-Fogerite et al 
1998). Proteosomes are also considered as outsiders in the liposome group as they are 
comprised of protein mainly. These vesicles are of bacterid origin (outer membrane) 
and are prepared by solubilization of bacterial membranes, followed by ammonium 
sulphate precipitation and dialysis against detergent containing buffer (Lowell et al 
1988). Electron micrographs revealed that these vesicles have a size of about 100 rmi, 
but the protein: lipid ratio is higher than that can be achieved with purified protein 
incorporated in liposomes. Proteins and peptides are non-covalently complexed to the 
proteosomes, making them highly immunogenic (Lowell et al 1997). Moreover, 
fiisogenic liposomes have been prepared from artificial lipid membranes consisting of 
synthetic arenavirus 'fusion peptide' (Glushakova et al 1992). In addition, it has been 
demonstrated that non-phospholipid liposomes composed primarily of dioxyethylene 
acyl ether and cholesterol have capacity to fuse with membranes composed primarily 
of phospholipids (Baraka et al 1996). 
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7. Plasmodium infection: 
7.1. Life cycle oi Plasmodium parasite: 
All strains of the malaria parasite have a complex life cycle that begins in the 
mammalian hosts when the female mosquito 'deposits 5 to 20 sporozoites 
subcutaneously during a blood meal (Rosenberg et al 1990, Ponnudurai et al 1991) 
(figure 1). The sporozoites enter the blood stream and within few minutes migrate to 
the liver and invade hepatocytes (Mota et al 2001 & 2002). Within this relatively 
immunoprotected intracellular environment, each sporozoite develops over a period of 
6 to 16 days into tens of thousands of schizonts. The schizonts rupture, releasing 
20,000 to 30,000 merozoites per original sporozoite in to the hepatic venous 
circulation and from there they disseminate systemically. Plasmodium vivax and P. 
ovale can develop into hypnozoites, which might remain quiescent in the liver from 
months to years. It is only after the parasites erupt from the hepatocytes that 
symptoms of clinical disease are apparent. In the blood stream, each merozoite that 
has escaped from phagocytic cells then invades, multiply, mature over 24 to 72 hours 
in the erythrocytes, and finally lyse them to invade further new erythrocytes (the 
blood stage of malaria). The blood stage culminates in death of the host. Finally, some 
of the merozoites develop into sexual stage gametocytes, typically about 10 days after 
P. falciparum enters the blood stage (3 days for P. vivax). When these are taken up 
during blood meal by mosquitoes, they can sexually combine and develop into 
sporozoites (10 to 22 days) and this leads to the restarting of the cycle. 
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Figure 1: Malaria vaccines by life- cycle target 
Target 1 (Sporozoites) = RTS, S, ICC-1132, NYU CS, Lausanne CS; 
Target 2 (Liver Stage) = DNA and viral vectors (NMRC, Vical, and Oxford), * 
RTS,S, * Lausanne CS 
Target 3 (blood stages) = MSPl, MSP2, RESA, MSP3, GLURP, FMPl, AMA-1; 
Target 4 (sexual stages) = Pvs 25 
The * in front of RTS, S and Lausanne CS indicates that these vaccines might also 
partly act against the liver stage as well as against sporozoites. (Moorthy et al 2004) 
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1.1. Pathogenesis and Epidemiology: 
The classical signs and symptoms of malaria in human beings include acute febrile 
episodes and rigors that occur every 48 to72 hours, which in fact coincide with the 
synchronized lysis of erythrocytes by newly matured merozoites. Systemic signs and 
symptoms associated with P. vivax include fever, malaise, headache, photophobia, 
muscle aches, anorexia, nausea, and vomiting (Markell et al 1992). Severe disease 
occurs most frequently with P. falciparum because of its ability to infect a greater 
percentage of erythrocytes and to cytoadhere to capillary walls (Markell et al 1992, 
Miller et al 2002). Clinical sequelae (such as acute renal failure, anemia, 
hypoglycemia, cerebral malaria, and pulmonary edema) occur most commonly in 
populations that are relatively naive to the parasite, such as children and travelers 
from non-endemic area (Chen et al 2000). Pregnant women are at special risk for 
severe disease and sequelae, having a unique mechanism of pathogenesis (Reeder 
1999). 
Quantification of the malaria parasite burden in affected populations is imprecise, 
impacted mainly by their access to diagnostic and therapeutic health centers, species 
prevalence, case definition, and low specificity of diagnosis (Breman 2001, Murphy 
and Breman 2001). It is thought that there are 300 to 500 million clinical cases per 
year globally, about 25% of which are caused by P. vivax. Estimated annual malaria 
attributed deaths vary from 1.4 to 2.7 million (Breman 2001, Snow et al 1999) with 
the majority of deaths occurring in children in the African continent (Snow et al 
1999). This translates into 39 million disability-adjusted life years lost annually 
(WHO 1999), which in turn tells about the impact of the disease on economic and 
social disruption in developing countries (Gallup and Sachs 2001). 
The number of malaria cases diagnosed within the United States usually stable and 
ranges at approximately 1000 to 1500 per year over the past decade, with the vast 
majority of cases are reported among travelers and military personnel overseas. 
However, the United States has very small number of congenital, blood transfusion, 
and locally acquired cases (Holtz et al 2001, Sunstrum et al 2001). On the other hand, 
European countries has a much higher rate of malaria, with 37,000 autochthonous and 
13,000 imported cases as per survey made in 1999 (Sabatinelli et al 2001). 
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7.3. Vaccinology: 
Multiple lines of evidence suggest that a malaria vaccine for humans is feasible. 
Immimization of humans with irradiated (and thus attenuated) sporozoites confers 
sterile protection in roughly 90% of naive volunteers when they are subsequently 
exposed to malaria (Clyde 1990, Egan 1993, Rieckmann et al 1979). Because this 
model requires each volunteer to be bitten by hundreds of mosquitoes over a period of 
several months, it is not a practical vaccination strategy but is useful in probing 
immune responses (Hoffman et al 2002). Naturally acquired clinical immunity occurs 
during the first two decades of life in people living in malaria-endemic areas (Trape et 
al 1994, Baird 1991). In general, this immunity is imperfect, can wane rapidly, 
appears to be linked to intensity of exposure, and primarily impacts the severity of the 
clinical disease (Day and Marsh 1991, Baird 1998, Hogh 1996, Smith et al 2001). 
Additionally protection can be mimicked by the passive transfer of hyperimmune 
immunoglobulin into human volunteers (Sabchareon et al 1991). 
The immunologic correlate for clinical protection has yet to be identified. Through its 
complex life cycle, the malaria parasite exists in various immunologic 
"compartments." It is advisable to explore nature of immune responses that might 
impact various stage life cycle of parzisite in specific manner. Furthermore, it is 
possible to extrapolate fi-om other malaria intervention studies how exactly the 
various stage specific vaccines might work. Ultimately, it might be necessary to 
combine antigen from various stages of the Plasmodial life cycle into a single vaccine. 
Presently, there are three intermediate goals of vaccine research (Beverley 2002): 
identification of protective antigens for stage specific immunity; successfiil 
combination of candidate immunogens; and finally, the induction of strong, strain-
transcending, durable immune responses. Whereas, the main strategy for development 
of a malaria vaccine falls under following categories: 
I. Blocking the sporozoite from invading or developing within hepatocytes; 
II. Blocking merozoite invasion of red cells and inhibiting development of 
schizonts; 
III. Blocking the adverse pathology-inducing effects of cytokines and parasite 
sequestration; and 
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IV. Developing an 'altruistic' vaccine that would block host-mosquito 
transmission by immunizing against the sexual stages or gametes. 
7.3.1. Pre-Erythrocytic vaccines: 
Vaccine strategies targeting the sporozoites aim to generate a humoral immune 
response to neutralize the sporozoites and prevent it from invading the hepatocytes. 
Once the sporozoite has entered the relative immunoprotected intracellular 
environment of a hepatocyte, a successful vaccine strategy would rely upon 
elimination of infected hepatocytes with the help of CTL (Doolan and Hoffman, 
2000). Experiments in ortholog model systems and irradiated sporozoite challenge 
studies have implicated CD4^ CD8*, natural killer T-cell, and yS T-cells in the 
inhibition of intrahepatic parasites (Gonzalez-Aseguinolaza et al 2000, Nardin and 
Nussenzweig 1993, Tsuji et al 1994, Good and Doolan 1999, Doolan and Hoffman 
1997, Nardin et al 1999). The leading candidate vaccine of this category is RTS,S - a 
recombinant protein vaccine (Stoute et al 1997). 
The passive transfer of antibodies specific to the sporozoite was found to be 
protective in the murine ortholog model systems (Marussig et al 1997). Moreover, a 
dominant feature of the immune response induced by infected humans with irradiated 
sporozoites is an antibody response to the circumsporozoite protein (CSP), the major 
component of the sporozoite surface coat oi Plasmodium sp (Herrington et al 1991, 
Egan et al 1993). The role of antibodies in mediating protection was elegantly 
demonstrated with the use of MAbs that neutralized the infectivity of sporozoites in a 
rodent model (Potocnjak et al 1980). Initial clinical studies using either a synthetic 
peptide or recombinant protein containing multiple copies of the immunodominant 
repeat sequences found in the CSP (Herrington et al 1987, Ballou et al 1987). For 
example, the peptide (NANP)^ was conjugated to tetanus toxoid, whereas the 
recombinant protein containing 32 CSP repeats fused to an out-of-frame 32 amino 
acid sequence from the gene encoding bacterial tetracycline resistance. A small 
number of subjects immunized with each of these CSP vaccines, formulated with 
alum, were challenged with infected mosquitoes. One of the three high titer 
responders to the peptide vaccine was protected (Herrington et al 1987), whereas only 
one of six individuals challenged after receiving the recombinant CSP vaccine was 
protected (Ballou et al 1987). Ironically, the following studies including numerous 
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additional trials were carried out over a period often years with disappointing results 
(Rogers and Hoffman 1999). 
More recently, results with a recombinant hepatitis B surface antigen vaccine 
incorporating repeat and non-repeat CSP sequences have been much more 
encouraging. When the hybrid hepatitis B particles were formulated in an oil-in-water 
emulsion containing monophosphoiyl lipid A and QS21, six of the seven immunized 
volunteers were protected against subsequent malaria challenge (Stoute et al 1997). 
This vaccine was designated as RTS, S and assessed with thrombospondin-related 
anonymous protein (TRAP) which failed to impart protective immunity against 
malaria (Stoute et al 1997). In a randomized controlled field trial of three-dose RTS, S 
in Gambian adults, vaccine efficacy was 34% (p=0.014) during the 15-week 
surveillance period, but with 71% efficacy in the first 9-weeks and 0% in the next 6 
weeks (Bojang et al 2001). Moreover, the protection was not strain specific 
(AUoueche et al 2003), although the duration of the efficacy was short, RTS, S is the 
first pre-erythrocytic vaccine to show clear protection against natural P. falciparum 
infection. Another vaccine candidate ICC-1132 is a hepatitis B core particle, includes 
a region of CS for high antibody production. High titers of biologically active CS 
antibodies have been noted in preclinical studies (Birkett et al, 2002). Although, 
latest trials with DNA vaccination proved to be efficient priming vaccines but failed 
to boost efficiently (Schneider et al 1999), still intense efforts are being made to 
develop effective DNA based vaccines, each encoding a pre-erythrocytic antigen, 
have undergone phase I studies (McConkey et al 2003). 
Other CS-based candidate vaccines that have reached phase-I studies include a 
multiple antigen peptide, a type of synthetic delivery system, which induced strong 
antibody responses; a polyoxime construct, containing a universal T-cell epitope; and 
a long synthetic peptide in an oil-based adjuvant, which induced detectable antibodies 
and CD4"^  and CDS"^  T-cell responses with a good safety profile (Nardin et al, 2000 & 
2001, Lopez e/a/2001). 
7.3.2. Asexual Blood-Stage Vaccines: 
There are two possible classes of blood-stage vaccine: anti-invasion and anti-
complication. Merozoites enter the blood stream after erupting from the hepatocyte. 
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Within seconds they invade red blood cells that do not express MHC molecules. 
Hence, a vaccine that could prevent invasion would prevent malaria disease. For this 
reason, the vaccine strategy has classically been considered antibody dependent, 
either by inactivating the merozoites or by targeting malarial antigens expressed on 
the red blood cell surface to anibody dependent cellular inhibition (or possibly 
complement lysis) (Bouharoun-Tayoun 1995, Long 1993, Holder et al 1999). 
Recently, ortholog malaria models have implicated CD4^ T-cells, nitric oxide, and yS 
T-cells in helping control blood stage parasites (Good 2001, Bouharoun-Tayoun 1995, 
Long 1993, Holder et al 1999), and there is increasing evidence that CMI can play a 
role in human protection (Plombo et al 2002). Vaccines developed against this stage 
would serve as disease-reduction vaccines, mimicking naturally acquired immunity by 
suppressing the exponential multiplication of merozoites (Tsuji et al 2001, Richie and 
Saul 2002). 
The two leading asexual blood stage vaccine candidates against Plasmodium are 
merozoite surface protein 1 (MSP-1) and apical membrane antigen-1 (AMA-1). Both 
of these antigens have been identified in all Plasmodium spp and examined for of 
their homologues in rodent and simian parasites that eventually has facilitated the 
assessment of MSP-1 and AMA-1 vaccines in several animal models. MSP-1 is the 
most well characterized antigen involved in invasion, and is the basis of several 
candidate vaccines. Most interest in MSP-1 is currently focused on fragments that 
include the two C-terminal epidermal growth factor (EGF)-like domains. Inhibitory 
MAbs react with a 19 kDa fragment (MSP-119) but this fragment is poorly 
immunogenic (Chappel and Holder 1993). Immunity induced by immunization with 
C-terminal fragments of MSP-1 appears to be mediated by antibodies reacting with 
conformational epitopes in the EGF-like domains. The effective antibodies to MSP-I19 
block invasion of merozoites, while the other antibodies reacting with the EGF-like 
domains are either neutral or block the action of the inhibitory antibodies (Blackman 
et al 1994). In a small efficacy study in Papua New Guinea, a blood stage vaccine 
incorporating the antigen MSP-2 and two other blood stage antigens reduced parasite 
density in vaccine recipients (Genton et al 2002). Participants were protected from 
infection with the vaccine strain of malaria, suggesting that polymorphic antigen such 
as MSP-2, a vaccine including just one allelic form of the antigen is not likely to give 
sufficient protection. Immunization with recombinant forms of AMA-1 has protected 
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monkeys and mice against challenge with P. fragile and P. chabaudi, respectively 
(Collins et al 1994, Crewther et al 1996). 
A recombinant viral vaccine, NYVAC Pf-7 encoding seven antigens from different 
stages of Plasmodium life cycle (Ockenhouse et al 1998) has been shown to suppress 
parasitemia upon challenge with sporozoites. The immune response generated by this 
vaccine included some humoral as well as CTL immune response. Two more blood-
stage candidates, glutamate rich protein (GLURP) and MSP-3, have been clinically 
assessed (Oeuvray et al. 2000 & 1994). Main emphasis of all such protein candidates 
is the identification of a safe, immunogenic adjuvant, since the traditional adjuvant 
alum seems to be insufficiently immunogenic for many malaria proteins. In addition, 
this adjuvant induces a Th-2 response rather than a desirable Th-1 response. 
The erythrocyte membrane protein-1 antigen (PfEMP-1), the ligand responsible for 
adherence of malaria parasite to vascular endothelial cells in the brain, kidneys and 
placenta, is being used in experimental laboratory vaccine trials. However, due to 
high degree of variability, rapid antigen variation and high copy number within each 
parasite, use of this antigen as a vaccine becomes complicated as researchers believe 
in using a conserved part of the antigen to be more promising. The P. falciparum 
glycosyl phosphatidylinositol (GPI) molecule that is an inflammatory mediator 
released during schizont rupture has shown its efficacy as vaccine candidate in 
experimental animals (Schofield et al 2002, Molano et al 2000). Two more GPI-
anchored membrane proteins of trophozoite and merozoites stages of P. yoelii offered 
protection against lethal malaria infection in BALB/c mice (Bums et al 2000). On 
sequencing these antigens were found to contain two epidermal growth factor (EGF)-
like domains. 
7.3.3. Transmission-Blocking vaccines: 
Transmission-blocking vaccine relies on the mosquito imbibing both anibody and 
complement along with the parasite during a blood meal. Within the mosquito, the 
antigens become exposed to antibodies during the parasite's maturation, thus 
neutralizing the sexual stages (Kaslow 1993, Lobo et al 1999, Hisaede et al 2000). 
This type of vaccine would not prevent illness or infection in the vaccinated 
individual, but would prevent the further spread of malaria by mosquitoes feeding 
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from the vaccinated host (Kaslow 1997, Stowers and Carter 2001). The vaccine 
could be useful in areas of low endemicity to halt transmission or as an important 
component of a multi-antigen vaccine. 
Only few reports are available addressing the exciting developments with DNA 
vaccines (Hedstrom et al 1998), multiple antigenic peptides (Moreno et al 1999), or 
artificial proteins containing multiple epitopes and or domains (Shi et al 1999). There 
has been a remarkable increase over a past decade in our understanding and 
knowledge of the malaria parasite and the disease that it causes. Never before has one 
been in the position to appreciate what a sophisticated and complex organism we are 
attempting to defeat through vaccine development. Nevertheless, we believe that pre-
erythrocyte and asexual blood stage vaccines are now a reality and priority of malaria 
vaccine development is to field-test the large number of vaccine candidates that have 
been identified with various adjuvant combinations. 
7.3.4. Subunit vaccination: 
The production of live attenuated or killed inactivated vaccines is not practical for 
many diseases. In subunit vaccination, part or complete antigen are identified from a 
pathogen's proteomic complement, which can induce protective immunity to the 
whole pathogen on vaccination. However, for successful elimination of the parasite, 
induced antibodies must have the correct avidity, specificity, biological activity, and 
be produced at a high enough titer to block the infection. To this end, varying 
immunogenicity of the proteins may be the key factor for successful vaccination. 
Increased understanding of antigen processing, adjuvant and their effects on innate 
immunity, genetic engineering techniques, and novel antigen delivery systems have 
facilitated the increased immunogenicity of proteins. Unfortunately, recombinant 
protein subunit vaccines are generally poor at induction of effectors T-cell responses, 
such as CDS"^  cytotoxic T lymphocytes, that are necessary for elimination of 
intracellular pathogens such as liver-stage malaria parasite. 
Presently, several laboratories are emphasizing on DNA based subunit vaccines 
(Ulmer et al 1993, Li et al 1993). The strategies in such kind of vaccination may be 
either to use DNA sequences from malaria parasites that have been inserted into 
plasmid DNA molecules (DNA vaccines) or using various recombinant attenuated 
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DNA viruses (recombinant viral vaccines) to generate candidate vaccines (Schneider 
et al 1998). One of the benefits associated with DNA vaccines may be in the 
induction of memory T-cell population (Gurunathan et al 2000). Recombinant viral 
vaccines actively infect cells and express the recombinant malaria proteins before 
aborting infection (Miyahira et al 1998). DNA or recombinant viral subunit vaccines 
can induce high levels of effectors T-cell immune responses, but poor antibody 
responses limits use of such vaccines (Gurunathan et al 2000, Paoletti 1996). 
7.3.5. Liposomal malaria vaccines: 
The identification of protective antigens and adjuvant is a challenge for vaccine 
development in the fight against the world's most conmion infectious killers, 
including malaria. In this regard, merely identification of antigen does not help in 
solving some key problems in malaria vaccine development while induction of a 
strong and durable immune response is prerequisite for successful vaccination against 
this deadly parasite. Adjuvant imparts variety in humoral as well as cell mediate 
immune responses or may even stimulate a differential IgG isotype expression 
(Richards 1998, Kenney et al 1989). Hence, the selection of adjuvant or antigen 
delivery systems is crucial for achieving high efficiency of malaria subunit vaccines. 
In this regard, new vaccine delivery methods and adjuvants can be brought into 
practice that may eventually lead to the induction of desirable humoral as well as 
cellular immunogenicity. 
By using^ experimental animal models, number of workers have tried to achieve 
various levels of protection with crude preparations of blood-stage antigens with 
adjuvants against Plasmodium sp. (Bums et al 1997. McColm et al 1982, Playfair and 
De Souza 1987, Playfair et al 1977, ten Hagen et al 1993, Patterson et al 1999, Hunter 
et al 1995, Desowitz 1975, Murphy and Lefford 1978, Kumar et al 1990, Reese et al 
1978, Siddiqui 1977 & 1978, Targett and Fulton 1965, Mitchell et al 1979, Brown et 
al 1970). Adjuvants used in these studies included Freund's adjuvant, saponin, 
alhydrogel, IFN-y, nonionic block polymers, detoxified LPS, Quil A as well as 
bacteria, including Bordetella pertusis, Cornybacterium parvum and Salmonella 
typhimurium all of which produced mixed results. Apart from these adjuvants, 
protective immunity against experimental P. falciparum challenge was achieved after 
immunization of humans with Al(OH)3-adsorbed recombinant proteins, or a peptide-
~ 3 7 ~ 
patient (Egile/a/2003). 
Hence, the selection of adjuvants or antigen delivery systems without any side effect 
is crucial for achieving high efficiency of subunit vaccines. In an effort to improve 
immunogenicity of repeat based malaria antigen, variety of Al(OH)3-adsorbed 
candidate liposomal vaccines containing lipid A or monophosphoryl lipid A (MPLA) 
were evaluated in animal models (Alving et al 1986, Richards 1988 & 1989, Alving 
and Richards 1990). Moreover, recombinant antigen (R32NSl8i) was found to be 
more effective in humans in its liposomal form rather than with A1(0H)3 or other 
adjuvants (Fries et al 1992). Purified parasite gp 195 entrapped in liposome B30-
MDP with LA-15-PH (synthetic equivalent oiE. coli derived MPLA), evoked higher 
humoral response than FCA in mice (Hui et al 1991). In a study on MSP-1 derived 
83.1 portion spf66 on its encapsulation into influenza virosomes elicited higher 
immune response than commercial whole virus influenza vaccine (Poltl-Frank et al, 
1999). Interestingly, efficacy of liposome as antigen delivery vehicle against malaria 
was also found effective against other stages of P. falciparum as CSP antigen 
entrapped in MPLA/liposomes revealed the higher efficacy of liposomal vaccine as 
compared to previously used CSP/A1(0H)3 formulation (Alving et al 1986 Richards et 
al 1988). 
The use of adjuvant can critically influence the quality of immune responses. For 
example, it is well known that the Ig subclasses can be influenced by the use of 
adjuvants. Studies on rodent and humans malarias have suggested that immunity may 
be associated with differential expression of malaria specific Ig classes (White et al 
1991, Bouharoun-Tayoun and Druilhe 1992). Enhancement of certain Ig isotypes {e.g. 
IgG2a/IgG2b) can be achieved by adjuvant formulations such as Thr-MDP and or 
nonionic, pluronic polymer vesicles, liposomes, lipid A derivatives, and their use may 
favor induction of a protective antibody population. Nevertheless, CTL response has 
been demonstrated to play a key role in immunity to the liver stages of malaria 
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(Schofield 1989) and the use of liposomes may facilitate antigen specific CTLs 
(Alving 1995). 
Taking into consideration the need of desired immune response against malaria, 
choice of an adjuvant formulation is likely to have a major impact on immunologic 
recognition of parasite and help in designing of subunit vaccines. Since most basic 
studies on immune specificity and mechanisms of immunologic recognition require in 
vivo priming of animal hosts by delivery of the antigen together with an adjuvant, the 
nature and characteristics of immune responses observed and the interpretation of the 
results may largely be restricted within the context of the adjuvant used. Along the 
same line, in the design of subimit vaccines, it may not be useful to exhaustively 
define immune responses to vaccine antigen using FCA adjuvant because it is too 
toxic to be used clinically. Therefore it will be necessary to characterize the 
immunogenicity of antigens using clinically acceptable adjuvant such as liposomes. 
8. Immunopotentiating Role of Immunomodulator 
8.1. Immunomodulators: 
Immunomodulators may be defined as substance biological or synthetic which can 
stimulate, suppress or modulate any of the components of immune system. The basic 
function of immune system is to protect individual against infectious agents and 
potential pathogens which puts the immune system in a vital position between a 
healthy and diseased state of the host. Networking and interaction with in the immune 
system are so complex that modulation of immune system to achieve designed 
therapeutic success is still in the realm of philosophical editorials rather than definite 
efficacy studies (Benson 1993). The use of immunostimulants, particularly as an 
adjunct to chemotherapy for control and prevention (Chatterjee et al 1988) holds great 
promise but has not yet received the attention that it deserves. 
Immunomodulators can be classified immuno-adjuvants, immunostimulants and 
immuno-supresants. Immunoadjuvants are used to increase the efficacy of vaccines 
and since specific immunoadjuvants are used with specific vaccines, therefore could 
be considered as specific immunostimulants. Lack of availability of suitable adjuvant 
for human use has been one of the important stumbling blocks in our ability to 
develop various prophylactic means to control the infection (Allison 1997). 
Immunostimulants by definition are inherently non-specific in nature as they are 
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envisaged to enhance body s resistance against infection. They can act through innate 
as well as adaptive immune response. In healthy individuals the immunostimulants 
are expected to serve as prophylactic or promoter agents i.e. immunopotentiater by 
enhancing the basic level of immune response. Immunosuppressants could be used 
for control pathological immune response and are active in autoimmune diseases, 
immediate and delayed type of hypersensitivity immune reactions and graft rejections. 
Objective of immunomodulation as observed by modem researchers are many. In 
clinical medicine, both aspects of immunomodulation viz. immunostimulation and 
immunosuppression are equally important. In conventional chemotherapy 
immunopotentiation is an ideal choice when the host defense mechanisms are to be 
activated under conditions of impaired inmiune response. 
8.2. Plant derived products as immunomodulator: 
Natural products offer resource for the maintenance of life for ages. Already in the 
earliest written traditions, e.g. the Rigveda of South Asia {ca. 1500-900 BC), plants 
had been considered as best of source of mediciene. One of the best-known examples 
is Soma, the juice extracted from the plant, which was used as a medicine 
(Mukhopadhyaya, 1922-1929, Mahdihassan and Mehdi 1989). The interest in 
medicinal plants has never ceased since. Even today, natural products become 
increasingly important as a source of pharmacotherapeutics, either directly, for 
example in the application of herbal drugs for the treatment of chronic diseases, or as 
raw material from which more or less complex chemical structures with particular 
biological activity are isolated. Cragg reviewed the role of natural products in drug 
discovery, and concluded that for the disease indications anticancer and anti-infection, 
more then 60% of new approved drugs are derived from natural sources. Furthermore, 
there is a global concern about emerging infectious diseases, and an urgent need to 
identify novel means for effective treatment thereof. The National Cancer Institute 
(USA) has screened randomly a hundred thousand plant extracts for antineoplastic, 
anticarcinogenic, and antitumor activity in several model systems. This strategy did 
not prove very effective. Traditional systems of medicine, however, provide an 
extremely vast body of source material for the development of new drugs. Evaluation 
of traditionally used medicines, keeping into account the traditional principles that are 
applied in drug therapy, may offer a lead towards effective drug discovery. 
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Several medicinal plants used in Indian traditional medicines called Rasaynas 
(devoted to enhancement of body,'' resistance) have attracted the attention of many 
scientists. Ironically, most of the investigations were carried independently without 
any significant interdisciplinary approach. In literature many plants have been listed 
having immunomodulatory effect and some of them have been proved by using 
modem scientific methodologies. These plants include Allium sativum (Lahsun), Aloe 
Vera (Gharita Kumari), Andrographis paniculata (kirayat). Asparagus racemose 
(satawar), Azadirachta indica (neem). Curcuma longa (haldi), Ocimum sanctum 
(Tulsi), Panax ginseng (ginseng), Phyllanthus emblica (amla), Pichrorhiza kurroa 
(kutali), Tinospora cordifolia (giloe) and Withania somnifera (ashwagandha) etc. 
9. Picrorhiza kurroa 
Picrorhiza kurroa is a well-known herb in the Ayurvedic system of medicine and has 
traditionally been used to treat disorders of the liver and upper respiratory tract, 
reduce fevers, and to treat dyspepsia^ chronic diarrhea, and scorpion sting. It is a small 
perennial herb from the Scrophulariaceae family, found in the Himalayan region 
growing at elevations of 3,000-5,000 meters. Picrorhiza kurroa has a long, creeping 
rootstock that is bitter in taste, and grows in rock crevices and moist, sandy soil. The 
leaves of the plant are flat, oval, and sharply serrated. The flowers, which appear in 
June through August, are white or pale purple and borne on a tall spike, manual 
harvesting of the plant takes place from October to December. The active constituents 
are obtained from the root and rhizomes. The plant is self-regenerating but 
unregulated over-harvesting has caused it to be threatened to near extinction. Current 
research on Picrorhiza kurroa has focused on its hepatoprotective, anticholestatic. 
antioxidant, and immune-modulating activity (Atal et al 1986, Subedi 2000). 
9.1. Active Constituents 
Kutkin is the active principal of Picrorhiza kurroa and is comprised of kutkoside and 
the iridoid glycoside picrosides 1, II, and III. Other identified active constituents are 
apocynin, drosin, and nine cucurbitacin glycosides (Weinges et al, Stuppner H and 
Wagner H 1989). Apocynin is a catechol that has been SIIOVVTI to inhibit neutrophil 
oxidative burst in addition to being a powerful anti-inflammator>' agent, (Simons et al 
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1990) while the curcubitacin has been shown to be highly cytotoxic and possess 
antitumor effects (Stuppner H and Wagner H 1989). 
9.2. Mechanisms of Action 
The hepatoprotective action of Picrorhiza kurroa is not fully understood but may be 
attributed to Picrorhiza's ability to inhibit the generation of oxygen anions and to 
scavenge free radicals (Russo et cil 2001). Picrorhiza's antioxidant effect has been 
shown to be similar to that of superoxide dismutase, metal-ion chelators, and xanthine 
oxidase inhibitors (Chander et al 1992). In malaria infected rats, Picrorhiza restored 
depleted glutathione levels, thereby enhancing detoxification and antioxidation, and 
helping maintain a normal oxidation-reduction balance (Chander et al 1992). In tliis 
same animal model, Picrorhiza also demonstrated an anti-lipid peroxidative effect 
(Chader et al 1998). Like silymarin, Picrorhiza has been shown to stimulate liver 
regeneration in rats, possibly via stimulation of nucleic acid and protein synthesis. 
(Singh et al 1992). Picrorhiza's anti-inflammatory action is attributed to the apocynin 
constituent, which has been shown to have potent aiiti-inflammatoiy properties in 
addition to inhibiting oxidative burst in neutrophils (Simons et al 1990). Although the 
mechanism is unclear, animal studies indicate Picrorhiza's constituents exhibit a 
strong anticholestatic activity against a variety of liver-toxic substances, appearing to 
be even more potent than silymarin. Picrorhiza also exhibits a dose-dependent 
choleretic activity, evidenced by an increase in bile salts and acids, and bile flow. 
(Shuklat'/al 1991). 
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1. Introduction: 
The protein antigens delivered to APCs, normally undergo processing within the 
endosomes to produce the peptides that bind to MHC class-II molecules. The MHC II 
processing and presentation of the antigen results in the activation of CD4^ T cells 
(Unanue and Allen 1988, Braciale et al 1987). On the other hand, CD8* T cell responses 
can be elicited by the endogenous antigens, which are processed within the cytosol and 
produce peptides, which bind to MHC-I molecules (Braciale et al 1987). Nevertheless, 
exogenous antigen can also enter the class I processing pathway, if it is delivered in a 
vehicle that can fuse either with the plasma membrane under normal physiological 
conditions or with the endosomal membrane at low pH (Braciale et al 1987, Hayashi et al 
1999, Fukusawa et al 1998, Harding e/ a/ 1991, Reddy et al 1991). Since both cytotoxic 
as well as T-helper cells are crucial for protecting the host against intracellular pathogens 
to mount an effective immunity against such infections, it is important to develop 
vaccines that generate strong CD4* and CD8^ T-cell responses (Tarleton et al 1992, Flynn 
et al 1992, Bottomlyl988). In our previous study, we isolated the fusogenic lipids from 
yeast cells and utilized them for the first time to prepare liposomes (Owais and Gupta 
2000). We demonstrated that the yeast lipid liposomes very effectively fuse with the 
membrane of macrophages. In the present report we established that antigen encapsulated 
in the liposomes could be readily introduced into the cytoplasmic as well as endosomal 
compartments of the target cells. Moreover, these studies have revealed that antigen 
entrapped in these liposomes could generate strong OVA-specific, CD4^ T helper as well 
as CD8* cytotoxic T cells. The T-helper response was chiefly of Th-2 type, as evidenced 
by the secretion of interleukin (IL)-4 and immunglobulin (Ig) Gl- isotype (Stevens et al 
1988). On the contrary, the same antigen after encapsulation in egg PC liposomes was 
able to induce humoral immune response mainly. 
2. Materials and Methods: 
2.\. Animals 
Inbred female BALB/c mice (6- 8 weeks-old), of 20± 2 gm weight were obtained from 
the institutes animal house facility. 
2.2. Chemicals and Reagents 
Egg phosphatidyl choline (EPC) was isolated and purified using the standard method 
(Singleton et al 1965). Cholesterol (chol) was purchased from Centron Research 
Laboratory, Mumbai, India. Ovalbumin (OVA) was from Sigma Chemical Company (St. 
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Louis, MO, USA). Antibodies to IL-2 (HB 8794), IL-2 receptors (CRL 1698 and TIB 
222), I Ad (MKD6), Mac 2 q 2001 Blackwell Science Ltd (TIB 166), L3T4 (GK1.5), lyt 
2.2 (TIB 210) and IL-4 (I IBl 1) were used as culture supematants of the hybridomas. The 
P815 cells, an MHC matched (H-2d) mastocytoma cell line, EL-4 cells, an MHC 
disparate (H-2b) lymphoma cell line, HT-2 cell line (CRL-1841) and hybridomas used in 
the study were procured from ATCC (Rockville, MD, USA). ['H]-thymidine and [ '^Cr] 
sodium-chromate were bought from Bhabha Atomic Research Center, Mumbai, India. 
2.3. S. cerevisiae lipid 
S. cerevisiae was procured from MTCC, Chandigarh and cultured in YPD (yeast extract, 
peptone and dextrose) medium. The cells were harvested from mid log phase (18-20h) 
and phospholipids were isolated by the method of Bligh & Dyer as modified in our lab. 
Briefly, cell suspension was treated with 2:1 chloroform and methanol mixture to extract 
lipid. Subsequently, the organic phase was extensively washed with normal saline and 
evaporated under vaccum to finally isolate S. cerevisiae lipid (Owais and Gupta 2000). 
The protein entrapped in the liposomes was estimated as described elsewhere (Owais and 
Gupta 2000). 
2.4. Preparation of liposomes 
DRVs were prepared using published procedure as standardized in our lab (Suss and Pink 
1992). Briefly, EPC/Chol (2:1 molar ratio, total lipid 20mg) or S. cerevisiae membrane 
lipid (20 mg) were reduced to thin dry film in clean round bottomed flask. The dried lipid 
film was hydrated with pyrogen free normal saline and sonicated in a bath type sonicator 
for 2 h at 4 '^ C under nitrogen atmosphere. The vesicles thus formed were mixed with 
equal volume of OVA (20mg/ml) solution. The mixture was flash frozen and thawed 
(three cycles) followed by the lyophilization. The free flowing, dried power obtained was 
rehydrated with distilled water (120fal) and finally reconstituted with PBS. The 
preparation was washed at least three times with PBS to remove traces of un-entrapped 
protein. 
2.5. Estimation of protein content in Liposomes 
Prepared vesicular formulations were separated from the free (unentrapped) antigen by 
pelleting at lOOOOg for 5 min. The washing was repeated thrice with a fresh phosphate 
buffer saline (pH 7.4) to accomplish complete removal of free form of antigen. To 
determine the protein content, an aliquot of vesicular fraction was mixed with minimum 
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amount of triton X-100 (0.5%, w/v) to disrupt the vesicles and released protein (antigen) 
was estimated using a BCA (bicinchonic acid) protein assay. The protein concentration 
was calculated using a standard curve of OVA plotted in the presence of Triton X-100. 
2.6. Immunization 
The immunological studies were performed in inbred female BALB/c mice. Each group 
was consisted of five animals. The animals were immunized with different preparations 
(free OVA or entrapped in liposomes) of antigen on various days. The following 
immunizing schedules were adapted for administration of OVA into the animals, for 
different immunological studies. 
2.7. Cell Preparation 
(a) CDS* T cells: Different groups of BALB/c mice were injected separately, through an 
intravenous route, with a total of three doses (day 0, 7, and 14) of free OVA, OVA 
encapsulated in egg PC/chol or yeast lipids liposomes and also with free OVA mixed with 
empty liposomes [100 ng OVA (which correspond to 500 nmoles of lipid)/animal/week] 
for 3 weeks. On day 21, the animals (five animals each group) were sacrificed and spleens 
were removed aseptically. The cells were prepared as described elsewhere (Mishell and 
Shiigi 1980). The cells obtained from different animals in a given group were pooled, 
purified and used in cytotoxicity assay. The enriched population stained with anti-CD8 
antibodies (Ab), was 98 % pure, as evaluated by FACScan. 
(b) CD4*T cells: Animals were immunized with single dose of free OVA, OVA 
encapsulated in egg PC/chol or yeast-lipid liposomes (100 ng OVA/anima!) through 
intravenous route. On day 7, the animals (five animals each group) were sacrificed and 
their spleens were removed aseptically and CD4* T cells were isolated as described 
elsewhere (Mishell and Shiigi 1980). For lymphokine assay experiments, the animals 
were immunized intravenously using two different immunizing schedules. In one set, the 
animals (five animals each group) were immunized with single dose of OVA (100 ng 
OVA/animal), while in another set, the animal were immunized with total three doses of 
OVA (100 ng OVA per animal, on day 0, 7, and 14). On day 21, the animals were 
sacrificed and CD4"^  T cells were isolated as described above. The enriched population of 
CD4'' T cells was stained with anti-CD4 and CD3 Abs and the purity was 98%, as 
revealed by FACScan. 
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2.8. CD8^T lymphocyte response 
(a) Target cell: BALB/c mice were injected with thioglycollate broth. On day 4, the 
macrophages were isolated from the peritoneal exudate cells (PEC) by adherence on Petri 
plates. The harvested cells (2 X 10^  cells/ml) were washed 3 times with Hank's balanced 
salt solution (HBSS) and incubated at 37 °C for 3±4 h with either free OVA, OVA 
entrapped in egg PC/chol or encapsulated in yeast-lipid liposomes. The cells were again 
washed 3 times to remove free antigen. This was followed by incubation with Cr (100 
mCi/ 2 XIO^ cells) for 45±60 min at 37 °C. The cells were finally washed with RPMI 
solution and were used as target cells. 
(b) Cytotoxicity assay: The '^Cr-labelled macrophages/P815 cells (5 XlO'/well) were 
used as target cells. The antigen primed target cells were incubated with CDS"^  T cells 
(effector cells isolated from the spleen of the five mice were pooled, and used for assay) 
at an effector to target (E/T) ratios of 2.5 : 1±20 : 1. The cells were incubated at 37 °C for 
6 h, after completion of incubation period, the cells were pelleted at 3000 X g (15 min at 
5 °C), and the amount of ^'Cr released was determined by measuring the radioactivity in 
the supernatant. The experiments were performed three times and the error bars represent 
standard deviation of the means from three different experiments. 
The total Cr release was calculated by treating an aliquot of the target cells with Triton X-
100 (10 % final concentration). The spontaneous release of ^'Cr in the supernatant was 
determined by incubating the labeled macrophages for 6 h. An amount of auto-release 
was subtracted from the total release to determine the extent of macrophage lysis. In most 
of the experiments, the auto-release was less than 25 %. The percentage specific release 
was calculated as the (mean sample cpm-mean spontaneous cpm/ mean maximum cpm-
mean spontaneous cpm) XI00%. 
2.9. CD4^ T-cell proliferation 
The CD4* T cells (2 XloVwell) obtained from pool of the splenic cells of five mice from 
different groups were cultured in triplicate wells. The cells were incubated with 
macrophages (6 X10''/well) pulsed with different doses (0.001±100 ng/ml) of free OVA 
or encapsulated in egg PC/chol or yeast lipid liposomes. The macrophages were treated 
with mitomycin C (50 |ig/ml). The cultures were incubated for 72 h at 37 °C/7 % CO2. 
The cells were pulsed with 1.0 nCi [^H]-thymidine for 16 h before harvesting with an 
automatic cell harvester (Skatron, Tranby, Norway). The [^H]-thymidine incorporation 
was measured by a standard liquid scintillation counting method. The results are 
expressed as mean cpm of triplicate cultures. 
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2.10. Lyntphokine assays 
The cultures were set up as described for Th cell proliferation. The supematants were 
collected after 48 h for estimation of IL-2, IL-4 and interferon (IFN)-y levels. The IL-2 
and IL-4 were assayed using the HT-2 cell line, while IFN- y was estimated by its ability 
to inhibit the proliferation of WEHI-279 cells (Agrewala et al 1998). The lymphokines 
data were expressed as pg/ml in the culture supematants as computed by comparison with 
the standard curve plotted using r IL- 2/rIL-4 and rIFN- y (Genzyme, Cambridge, MA, 
USA). 
2.11. Determination ofOVA-specific IgGisotypes by ELISA. 
The production of OVA-specific antibodies was measured in the sera of the different 
groups of mice. The animals were injected, intravenously, with two doses of free OVA, 
OVA entrapped in the egg PC/chol or yeast lipid liposomes (100 ^g OVA/animal) on day 
0 and 7, and bled on day 14 to monitor the presence of antibodies as described earlier 
(Agrewala et al 1998). Briefly, 96 well microtitre plate was incubated overnight with 50 
Hl of OVA (25 ng/ml) in carbonate-bicarbonate buffer (0.05 M, pH 9.6) at 4 °C. After the 
usual washing and blocking steps the plate was finally incubated with 1: 500 dilutions of 
test and control sera at 37 °C for 2 h. After excessive washing of the plate, it was further 
incubated with 50 yA of biotinylated goat antimouse IgGl and IgG2a antibodies. The plate 
was incubated at 37 ''C for 1 h. After the usual washing steps, 50 i^l of streptavidin-HRP 
were added to each well and the plate was incubated at 37 °C for 1 h. The plate was 
washed again before adding 50 \i\ ABTS (Sigma) and was finally incubated at 37 "C for 
20 min. The reaction was terminated by the addition of 50 ^l of 70 % H2SO4. The 
absorbance was read at 492 nm with a microtitre plate reader (Eurogenetics, Torino, 
Italy). 
2.12. Statistical analysis: 
The data were analyzed by one-way analysis of variance (anova) following Dunnet's t-test 
method. P < 0.05 was considered statistically significant. 
3. Results: 
3.1. Delivery of the antigen entrapped in the fusogenic yeast-lipid liposomes elicits 
effective immune response 
CDS T-lymphocyte response: Since our preliminary experiments demonstrated that the 
yeast-lipids liposomes possess a strong fusogenic character, the protein entrapped in 
It was found that a dose of 100 fig per animal induced cytotoxic T lympocyte (CTL) 
response, which generated 30±40% target lysis at an effector to target ratio of 10 : 1 (data 
not shown). This dose was selected for subsequent studies performed for '^Cr release 
assay. Interestingly, immunization with OVA entrapped in the yeast-Iipid liposomes, but 
not other forms of OVA viz. free OVA or OVA entrapped in egg PC/chol liposomes and 
free OVA mixed with yeast-Iipid empty liposomes (sham liposomes), generated cytotoxic 
T cells. A considerably high degree (30±40%) of macrophage lysis occurred when the 
OVA was encapsulated in the yeast-Iipid liposomes, as compared to less than 1% specific 
lysis in free OVA or OVA incorporated into the egg PC/chol liposomes or sham yeast-
Iipid liposomes (P , 0.001) (Fig. lA). We also found concentration optima for antigen 
(Fig. IB) for percentage specific lysis of the target cells. Results shown in Fig. 2(A) 
confirm the phenotype of the effector cells. The pretreatment of the purified effector cells 
with anti-CD8"^  antibodies, followed by treatment with baby rabbit complement, 
abolished target cell lysis. We further demonstrated that macrophages, primed with free 
or egg PC liposomes encapsulated OVA, can not act as target cells (Fig. 2B). The effector 
cells, obtained from the animals immunized with yeast lipid liposomes, were allowed to 
incubate with the target cells, which were primed with different forms of OVA, i.e. the 
free OVA, OVA encapsulated either in egg PC liposomes or yeast liposomes. The ^'Cr 
release assay shows that OVA-specific CTL successfully distinguished the target cells, 
which were incubated with yeast lipid liposomes for antigen presentation, however, egg 
PC liposomes pulsed target cells were not recognized by the same CTLs (P<0.001). The 
results discussed in Table 1 demonstrated that, beside macrophages, yeast lipid induced 
effector cells can lyse other target cells with equal propensity. However, the recognition 
of target cells is confined to the MHC compatible cells only, thus, effector cells were able 
to induce lysis of P815, an MHC matched (H-2d) mastocytoma cells, while allogenic EL-
4 cells (H-2b) were not recognized at all by the same effector cells. 
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Fig 1. (A) Induction of antigen specific cytotoxic T lympocyte (CTL) activity by 
immunization with yeast lipid liposomes containing different forms of ovalbumin 
(OVA). 
The BALB/c mice were immunized with saline (D) Sham yeast liposomes (Sham 
YL)(0); Free OVA (^) ; yeast liposomes mixed with OVA (YL + OVA) ( • ) ; OVA 
encapsulated in Egg PC liposomes (PC-OVA) (• ) and OVA encapsulated in yeast 
liposomes (YL-OVA) (-»-), as described in Materials and Methods. The effector cells 
were isolated from the spleen of five mice, belonging to the different groups above. The 
cells were pooled, purified and used for target cell lysis assay. The target cells 
(macrophages) were pulsed with saline, Sham ES, Free OVA, Yeast liposomes mixed 
with OVA (YL + OVA), OVA encapsulated in Egg PC liposomes (PC-LIP-OVA) and 
OVA encapsulated in YL liposomes (YL-LIP-OVA), respectively (30 mg OVA/2 XIO^ 
cells), and labelled with ^'Cr. The lytic activity was measured by the incubation of 
suitable effector cells with target cells (primed with matching formulation of OVA). The 
results are represented as, percent specific lysis ( '^Cr release) of the target cells. Each 
value represents the mean of three determinations S.D. Data are representative of five 
independent experiments performed with similar results. 
(B) Dose response of antigen on the induction of target cell lysis. 
The macrophages were sensitized with different concentrations of free OVA, OVA 
loaded in either egg PC/chol liposomes (PC-OVA) or yeast lipids liposomes (YL-OVA) 
and then incubated with OVA reactive CD8^ T lymphocytes isolated from the animals 
immunized with OVA, PC-OVA, and YL-OVA, respectively. The E/T ratio was 10 : 1. In 
the case of control wells, target cells incubated with effector cells (OVA reactive CD8* T 
cells) in the absence of antigen or with sham liposomes (no antigen), YL mixed with 
OVA and unrelated antigen (lysozyme entrapped in yeast lipids liposomes), there was not 
more than 2% of ^'Cr release. Values represent the mean of three determinafions ±S.D. 
The experiment was performed three times with similar results. 
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Fig. 2. (A) OVA encapsulated in yeast lipid liposome can induce T lymphocytes with 
CD8* phenotype. 
Effector cells obtained from the OVA (encapsulated in yeast liposomes) primed animals 
were pretreated with anti-CD4* or anti-CD8* monoclonal antibodies (MoAbs) followed 
by incubation with baby rabbit complement. The effector cells were incubated with 
peptide pulsed, ^'Cr loaded target cells. The lysis of the target cells was measured by ^'Cr 
release assay. Anti-CD8 ^antibody pretreatment (•) ; anti-CD4* antibody pretreatment 
( • ),Pretreatment with complement alone (O); and no pretreatment {ZS). Values are 
mean of three determinations ± S.D. Data are representative of five different experiments 
with similar results. 
(B) Yeast liposomes provide an efficient means of sensitizing target cells to class I 
restricted CTL recognition. 
BALB/c mice were immunized with OVA encapsulated in yeast liposomes. Cytotoxic T 
cells from the spleen of five mice were pooled, and used as effector cells for cytotoxic 
assay. The target cells were primed with various formulations of OVA viz. free OVA ( • 
); OVA encapsulated in egg PC liposomes ( \ / ) ; and OVA encapsulated in yeast lipid 
liposomes ( • ) and incubated with effector cells, isolated from YL-OVA treated animals 
(at the effector to target ratio of 10 : 1). The lysis of the target cells was measured by ^'Cr 
release assay. Data are mean of three determinations ± S.D. 
CD4*^ T-celi response: Antigen entrapped in the yeast-lipid liposomes enhances CEM"^  T 
cells proliferation. The T cells of the mice immunized with antigen encapsulated in the 
yeast-lipid liposomes induced significantly higher proliferation as compared to T cells 
obtained from animals immunized with egg PC/chol liposomes (Fig. 3). T-cell 
responsiveness to antigen was observed in a dose-dependent manner. Control cultures 
containing cells obtained from either OVA-immunized animals or the groups immunized 
with PBS or fusogenic lipids only (sham liposomes with no OVA), gave background 
levels of 2000 cpm of 3Hthymidine incorporation. 
3.2. Antigen encapsulated into yeast-lipid liposomes predominantly enhances the 
production ofIL-4. 
The animals immunized with single dose of antigen encapsulated in the yeast-lipid 
liposomes showed significantly higher levels of IL-4 (512 pg/ml) as compared to animals 
inoculated with egg PC liposomes (216 pg/ml) (Fig. 4A). In contrast, only marginal 
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secretions of lL-2 and IFN-y were observed when yeast-lipid liposomes (26 pg/ml IL-2, 
20.27 pg/ml IFN-y) and egg PC/chol liposomes (12.4 pg/ml IL-2, 15.69 pg/ml IFN-g) 
were used for immunization (Fig. 4B,C). No detectable amount of lymphokines was 
observed in the case of control animals inoculated either with PBS, sham egg PC/chol or 
yeast-lipid liposomes alone (no antigen). However, the animals which were boosted three 
times with YL liposomes demonstrated a substantial increase in the IL-2 and IFN-g level, 
while the IL- 4 level had decreased to some extent (Fig. 4). 
Table 1. Antigen specificity and MHC restriction of the OVA specific cytotoxic T 
lymphocytes 
Targets Treatment Specific lysis (%) 
P815 None 0.45 ±0.12 
P815 Free OVA 0.30 ±0.10 
P815 ShamYL* 0.48 ±0.13 
P8I5 YL + OVA^ 0.54 ±0.09 
P8I5 PC-OVA 0.78 ±0.20 
P815 YL-OVA' 38.5 ±2.20 
P815 YL-Lysozyme 0.65 ± 0.15 
EL-4 Free OVA 0.52 ±0.10 
EL-4 PC-OVA 0.65 ±0.18 
EL-4 YL-OVA 0.42 ± 0.08 
EL-4 YL-Lysozyme 0.42 ±0.10 
The BALB/c mice were immunized with yeast liposome encapsulated OVA, and effector 
cells were isolated and purified as described in the text. The MHC restriction as well as 
antigen specificity of the generated CTLs was demonstrated by ^'Cr release assay. The 
target cells, P815 (H-2d) and EL-4 (H-2b) were pulsed with different forms of OVA and 
lysozyme (an unrelated antigen) followed by ^'Cr labelling, as described in Materials and 
Methods. The antigen primed target cells were incubated with effector cells at effector to 
target ratio of 10 : 1. Each value represents mean of three determinations ± SD. The 
experiment was performed four times with similar results.* Liposome without antigen; 
^yeast liposome simply mixed with OVA; 'OVA encapsulated in yeast liposomes. 
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Fig. 3. Antigen incorporated in yeast-lipid-liposomes augmented the proliferation of 
OVA-specific Th cells. CD4^ T cells (2 X lO /^well) were isolated fix)in the groups of five 
animals immunized with OVA encapsulated either in yeast-lipid-liposomes (YL-OVA) or 
egg-PC/chol liposomes (PC-OVA) and cultured with the OVA, YL-OVA and PC-OVA 
pulsed macrophages (6 XIO'* cells/well). After 72 h, [^H]-thymidine was added, and its 
incorporation was measured 16 h later by liquid scintillation spectroscopy. The control 
cultures consisting of Th cells + medium (no OVA), macrophages + medium, Th cells + 
yeast lipid sham liposomes (no OVA), medium ITh cells obtained from the animals 
immunized with placebo (phosphate-buffered saline) showed 2000 cpm. The data 
represents mean cpm of three determinations ±S.D. The experiment was repeated four 
times with similar results. 
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Fig. 4. The cultures were set as mentioned in tlie legend to Fig. 3. The levels of different 
lymphokines were monitored in the following manner. (A) The interleukin (IL)-2 content 
in culture SN was measured by its ability to induce the proliferation of HT-2 cells. The 
cells were incubated in 96 well plate (I X lOVwell) in the presence of culture SNs 
(treated with anti lL-4 antibody [ l lBl l , 1 mg/ml] to block IL-4), for 16 h at 37 8C, 
pulsed with 0.5 |xCi [3H]-thymidine and harvested 8 h later. The thymidine incorporation 
was measured by liquid scintillation spectrometry. The lL-2 content was computed from 
standard plot of rlL-2, and expressed as pg/ml. 
(B) The IL-4 content was determined using same method as for that of IL-2, except that 
here, IL-2 was neutralized by anti-IL-2 MoAb (cocktail of 1:12 dilution of culture SN of 
CRL 1698, HB 8794 and TIB 222). The proliferation of HT-2 was assayed in similar 
manner and data were computed with the standard plot of rIL-4. All data were calculated 
from the mean cpm of triplicate observations and expressed as pg/ml ± S.D., after back 
calculation. (C) The secretion of IFN-g was measured by its ability to inhibit the 
proliferation of WEHI-279 cells. The data are computed in manner similar to that of IL-2, 
and represented as mean of triplicate observations ±S.D. Data are representative of three 
different experiments performed with similar results. 
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Fig 5. Yeast lipids liposomes increase the secretion of IgGl isotype. 
The BALB/c animals were immunized with different preparations of OVA as described in 
Materials and Methods. Sera (1 : 500 dilution) obtained from the control and 
experimental animals were analyzed for the presence of OVA-specific IgG isotype by the 
ELISA method as described in Materials and Methods. The levels of the two major 
isotypes of IgGs were expressed as absorbance (A492) of the coloured complex 
developed in the immunosorbent assay. The values expressed are the mean of the 
absorbance of the sera of five different animals ±S.D. The control animals immunized 
with phosphate-bufiTered saline (PBS), free OVA or sham liposomes (no antigen), could 
not induce any detectable level of IgG isotype. 
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3.3. Humoral immune response 
Enhancement of the secretion of IgGl isotype by immunizing the animals with the 
antigen encapsulated in the liposomes of the fiisogenic lipids derived from yeast. The 
significant increase in the level of antibodies was detected in sera of the animals, which 
were primed with OVA entrapped in the yeast-lipidliposomes as compared to the animals, 
inoculated with egg PC/ chol liposomes (Fig. 5). However, mainly IgGl antibodies were 
generated in both the cases, while the IgG2a type of antibody were induced to lesser 
extent only (P < 0.05). No IgGl and IgG2a isotypes were detected in the control group of 
mice injected with either sham yeast-lipid/egg PC/chol liposomes (no antigen) or PBS. 
4. Discussion 
Protective immunity against intracellular pathogens (e.g.tuberculosis, leprosy, 
leishmaniasis, malaria, viruses, etc.) and cancer is considered to be controlled essentially 
by cellmediated immunity. The important role of CD4^ and CD8* T lymphocytes has 
been suggested by several studies of murine and human infections (Flynn et al 1992, 
Bottomlyl988, Sasiain et al 1998, Malik et al 1993). The majority of the vaccines 
available to date, mainly induce the humoral immune responses, conversely the 
generation of cytotoxic T cells always remains a major uphill task against most of the 
infections. Earlier investigators have attempted the use of virosomes as well as pH-
sensitive liposomes for delivery of protein antigens into the cytosol (Harding et al 1991, 
Reddy etal \99l, Alving et al 1995, Poltl- Frank et al 1999). Nevertheless, such vehicles 
proved to be toxic to the host and were additionally not simple to prepare, and were thus 
restricting their use as a vehicle to deliver the newer generation of vaccines against 
intracellular infections. We have shown eariier that the antigen incorporated into 
liposomes results in the increased production of IL-4 but not IFN-y (Agrewala et al 
1996). In another report, we recently demonstrated that yeast liposomes can readily 
deliver their contents to cytosol of the APCs (Owais and Gupta 2000). In the present 
study, we considered it to be of interest to exploit the inherent membrane±membrane 
fusion tendency of yeast lipids in the development of liposome-based vaccines. The 
antigen encapsulated in liposome was allowed to interact with the APCs. The following 
four major findings have emerged from the study. Firstly, the antigen entrapped in the 
yeast-lipid vehicles effectively delivers the contents into the class I and class II antigen 
processing pathways; secondly, the effector CD8* cytotoxic T cells were stimulated; 
thirdly, CD4'^  T-helper cells, predominantly of Th2 phenotype, were ^cncrsiC d; fourthly, 
a predominant secretion of IgGl isotype was observed. The results of the present study 
demonstrate that the immunogenicity of OVA is controlled by the nature of adjuvant/ 
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antigen carrier used for immunization (Fig. lA). While the antigen entrapped in the yeast 
lipid liposomes elicits antigen specific CTL generation, other forms of antigen, e.g. OVA 
entrapped in egg PC liposomes fail to do so. Furthermore, the processing and presentation 
depends on the mode of the antigen delivery, as evident from our results that OVA 
specific CTLs, obtained from animals immunized with yeast liposomes, can induce lysis 
of target cells which were primed in vitro with yeast liposomes. The same effector cells 
do not lyse target cells, which were primed in vitro with egg PC liposomes or free OVA 
(Fig. 2B). In other words, these experiments prove that target cells primed with OVA 
encapsulated in egg PC liposomes can not be recognized by effector cells, i.e. OVA 
specific CTLs isolated from mice immunized with OVA encapsulated in yeast liposomes. 
One can argue that macrophages can not be ideal APCs for determining the lytic activity 
of the CTLs, especially for conventional egg PC liposomes. In order to rule this 
possibility out, we repeated the same study using dendritic as well as syngenic P815 cells 
as APCs for performing the CTL assay. We found that the OVA-YL primed P815 cell, in 
manner similar to macrophages, can be specifically lysed by the OVA specific effector 
cells. These results also demonstrate the MHC-resticted lysis of the target cells, as MHC 
mismatched allogenic targets (EL-4 cells) were not identified by same effector cells. 
Furthermore, the CTL response was antigen specific, as the target cells which were 
primed with lysozyme (an unrelated antigen) were not recognized by the OVA specific 
CTLs (Table l).To confirm the phenotype of the effector cells, these were pretreated with 
anti CDS* antibodies, before using them for ^'Cr release assay. The result shows that such 
pretreatment abolish CTL response, which confirms the CDS"^  phenotype of the generated 
T lymphocytes (Fig. 2A). Typical of the effector cell mediated target lysis, the "Cr 
release assay depends on the concentration of antigen, used for the in vitro antigen 
presentation (Fig. IB). Moreover, the results of the present study, in conformity with the 
earlier reports, show that endocytosis of the antigen and generation of CD8* T-cell 
response is the only predominant mode, when egg PC liposomes interacts with the APC 
(Braciale et al 1987, harding et al 1991, Reddy et al 1991). In contrast, the yeast lipid 
liposomes appear to interact with the target cells by both endocytosis as well as 
membrane fusion mode. Thus, this helps in the activation of not only CD4* Thelper cells 
but also CDS"^  cytotoxic T cells. It is worth to mention here that the 004"^ T cell 
proliferative responses generated using the yeast lipids liposomes were better than those 
observed with the egg PC liposomes. Both the CD4^ T cell and CD8^ T-cell responses 
seem to be required for an effective control of the intracellular parasitic infections. 
Current evidence suggests that in addition to T helper cells that activate macrophages, in 
fact, it is primarily the T-cytotoxic cells, which play crucial role in the protection. Even 
though, optimum levels of CD4* T-cell response were generated, yet the disease develops 
in the absence of CTL cells (Tarieton et al 1992, Flynn et al 1992). Thus, encapsulation 
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of the protective antigens in the yeast hpids liposomes may elicit strong CTL response 
that may be necessary for protection against intracellular infections. Furthermore, the use 
of yeast liposomes leads to the generation of Th 2 cells and CTLs. Th2 cells are known to 
provide help to B cells leading to the production of antibodies, while Thl cells are crucial 
for the activation of the CTLs (Stevens et al 1988). The Thl/Th2 shift is crucial to the 
effective immunity and it is likely that many interlocking factors will contribute to that 
decision (Bottomly 1988). The yeast liposome mediated strong CTL generation, in spite 
of the observed polarization of the CD4*T-cell response in favour of the Th2 cells that 
can be attributed to the physical targeting of the entrapped antigen to the cytosol of the 
APCs. The yeast liposomes like other particulate substances are avidly endocytosed by 
APCs and activate CD4* T cell. However, it can not be excluded that in addition to the 
endocytosis, a substantial portion of the entrapped antigen is delivered to the cytosol of 
the target cells, and form the basis of the observed antigen specific CTL response. The 
peculiar behaviour of the yeast lipid liposome based delivery system, might function in a 
way that could be a more desirable feature in activation of both cell mediated as well as 
humoral immune responses. Such a strategy could be appropriate for elimination of virus 
mediated infections. It is a well known fact that both CTLs and the neutralizing 
antibodies are essential for imparting protective immunity against the viruses as well as 
other pathogens (Tarleton et al 1992, Flynn et al 1992, Siegrist et al 1999, Mo et al 
1997). It may be inferred from our study that the lipids derived from S. cerevisiae possess 
a strong fusogenic character. The yeast lipid liposomes can effectively deliver antigen 
into the class I and class II processing compartments of APCs and consequently 
generating a strong antigen-specific CDS"^  (cytotoxic) and CD4'^ (helper) T cells. Such 
considerations, which could selectively enhance the CTL and the T-helper cells are 
pertinent in designing liposomes-based vaccines, and will hence subserve in the 
protection against infectious diseases. 
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1. Introduction: 
Malaria is one of the major public health problems with significant economic and 
social consequences for many developing countries (WHO 1997). In fact majority of 
the deaths involving children, under the age of 5 years, have been linked with one or 
other form of the disease. Global incidences of the malaria range from 300 to 500 
million cases per year, while 2 to 3 million are succumbing to deaths (Cohen 1994). 
Despite many preventive efforts, morbidity and mortality continue to rise. Ironically, 
chemotherapy and vector control programs against this dreadful disease are not 
adequate due to the emergence and spread of insecticide - resistant mosquito vectors 
and drug resistant Plasmodium sps. Keeping in to consideration non-effectiveness of 
chemotherapy, it is always imperative to deal this problem by developing prophylactic 
measures using effective vaccines. Interestingly, the complexity of the immune 
response against Plasmodia sps offers a better scope to understand the strategies 
required for protection against deadly parasite. It is well established that resistance to 
malaria as well as other severe complications of the disease develop with age. In fact, 
some adults living in endemic areas may not exhibit clinical manifestation of malaria 
even when circulating blood parasites are present (Day and Marsh 1991). It clearly 
suggests that sustained antigen delivery, stimulation of immune system and antibody 
production are crucial in maintaining this anti-disease state. 
An effective immunization protocol involves identification of immunogenic protein as 
well as suitable adjuvant/ antigen vehicle to achieve desirable immune responses. 
Most of the adjuvant evaluated for their ability to induce protective immune responses 
against blood stage crude antigens of Plasmodium yoelii infection provided only a 
limited activation of protective immune responses (Hunter et al 1995, McColm et al 
1982, Playfair et al 1997, Playfair et al 1987). For example, the commonly used 
adjuvant alum is not always the most appropriate adjuvant, as it stimulates a Th 2 type 
immune response in the immunized subjects (Davis et al 1998). 
Protection against intracellular pathogens including P. yoelii is generally dependent 
on Thl type immune responses however, protective immunity against blood-stage 
malaria is complex and requires a concerted effort by Thl type cellular immune 
response and Th -2 mediated humoral immunity (Langhome et al 2002, Mohan and 
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Stevenson 1998). Rodent studies have revealed a role for CD4^ T lymphocytes, B 
cells, as well as antigen specific antibody in mediating naturally induced immunity 
against primary blood-stage P.yoelii infection (Langhome et al 2002, Mohan and 
Stevenson 1998). 
We have earlier shown that liposomes made of lipids isolated from Saccharomyces 
cerevisiae (bakers yeast) have strong tendency to fuse with plasma membrane of 
target cells including professional antigen presenting cells and thereby delivering the 
entrapped contents into their cytosol (Gupta and Owais 2000). The yeast lipid 
liposome (saccharosomes) mediated delivery of antigens ensued in the activation of 
antigen specific humoral as well as cellular responses (Owais 2000). 
In the present study, we exploited saccharosome as a malaria parasite antigen delivery 
vehicle by loading them with the blood stage soluble antigens of P.yoelii (sAg) and 
evaluated its adjuvant effect by studying induced protective immune responses in the 
immunized animals. Of the various adjuvant tested, protective immune responses 
were driven primarily by immunization with saccharosome encapsulated antigen 
mainly. While other forms of the antigen (free or egg PC liposome encapsulated) 
failed to impart protective immune response. 
2. Materials and methods: 
2.1. Animals and Experimental infection 
Inbred female BALB/c mice (6- 8 weeks old), of 20± 2 gm weight were obtained 
from the institutes animal house facility. The Plasmodium yoelii nigeriensis MDR 
strain was obtained from Division of parasitolgy. Central Drug Research Institute 
Lucknow. The parasite was fully resistant to chloroquine 128mg/kg x 4 dose and 
quinine 600mg/kg x 4 dose and mefloquine 256mg/kg x 4 doses and was maintained 
in mice by routine passage (Dutta and Pandey 1986). 
Blood stage infection was initiated by intraperitoneal injection of parasitized 
erythrocytes obtained from donor mice. Resulting parasitemia in the infected mice 
were monitored by enumerating parasitized erythrocytes in thin blood smears stained 
with Giemsa stain (Hoffman et al. 1984). Routine screenings were conducted through 
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out the study to ensure that mice were free of infection with common mouse 
pathogens. 
2.2. Chemicals and Reagents 
Egg phosphatidyl choline (EPC) was isolated and purified using the standard method 
(Singleton et al 1965). Cholesterol was purchased from Centron Research laboratory, 
Mumbai, India. [^H]- thymidine was bought from Bhabha Atomic Research Center 
Mumbai, India. Monoclonal anti mouse CD4^ and CD^^, CD80 and CD86 FITC 
conjugates and its purified control (Rat IgG2a isotype) were from Sigma inmiuno 
chemical St. Louis USA. 
2.3. S. cerevisiae lipid 
S. cerevisiae was procured from MTCC, Chandigarh and cultured in YPD (yeast 
extract, peptone and dextrose) medium. The cells were harvested from mid log phase 
(18-20h) and phospholipids were isolated by the method of Bligh & Dyer as modified 
in our lab (Kirby and Gregoriadis 1984). Briefly, cell suspension was treated with 2:1 
chloroform and methanol mixture to extract lipid. Subsequently, the organic phase 
was extensively washed with normal saline and evaporated under vacuimi to finally 
isolate S. cerevisiae lipid. 
2.4. Antigen preparation 
Blood was collected from BALB/c mice infected with P. yoelii (MDR) parasitized 
erythrocyte with average 35 to 40 % parasitemia. The leucocytes were removed by 
passage of blood over microcrystalline column (Alving 1977). The isolated blood 
contained a mixture of ring, trophozoite and schizont- stage parasite as described 
earliar (Sharad et al 2006). The infected RBCs were lysed with 0.01% saponin. Intact 
parasites were resuspended in 10 volumes of 50mM KCl- 5mM MgCb followed by 
10 cycles of rapid freezing and thawing, followed by brief sonication. Soluble antigen 
(sAg) fractions were recovered by centrifugation for 15 min at 2000X^ (4 °C). Of the 
60 mg of total protein obtained in each of these preparations, 50-60% was recovered 
in the soluble fraction. 
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2.5. Preparation of liposomes 
DRVs were prepared using published procedure as standardized in our lab (Suss and 
Pink 1992). Briefly, EPC/Chol (2:1 molar ratio, total lipid 20mg) or S. cerevisiae 
membrane lipid (20 mg) were reduced to thin dry film in clean roimd bottomed flask. 
The dried lipid film was hydrated with pyrogen fi-ee normal saline and sonicated in a 
bath type sonicator for 2 h at 4 °C under nitrogen atmosphere. The vesicles thus 
formed were mixed with equal volume of sAg (20mg/ml) solution. The mixture was 
flash frozen and thawed (three cycles) followed by the lyophilization. The free 
flowing, dried power obtained was rehydrated with distilled water (120nl) and finally 
reconstituted with PBS. The preparation was washed at least three times with PBS to 
remove traces of unentrapped protein. 
2.6. Estimation of protein content in Saccharosomes 
Prepared vesicular formulations were separated from the fi-ee (unentrapped) antigen 
by pelleting at lOOOOg for 5 min. The washing was repeated thrice with a fi^esh 
phosphate buffer saline (pH 7.4) to accomplish complete removal of free form of 
antigen. To determine the protein content, an aliquot of vesicular fraction was mixed 
with minimum amount of triton X-100 (0.5 %, w/v) to disrupt the vesicles and 
released protein (antigen) was estimated using a BCA (bicinchonic acid) protein 
assay and percent entrapment was calculated. 
2.7. Immunization 
BALB/c mice (ten animals per group) were immunized subcutaneously with 100 ng 
of various forms of sAg (free, sAg- IF A, sAg entrapped in EPC liposomes and sAg 
entrapped in saccharaosomes, empty saccharosomes (sham YL) on days 0, 21 and 28. 
For protection studies, BALB/c mice (n=10) were challenged on day 35 post primary 
immunization, intraperitoneally, with 10^  parasitized RBC of P. yoelii nigeriensis 
(MDR) strain. 
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2.8. Immunoblot analysis 
The Plasmodial antigens were subjected to SDS- PAGE (10 %) analysis under 
standard conditions described earlier with minor modification (Laemmli 1970, Mishra 
et al. 1994). For immunoblot analysis, the resolved proteins were electrophoretically 
transferred to nitrocelluse membranes and the assays were performed according to the 
published procedure. Briefly, nitrocellulose strips were blocked overnight in 100 mM 
tns buffered saline, pH 7.6 (TBS), containing 0.1% Tween 20 washed once with 0.05 
% T-20 in TBS (washing buffer) and incubated for the 90 min at 37 °C with the 
mouse sera in the dilution of 1:200 dilution. Further these strips were washed three 
times with TBS-T and incubated with a 1: 1000 dilution of HRP- conjugated goat 
anti-mouse immunoglobulin (Sigma Immunologicals, USA) for 90 min at 37 "C. The 
strips were washed thrice, incubated with substrate (0.3% DAB (Sigma) in PBS with 
0.4% H2O2) till development of color, and finally washed thrice with distilled water. 
2.9. IgG response in immunized mice 
The production of antigen specific total IgG as well as their isotypes were monitored 
in the sera of immunized mice bled on day 35 post first immunization (prior to 
infection) using ELISA method as standardized in our lab (Agrewala et al 1996, 
Agrewala et al 1998). Briefly, ninty six well microtitre plate was incubated overnight 
with 50 jil of crude P. yoelii antigen (25 ng/ml) in carbonate - bicarbonate buffer 
(0.05 M, pH 9.6) at 4 C. After usual steps of washing and blocking, the plate was 
finally incubated with 1:500 dilutions of various experimental as well as pre-immune 
sera at 37 C for two hour. After excessive washing of the plate, it was fiirther 
incubated with 50 \i\ of biotinylated goat anti-mouse IgGl, IgG2a and IgG2b 
antibodies. The plate was incubated at 37 °C for 1 h. After usual washing steps, 50 ^1 
of streptavidin- HRP were added to each well and the plate was incubated at 37 °C for 
1 h. The plate was washed again before adding 50 |J,1 A B T S and was finally incubated 
at 37 C for 20 minutes. The reaction was terminated by the addition of 50 |al of 70 % 
H2SO4. The absorbance was read at 492nm with an ELISA plate reader (Eurogenetics, 
torino, Italy). 
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2.10. Assessment of delayed-type hypersensitivity (DTH) response 
DTH was detennined as an index of cell mediated immunity elicited in the 
immunized animals. The response was evaluated by measuring the difference in the 
foot pad swelling at various time periods after post subcutaneous inoculation of 
various forms of sAg. The increase in footpad thickness of mice was measured in both 
footpads using a digital Vernier caliper. Percentage of increase in footpad thickness 
was calculated as follows: 
Percent increase in footpad thickness = 
left footpad thickness - right foot pad thickness 
XlOO 
nght footpad thickness 
2.11. Isolation of macrophages and macrophage uptake assay 
The PEC (peritoneal exudates cells) was harvested from immunized BALB/c mice as 
described eariier (Sharad et al 2006). The cells were maintained in RPMI (GIBCO 
BRL) supplemented with 10 % Fetal calf serum (Himedia, India) in 5 % CO2 at 37±1 
°C 5x10^ cells/well were plated in a 24 well plate and incubated overnight. After 
incubation, media supernatant was removed; cell monolayers were washed thrice with 
50mM PBS (pH 7.4). 200 ^1 aliquot of liposomal formulation were added to each 
well and plates were incubated again for 30 min. After incubation, cells were washed 
thrice with 50mM PBS (pH 7.4) and observed under a fluorescent microscope (Nikon 
TE2000-U, Japan). 
2.12. Saccharosomes induces reactive oxygen and nitrogen species in the 
immunized animals 
In an attempt to assess the intracellular redox state of macrophages, the cells were 
incubated with DCFDA dye. Cells were seeded on to multi well glass slides at equal 
density (1x10^) and treated with H2DCFDA (lO^iM) for 30 min. 
2.13. Saccharosome mediated induction ofThl/Th2 cytokines 
To assess the effect of saccharosome-sAg mediated immunization on production of 
various cytokines, spleens of the immunized mice were removed aseptically at 
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indicated time periods. Tissue samples were minced and grounded to get primary cell 
culture. Ceil suspension was prepared in RPMI 1640 (Life technologies), 
supplemented with 10 % heat inactivated FCS (Life technologies). Isolated spleen 
cells were cultured by seeding them at density of 2x 10*^  cells per well in 100 |al of the 
medium in 24 well tissue culture plates. The cells were incubated for 48 h at 37 C in 
humidified 5 % CO2 incubator to monitor cytokine production. Culture supematants 
were stored at - 80 °C till further analysis for the presence of cytokine by ELISA 
method. The production of IL-2, IFN-y and IL-4 were measured in triplicate using 
commercial ELISA kits following the manufacturer's instructions. The quantitative 
estimation was done using standard curves obtained for individual cytokines. The 
cultures were harvested at different time points (preliminary experiments), indicated 
that IL-2 is difficult to measure at later time points presumably because of its 
utilization. IFN-y production was estimated 24 hr post harvest. 
2.14. Lymphocyte proliferation assay 
The CD4* T- cells (2xl0Vlls/well) were incubated with macrophages (6x10 /well) 
pulsed with increasing amount of free or egg PC/Chol liposome or saccharosome 
encapsulated sAg. In the control group, macrophages were treated with mitomycin C 
(50 ng/ml). The experimental cultures were incubated for 72 hr (37 ^C, 5 % CO2) and 
DNA synthesis was monitored by pulsing with 1 i^Ci of labeled thymidine (^  H-
Thymidine, specific activity 18 Ci/mmole, BARC, India) per well to cultures at a 
terminal 18 h pulse. The radioactive incorporation was measured by standard liquid 
scintillation counting. The stimulation index (S.I.) was calculated as mean cpm values 
of stimulated culture/mean cpm of unstimulated culture. 
2.15. FACS analysis 
The development of CD4 * as well as CD8* T- cell population was determined in 
splenic cells isolated from various experimental groups by direct immunofluorescence 
staining. Spleen cells (Ix 10 )^ of mouse (n= 10 from each group) were stained with 
fluorescein isothiocynate (FITC)- conjugated monoclonal antibodies specific for 
mouse CD4'^  and CD8* T- cell receptor. The cells were incubated for 30 min at 4 "C, 
washed three times with dilution buffer (0.01 M phosphate buffer saline, pH 7.4 
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containing 1% bovine serum albumin) and resuspended in 500ml of 2% 
paraformadehyde. The percentage of positive cells was measured with a fluorescence-
activated cell sorter (Becton Dickinson) and data were analyzed by Cell Quest 
software (Becton Dickinson). The expression of CD80 and CD86 was detected on the 
surface of stimulated macrophages isolated from group of animals immunized with 
various types of vaccine following published protocol (Agrewala et al. 1998). The 
macrophages were isolated by adhering to plastic petri plates. The recovered adherent 
cells were consisted of > 99 % macrophages as judged by histochemistry and FACS 
analysis using labeled anti F4/80 antibodies. The macrophages were incubated with 
EPC-Ag or YL-Ag form of antigen. The macrophages were first incubated with Fc 
block and subsequently stained with FITC conjugated hamster anti mouse CD80 
diluted in FACS buffer. The stained cells were acquired on FACScan and population 
of macrophages was analyzed on macrophage/ monocyte zone using CELLQUEST 
software. The exclusion of debris and lymphocytes from cell suspension by suitable 
gating allowed analysis of scattering events consistent with macrophages size range. 
The analysis of mean fluorescence intensity (MFI) was performed on histograms in 
which the abscissa and ordinate denote log FITC fluorescence and relative cell count 
respectively. 
2.16. Flow cytometric detection ofROI 
To measure the ROI, cell- permeable redox sensitive dye CM- H2DCFDA was used. 
The reduced form of dye is non fluorescent; while it,s oxidized form is fluorescent, 
permitting its detection by flow cytometric analysis (Ha et al 1997, Kirkland et al 
2001, Royall and Ischiropoulos 1993). The cells (10^) were incubated with sAg 
(lO^g/ml) for 24 hr at 37 °C and 10 jiM H2DCFDA was added for 15 min at 37 "C 
and 5 % CO2. The change in fluorescence was assessed with a FACS Calibur flow 
cytometer (Becton Dickinson, Franklin Lakes, N.J.). 
2.17. Statistics 
The data were analyzed by one- way analysis of variance (ANOVA) following 
Dunnet'^  t test methods. The survival data was amalyzed by Mann -Whitney Test. P< 
0.05 was considered statistically significant. 
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3. Results: 
3.1. Immunoblot analysis 
Immune reactivity of sAg (P. yoelii cytosolic antigen) was determined by analysis of 
sera isolated from various groups of immunized animals. Reactivity of serum obtained 
from immunized animals indicates a strong IgG reaction against various polypeptides 
of Plasmodium yoelii. The blot analysis revealed that induction of antibody formation 
was mainly regulated by specific adjuvant co-administration along with sAg. The 
antibodies were reactive to polypeptides of P. yoelii demonstrating the multi-band 
patterns in the animals immunized with YL-sAg while pre- immune sera did not 
recognize any antigen. 
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Figurel. Immunoblot analysis of antibodies induced in the sera of animals 
immunized with cytosolic antigens of P. yoelii 
The reactivity of sera obtained from mice immunized with saccharosome entrapped 
sAg (lane 2), egg PC entrapped sAg (lane 3) or sAg emulsified with incomplte Freund 
adjuvant (lane 4) was analysed as immunoblots of P. yoelii blood stage antigens (10 
^g/lane) separated by SDS-PAGE (10 •%) gel. Pre immune sera (lane 1) resolved as a 
negative control. 
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Figure 2 (A - B). I^ G profile in animals immunized with various vaccine 
formulations 
Sera (1:500 dilution) obtained from normal and experimental animals were analyzed 
for the presence of malaria- specific IgG isotype by ELISA method as described in 
Materials and Methods. IgG isotype responses were determined in various group of 
animals immunized with saccharosome entrapped sAg, EPC liposomes or in sAg 
emulsified form with IFA. The level of IgG isotypes were expressed as absorbance 
(A492) of the colored complex developed in the immunosorbant assay. The values 
expressed are the mean of the absorbance of the sera of the five different animals ± 
S.D. [p value Saline Vs EPC Vs YL-sAg < 0.001) 
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Saline Sham Free PC Saccharo 
Figure 3. Delayed Type Hypersensitivity (DTH) response in animals upon 
immunization witit various forms ofsAg vaccine 
The DTH response in animals vaccinated with various forms of antigen was 
determined by injecting 50 ^g of sAg of P. yoelii antigen in 50 i^l of vehicle ( Sham, 
IF A, Free antigen, EPC liposomes and saccharosomes) in left hind footpad of mice. 
An equal volume of saline was injected into opposite footpad. The thickness of 
footpad was measured by Vernier caliper and DTH was expressed as the percentage 
increase in footpad thickness at 24 hr post immunization, the time at which maximum 
reaction was observed, (p value Saline Vs EPC Vs YL-sAg < 0.001] 
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3.2. Antibody response 
We determined production of total antibody in response to immunization with various 
forms of P. yoelii sAg. As shown in figure 2A, sAg entrapped in saccharosomes (YL-
sAg) elicited a significantly high total IgG response after first booster as compared to 
sAg- PC formulation. Immunization with sAg-IFA induced relatively less IgG 
response as compared to YL-sAg or PC-sAg group. Analysis of IgG isotype in the 
sera of immunized mice showed in Fig 2B, the highest level of IgGl was mduced in 
the mice inmiunized with YL-sAg as compared to PC- sAg as well as IFA-sAg 
combination. Besides IgGl, YL-sAg also induced substantial increase in the level of 
IgG2a isotype antibody as well. In contrast, PC-sAg induced very less IgG2a antibody 
as compared to YL-sAg (pYL- sAg Vs PC-sAg > 0.001). No significant rise in IgG2b 
level was observed after immunization with any forms of antigens. 
3.3. DTH responses 
DTH response is an indication of cell- mediated immunity that plays crucial role in 
elimination of intracellular pathogens. The immunized mice were tested for DTH 
response upon immunization with various forms of sAg. As shown in figure 3, sAg 
entrapped in saccharosomes induced strong DTH which was significantly higher (P< 
0.01) than the other control group animals receiving either sham, fi-ee sAg, PC 
liposomes or sAg emulsified with IFA respectively. 
3.4. In vitro cell fusion studies 
To examine potential of saccharosomes as a vehicle to deliver encapsulated sAg to 
target cells peritoneal exudates cells (PEC) were incubated with FITC-labeled 
saccharosomes. The punctuate fluorescence was observed in the cells incubated with 
free or egg PC encapsulated sAg liposomes alone (Fig. 4A) whereas a strong diifuse 
fluorescence was observed when the cells were treated with saccharosomes, (Fig. 4B). 
This is a predictable observation because saccharosomes fiise with the cell membrane 
and deliver encapsulated fluorescent probe to the cytoplasm of the target cells. The 
results are direct evidence to establish the fact that fiisogenic liposomes 
(saccharosomes) could deliver the encapsulated proteins into the cells in an effective 
manner. 
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3.5. Saccharosome induces the ROI 
By observing the fluorescent microscope it was found that the macrophages treated 
with of YL- sAg acquire more fluorescence than PC- sAg as saccharosomes 
encapsulated DCFDA oxidized to H2DCFDA form, more significantly indicating the 
presence of H2O2, 0N00_, or 0H» (Fig 5). Dye oxidation was found to peak after 
15 min. In contrast, PC-sAg, IFA-sAg did not induce oxidation of H2DCFDA. 
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Figure 4. Fluorescence light micrograph of the macrophages upon their interaction 
with FITC encapsulated in DRVs. 
A, B, fluorescence light microgaphs, of the macrophages incubated for 60 min. with 
FJTC encapsulated saccharosome and egg PC Jjposome. Fig C represents the 
macrophages, with no substantial fluorescence. 
.a A«^ dtr 
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Figure 5. ROI detrermination of macrophages binding with DCFDA 
Macrophages were isolated from the animals immunized with sAg entrapped in egg 
PC liposomes or saccharosome. For the ROI detrermination macrophages were 
treated for 15 min with DCFDA and observed for the presence of H2DCFDA using 
fluorescent microscope. 
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3.6 Effect of saccharosome mediated immunization on induction of Thl/ Th2 
cytokines 
The animals immunized witii multiple doses of sAg encapsulated in saccharosomes 
induced significantly higher levels of IFN-y, IL-2 and IL-4 cytokines. Immunization 
with saccharosomes induced expression of IFN- y (60.65 pg/ml), IL- 2 (98.15 pg/ral) 
IL-4 (58.15 pg/ml) in the supernatant of spleen cells (exposed in vitro to P. yoelii 
antigen) were detected. There was no significant increase in the levels of both 
cytokines in animals immunized with conventional liposome or IFA form of sAg. 
3.7. T-lymphocyte proliferation in response to immunization with saccharosome 
encapsulated sAg 
The lymphocytes obtained from the animals immunized with saccharosome entrapped 
sAg underwent significantly better proliferation as compared with lymphocytes 
obtained from animals immunized with PC-sAg or sAg emulsified with IFA. The T-
lymphocyte proliferation was found to depend on dose of antigen (data not shown). 
Maximum proliferation occurred when cells were stimulated with 10 |J.g/ml antigen. 
The response was significantly higher for YL-sAg (S.I.>6) as compared to PC-sAg 
and IFA-sAg (S.I. <3, S.I. <2.5) respectively. Control sets containing cells obtained 
from either free sAg immunized animals or the groups immunized with PBS or empty 
liposomes only (Sham liposomes with no sAg), induced background level of 
<2000cpm of ^H-thymidine incorporation. Cells were also stimulated with Con A and 
LPS as a positive control. 
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Figure 6. Induction of cytokines (A) IFN-y, (B) 11-4 (C) JL-2 in animals immunized 
with saccharosomes encapsulated sAg. 
The CD4^ T cells obtained from various group of immunized animals were co-
cultured in presence of various forms of P.yoelii sAg as described in materials and 
methods section. The cuhure supematants from the wells were collected from animals 
of experimental groups (sAg entrapped in either egg PC/Chol or saccharosomes). 
Cytokine levels were measured by sandwich ELISA as described in Materials and 
Methods. The levels of cytokines were calculated by using of standard curves that 
were plotted employing recombinant cytokines and are expressed as picograms per 
milliliter. 
IFN-y: 
Uninduced 
[p value Saline Vs EPC Vs YL-sAg < 0.001] 
Induced 
[p value Saline Vs EPC Vs YL-sAg < 0.001] 
IL-4 
[p value Saline Vs EPC Vs YL-sAg < 0.001] 
IL-2 
[p value Saline Vs EPC Vs YL-sAg < 0.001] 
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Figure 7. Determination of T-cells proliferation by ^ [HJ-thymidine incorporation 
assay 
CD4^ T- cells (2xl0^/well) were isolated from immunized as well as control mice 
(n=5 each group) and cultured with free sAg, YL-sAg and EPC pulsed macrophages 
(6x10^ cells/well). After 72h, ^[H]- thymidine was added, and its incorporation was 
measured 16h later by liquid scintillation spectroscopy. The stimulation index (S.I.) 
was calculated as mean cpm values of stimulated culture/mean cpm values of 
unstimulated culture. Control cultures containing cells obtained from animals 
immunized with PBS or empty fiisogenic lipids only (sham liposomes with no sAg), 
gave background levels of <2000cpm of ^ [H]-thymidine incorporation. 
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3.8. Saccliaarosome encapsulated sAg induces specific CD4^ and CD8* T-cell 
immunity in BALB/c mice 
There was a substantial increase in both CD4^ (27.45 %) and CD8^ (24.92 %) T-cell 
populations upon immunization with saccharosome encapsulated antigen. On the 
other hand, mice immunized with EPC- sAg showed a relatively less increase in CDA^ 
T-cells (17.75 %) as compared to the unimmunized control animlas (12.53 %). IFA-
sAg immunized animals showed only marginal increase in both T cell populations 
(CD4^ and CD8^ 13.53 % and 14.64 %). 
3.9. Saccharosome encapsulated sAg upregulates CD80/86 molecules on antigen 
presenting cells 
The minimum requirements for activation of CD4^ T cells include presentation of 
processed antigen on class II MHC, and its subsequent recognition by T-cell receptor. 
The activation of macrophages and dendritic cells should be accompanied with 
expression of the appropriate co stimulatory surface markers (CD80 and CD86) on 
their surface (Nickell et al 1993). The data of present study clearly revealed that 
macrophages isolated from animals vaccinated with saccharosomes -sAg showed 
significantly higher expression of both CD80 and CD86 on their surface. In contrast, 
macrophages isolated from animals vaccinated with EPC-sAg expressed relatively 
low levels of co-stimulatory signals. 
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Figure 8. Determination ofCD4^ and CDS* T cell population by flow cytometry 
The freshly isolated spleen cells from experimental and control group animals (n= 10 
each group) were pooled and stained with FITC conjugated anti- CDS, anti CD4 anti 
monoclonal antibodies before analyzing them by flow cytometry. Various groups 
(unimmunized, sAg immunization with sAg entrapped with PC liposomes or 
Saccharosomes, and sAg emulsified with IFA). Each group contains the measurement 
of Blank, anti CD4, anti CDS. 
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Figure 9: Status ofej^ression of co stimulatory molecules (CD80 and CD 86) on 
macrophages isolated from animals vaccinated with EPC-Ag and YL-Ag by flow 
cytometry. 
Co-expression of CD80 andCD86 on macrophages of animals immunized with EPC-
sAg and YL-sAg vaccines was evaluated by flow cytometry as described in Materials 
and Methods. 
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3.10. Potential of saccharosome based sAg vaccine in imparting protection against 
P.yoelii infection in Balb/c mice 
To compare the efficacy of various sAg based vaccines in conferring protective 
immunity, BALB/c mice were challenged intraperitonealy with drug resistant isolate 
of P. yoelii (MDR), 2 weeks after last immunization. In a manner similar to control 
group (PBS only), mice immunized with free antigen, IFA-sAg or PC-sAg showed an 
abrupt increase in parasitemia levels with high mortality (Fig. 13 and 14). Mice 
immunized with YL-sAg adapted less severe courses of infection with significantly 
lower parasitemia levels (P< 0.001 and P< 0.001, respectively) (Fig. 13). There was a 
delay of 2 to 3 days in attainment of peak parasitemia level in mice immunized with 
antigen encapsulated in PC liposomes, or IFA-sAg as compared to non-immunized 
mice. As shown in Fig. 13, mice immunized with PBS or sham liposomes developed a 
progressive infection. On day 6 post challenge with infection parasitic burdens in all 
the control groups were found almost similar (2.7-3.9 %), while in the YL-sAg 
immunized animals, no parasitic load was detected. 
Further immunization with EPC-sAg resulted in partial protection 30 % on day 15, 
while 25 % protection was observed in IFA-sAg immunized group. Increased 
protection of animals was achieved in the group of animals immunized with sAg in 
saccharosomes (80.7 %). The results of the study indicate that YL-sAg was the best 
combination for conferring protection against blood-stage malaria in terms of and 
high survival rate of the immunized animals. 
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Figure 10: Prophylactic Effect of various sAg vaccine formulations on blood 
parasitic load of immunized mice 
Protection against P.yoelii malaria achieved by immunization with sAg of P.yoelii. 
Groups of BALB/c mice (n = 10) were immunized with EPC liposomes encapsulated 
sAg, or emulsified with IFA, or encapsulated in Saccharosomes were analyzed for 
blood parasite load. Control animals (n= 10) were immunized with empty liposomes 
(Sham) and one group (n=10) was kept unimmunized. Animals were boosted twice at 
3-weeks intervals and challenged with 10^  P.yoelii (MDR) parasitized erythrocytes on 
day 7 post last immunization. 
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Figure 11. The effect of various vaccine formulations on survival of animals 
Animals from immunized and control groups of animals were challenged with 10^  
parasitized RBC of the lethal Plasmodium yoelii strain i.p. at day 7 post final 
immunization. Percent survival was determined in various experimental animal 
groups (n== 5); viz. unimmunized normal mice, sham, animals immunized with sAg 
emulsified with Freund s adjuvant, sAg entr^ped in PC liposomes or saccharosomes. 
9 2 -
Chapter 3(A) Prophylactic implication ofS. Cerevisiae lipid 
liposomes against Plasmodium yoelii infection 
in BALB/c mice 
4. Discussion: 
Various stages of P. yoelii life cycle have adapted themselves against host immune 
system as per their residential requirements. Among the liver and blood stages of 
P.yoelii life cycle, the later seem to be of more strategic importance as it helps in 
avoiding both humoral as well as cell mediated inmiune responses. While liver stage 
is prone to target specific CTLs, the blood stage parasite can escape both antibody as 
well as parasite specific cell mediated immunity. Existing immunization protocols 
involving malaria parasite crude blood stage antigen have produced mixed results 
(Desowitz 1975, Kumar et al 1990, McCohn et al 1982, Mitchell et al 1979, Murphy 
et al 1978, Playfair and De Souza 1987, Siddiqui 1977, Siddqui et al 1978). 
It is likely that encapsulation of soluble antigens in fusogenic liposomes will ensue in 
simultaneous type I and type II antigen processing steps that could influence the out 
come of immune response. In an attempt to confirm this hypothesis we specifically 
evaluated adjuvant potential of liposomes made up of the membrane lipid of 
Saccharomyces cerevisiae (saccharosomes). 
The first part of the study was conducted to examine potential of saccharosomes as 
delivery vehicle for sAg to generate effective immune response in the host. In contrast 
to conventional PC liposomes, the enhanced immunological response elicited in the 
animals immunized with saccharosomes encapsulated antigen may be due to its 
cytosolic delivery to APCs that eventually leads to activation of significant CD8^ 
CTL response. Besides, the fraction of antigen delivered into endocytic pathway was 
found to activate MHC-II restricted antigen processing pathway that will help in 
activation of CD4"^  T cells as well. We also observed that beside Thl mediated 
activation of CD8^ T lymphocytes, saccharosomes based immunization leads to the 
generation of CD4"^  Th -2 type of cells as well. Although the expression of Thl and 
Th2 cytokines were initially considered to be mutually exclusive, both Thl as well as 
Th2 cells have been identified during differentiation of Th cells as well as in 
terminally differentiated cells (Polt-Frank et al 1999). Substantial population of 
sacchrosomes like other particulate substances are avidly endocytosed by APCs and 
activate CD4^ T cells. However, it cannot be ruled out that in addition to 
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endocytosis, saccharosome fuse with membrane of target cells and deliver entrap 
antigen to the cytosol of the target cells that form the basis of observed antigen 
specific CTL response. The observed sacchrosomes mediated strong CD8^ T cell 
generation, in spite of polarization CD4^ T cells response in favor of Th2 cells can be 
attributed to the physical targeting of entrapped antigen to the cytosol of APCs. 
Earlier studies (Lee et al 2002) have also demonstrated that genes for both type I and 
type II class of cytokines are independently regulated and that any combination of 
them can be observed without a clear distinction along the Thl and Th2 phenotype. 
Since it is well established fact that both CTLs and neutralizing antibodies are 
essential for imparting protective immunity against intracellular pathogens. Hence 
peculiar behaviour of the sacchrosome based delivery system may help in activation 
of both cell mediated as well as humoral immune responses (Kuninsawa et al 2001). 
The FACS results showed enhance expression of CD80 and CD86 on the surface of 
macrophages isolated from saccharosomes immunized animals. Expression of co-
stimulatory molecules are crucial in stimulating the optimum activation of T- cell 
signaling (Ahmad et al 2001, Siegrist et al 1999). 
The cell mediated immune response was also assessed by induction of DTH response 
in the immunized animals. There was significant increase in foot pad thickness in the 
animals that were immunized with sAg-saccharosomes in comparison of other 
control groups including those immunized with egg PC- sAg. Interestingly, there was 
good correlation between elevated foot pad swelling in the group of animals 
immunized with sAg-saccharosomes with induction of Thl cytokines viz. IL-2 and 
IFN-y . IFN-y activate monocytes and macrophages and with other chemokines play 
major role in induction of DTH response (De Rosell et al 1987, Bretscher et al 1992). 
CD4 Thl and Th2 subsets have role in B cell differentiation, proliferation and 
isotype regulation (Snapper and Paull 1987). Immunization of mice with 
saccharosomes-sAg elicited both IgGl and IgG2a responses, however the level of 
IgG2a was significantly higher than the groups received sAg in other forms, which is 
an indication of Thl response. 
The ability of liposomes to evoke antigen specific immune response has been 
attributed primarily to an increased uptake of antigen by antigen presenting cells and 
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processing and presentation of internalized antigen along with MHC I/II surface 
molecules (Gregoridis 1990). Normally, liposomes injected subcutaneously do not 
have direct acces to blood stream since the permeability of blood capillaries is 
restricted to water and small molecules (Qussroen and storm 2001). Instead liposomes 
are absorbed by lymphatic capillaries and drained to site where antigen is present. 
Lymphatic absorption strongly depends on physical attributes such as liposome size, 
charge and fusogenicity of liposome based vaccine. 
The saccharosomes, encapsulated sAg induped excellent cytokine and antibody 
response and greatly enhanced protective immunity against lethal P. yoelii strain. This 
was best seen with a discriminating dose of sAg, which failed to induce protective 
immunity in free form or in combination of reference adjuvant, PC and IFA. This is 
presumably due to inability of PC and IFA based adjuvant to switch on cytokine 
expression in desirable direction. In contrast, same amount of antigen induced good 
protective immunity when administered in saccharosomes encapsulated form, which 
elicited mixed Thl/Th2 cytokine antibody responses. The superior protective response 
upon immunization with saccharosomes correlates with the induction of early increase 
in IFN-y and its potential to induce both IgG2a and IgGl antibody subclasses 
(Finkelman et al 1988, Snapper 1990). In addition, it also successfully activate 
macrophages to express tumour necrosis factor alpha levels that might help in 
clearance of parasites (data not shown). It has been earlier demonstrated that besides 
other factors, IFN-y and TNF- a are also required for protection against blood stage 
P.chabaudi infections (Stevenson 1995). 
As evident from the present data, it seems both Thl and Th2 T-cell subsets were 
activated simultaneously and play role in resolving parasitemia. Alternatively, it is 
possible that both cytokines are produced by activated ThO cells, although increased 
IFN-y responses preceded those of IL-4 by two days. In a previous report describing 
the case of the self resolving P. chabaudi infection, it has been reported that an initial 
Thl response is replaced by Th2 response, which is thought to be responsible for the 
final elimination of parasitemia (Langhome 1989 , Stevenson and Tam 1993). 
It is believed that phagocytic cells such as monocytes are important in the clearance of 
blood stage parasites (Lee et al 1986, Playfair et al 1985). However, the mechanism 
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by which monocytes and other phagocytic cells affect kilHng of parasites is as yet 
unknown. Superoxide and its derivatives such as hydrogen peroxide (H2O2) and *0H, 
which are collectively referred to as reactive oxygen species are released into 
phagosome with the involvement of NADPH oxidase and are essential in the killing 
of the ingested pathogen (Karupiah et al 2000, Verhoeven 1997). 
Nitric oxide (NO) is another free radical species generated by phagocytes to kill 
invading pathogens. The importance of NO in the immune response to hepatic stages 
of malarial infection has been reviewed (Rockett et al 1998). A role for NO in the 
killing of blood stage malarial parasites in mice is less clear (Farve et al 1999, 
Dascombe and Nahrevanian 2003, Jacobs et al 1995, van der Heyde et al 2000). We 
therefore considered it of interest to establish role of YL-sAg in induction of NO and 
ROS that ultimately help in parasite clearance, as has been shown to occur during the 
host response to infection with the intracellular bacterium Rhodococcus aqui (Darrah 
et al 2000). The data of present study demonstrate direct correlation between 
saccharosome mediated induction of NO production and elimination of parasite from 
immunized animlas. 
Finally, to establish vaccine potential of saccharosome encapsulated sAg, we 
performed protection studies in terms of parasite burden in blood of immunized mice. 
At each time point, mice vaccinated with saccharosome encapsulated sAg showed 
significantly higher protection than other control groups. For example, the protection 
conferred by all the groups in the terms of blood parasetimia was 2.7-3%, while no 
detectable parasite was there in blood of the animals which were immunized with 
saccharosome encapsulated sAg of Plasmodium yoelii by the day 6 post challenge 
with infection. Immunization with PC antigen resulted in partial protection on day 15 
(30%), while 25% protection was observed in IFA-sAg immunized group. On day 15, 
Higher levels of protection were obtained in the group of mice immunized with 
saccharosomes encapsulated sAg (80.7%). 
In conclusion, data of present study demonstrated great potential of saccharosomes as 
delivery system for antigen where cellular as well as humoral responses are desirable. 
Saccharosomes based vaccines are more crucial for imparting protection against 
pathogens which avoid antibody mediated onslaught by seeking intracellular shelter 
inside the cells locations of the cells. 
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1. Introduction: 
Despite many serious efforts, morbidity and mortality due to malaria continue to rise. 
A recent survey declares that this dreadful disease is supposed to affect more than 3 
billion people worid wide. With the emergence and spread of insecticide - resistant 
mosquito vectors and drug resistant Plasmodia sps, chemotherapy and vector control 
programs have remained largely ineffective (Korenromp et al 2005). In such 
circumstances, developing an effective malaria vaccine has been a primary focus in 
many research laboratories across the world. Unfortunately, development of an 
effective malaria vaccine has remained an uphill task primarily due to the complexity 
of the life cycle of parasite (Richie and Saul 2002, Xiao 2002). Nevertheless, in an 
attempt to develop an effective malaria vaccine, parasite derived antigens have been 
evaluated for their potential to inhibit hepatocyte invasion by sporozoites, erythrocyte 
invasion by merozoites, as well as various other stages of it's life cycle (Richie and 
Saul 2002, Miller et al 1986). 
In general, vaccines are administered in combination with suitable immunological 
adjuvants. This is primarily because of the fact that new generation vaccines are 
generally based on weakly immunogenic protein subunits or synthetic peptides. 
Unfortunately, aluminium based adjuvants, which have been approved for uses in 
humans do not fulfill essential attributes of an effective novel vaccine due to various 
limitations. A number of newer adjuvants are under various stages of investigation, 
which can establish their potential to activate immune system. These adjuvants 
comprise a vastly diverse group of compounds and indeed their adjuvanticity may be 
the only common functional characteristic (Kersten and Crommelin, 1995). 
Non-ionic surfactant vesicles (NISV) are liposome-like vesicles but their increased 
chemical stability gives them an extra edge over later (Baillie and Florence et al 
1985). In fact, one of the most significant problems associated with liposome based 
adjuvants is the susceptibility of phospholipids to oxidative degradation. This requires 
that purified phospholipids and liposomes have to be stored and handled in an inert 
(e.g. nitrogen) atmosphere (Baillie and Florence et al 1985) and making this whole set 
up a cost effective affair. 
Protective immunity against intracellular pathogens is generally dependent on Thl 
type immune responses. While it is valid for liver stage, protective immunity against 
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blood-stage malaria parasite is particularly complex and requires a concerted effort of 
both Thl mediated cellular immune response and Th2 regulated humoral immunity 
(Langhome et al 2002, Mohan and Stevenson. 1998). In this regard, usage of an 
antigen delivery system that favors class I processing and presentation of 
encapsulated antigen is of prime importance. 
In the present study, we evaluated potential of niosomes as an adjuvant by 
encapsulating the blood stage soluble antigens of Plasmodium yoelii. The 
immunization protocol successfully induced protective immune responses against P. 
yoelii infection. Interestingly, niosome have been found to evoke malaria specific 
strong CTL response in the immunized animals as well. 
2. Materials and Methods: 
2.1. Animals and Experimental infection 
Inbred female BALB/c mice (8- 10 weeks old), of 20± 2 gm weight were obtained 
from the institute's animal house facility. The Plasmodium yoelii nigeriensis MDR 
strain was obtained from division of parasitolgy. Central Drug Research Institute 
Lucknow. The parasite was fully resistant to chloroquine 128 mg/kg x 4 dose, quinine 
600 mg/kg X 4 doses and mefloquine 256 mg/kg x 4 doses and was maintained in 
mice by routine passage (Dutta and Pandey 1986). Blood stage infection was initiated 
by intraperitoneal injection of parasitized erythrocytes obtained from donor mice. 
Resulting parasitemia in the infected mice were monitored by enumerating parasitized 
erythrocytes in thin blood smears stained with Giemsa stain (Hoffman et al 1984). 
Routine screenings were conducted through out the study to ensure that mice were 
free of infection with common mouse pathogens. The techniques used for bleeding, 
injection as well as sacrifice of animals were strictly performed following mandates 
approved by the Animal Ethics Committee (Committee for the purpose of control and 
supervision of Experiments on Animals, Govt, of India). 
2.2. Chemicals and Reagents 
Egg phosphatidyl choline (EPC) was isolated and purified using the standard method 
(Singleton et al 1965). Cholesterol was purchased from Centron Research laboratory, 
Mumbai, India. [^H]- thymidine was bought from Bhabha Atomic Research Center 
Mumbai, India. Monoclonal anti mouse CD4* and CD8*, CD80 and CD86 FITC 
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conjugates and its purified control (Rat IgG2a isotype) were from Sigma immuno 
chemical St. Lx)uis USA. 
2.3. Antigen preparation 
Blood was collected from BALB/c mice infected with P. yoelii (MDR) parasitized 
erythrocyte with average 35 to 40% parasitemia. The leucocytes were removed by 
passage of blood over microcrystalline column (Eling 1977). The isolated 
erythrocytes were a mixture of ring, trophozoite and schizont- stage parasite and 
subjected to gradient centrifugation as described earliar (Sharad et al 2006). The 
infected RBCs were lysed with 0.01% saponin followed by centrifugation at lOOOXg 
to settle parasites. Intact parasites were resuspended in 10 volumes of 50mM KCl-
5mM MgCb followed by 10 cycles of rapid freezing and thawing, followed by brief 
sonication. Soluble antigens (sAg) fraction was recovered by centrifugation for 15 
min at 2000xg (4 °C). Of the 60 mg of total protein obtained 50-60 % was recovered 
in the soluble fraction. 
2.4. Preparation ofniosomes 
Tween (150mM) were solubilized in chloroform - methanol mixture (2:1 v/v) by 
vigorous stirring. Normal saline (5.0 ml pH 7.4) was added to the surfactant film and 
the samples were heated in water bath (60 "C) for 60 min with 2 min pulse. The 
samples were sonicated for 5 min using a Probe sonicator. 
2.5. Preparation of dried reconstituted vesicles 
The soluble fraction of cytosolic proteins of Plasmodium yoelii was encapsulated in 
niosomes using hiethod of Kirby and Gregoriadis (1984). Briefly, the niosomes and 
protein mixture (1.5 ml of 10 mg/ml stock) was flash- frozen to a thin film, followed 
by lyophilization to get free flowing powder. 
2.6. Estimation of protein content in niosomes 
The niosome based vesicular formulation separated from the free (un-entrapped) 
antigen by centrifugation at lOOOOg for 5 min. The pellet was washed three times with 
normal saline (pH 7.4). An aliquot of the suspension was lysed with triton X-100 (0.5 
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%, w/v) and released antigen was estimated using BCA (bicinchoninic acid) protein 
assay protocol. 
2.7. Immunization 
BALB/c mice (ten animals per group) were immunized subcutaneously with 100 ng 
of various forms of sAg (free, sAg-IFA, sAg entrapped in EPC liposomes and sAg 
entrapped in niosomes, empty niosomes (sham Nio) on days 0, 21 and 28. For 
protection studies, BALB/c mice (n=10) were challenged on day 35 post primary 
immunization, intraperitoneally with 10^  parasitized RBC of P. yoelii nigeriensis 
(MDR) strain. 
2.8. Lymphocyte proliferation assay 
The CD4*T- cells (2xl0''cells/well) were co-cultured with macrophages (6xl0'*/well) 
in presence of increasing amount of free or EPC/Chol liposome or niosomes 
encapsulated sAg. In the control group, macrophages were treated with mitomycin C 
(50 i^g/ml). The experimental cultures were incubated for 72 hr (37 °C, 5% CO2) and 
DNA synthesis was monitored by pulsing with 1 nCi of labeled thymidine ( H-
Thymidine, specific activity 18 Ci/mmole, BARC, India) per well to cultures at a 
terminal 18 h pulse. The radioactive incorporation was measured by standard liquid 
scintillation counting. The stimulation index (S.I.) was calculated as mean cpm values 
of stimulated culture/mean cpm of unstimulated culture. 
2.9. FACSanalysis 
The expression of €04"*^  as well as CD8^ T cells was compared in the total cell 
population derived from spleens of various experimental animals by direct immuno-
fluorescence staining. As per manufacturer's instruction, IxlO^ spleen cells of mouse 
(n = 10 from each group) were stained with fluorescein isothiocynate (FITC)-
conjugated monoclonal antibodies specific for mouse CD4^ and CD8^ T- cell 
receptor. The cells were incubated for 30 min at 4 °C, washed three times with 
dilution buffer (0.01 M phosphate buffer saline, pH 7.4 containing 1% bovine serum 
albumin, 0.1% sodium azide) and re-suspended in 500 |il of 1 of 2 % 
paraformadehyde. The percentage of positive cells was measured with a fluorescence-
activated cell sorter (Becton Dickinson) and data was analyzed by Cell Quest software 
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(Becton Dickinson). To determine the expression of CD80 on the surface of antigen 
presenting cells from group of animals immunized with various types of vaccine, the 
macrophages were isolated by adhering to plastic petri plates. The isolated 
macrophages were incubated with various form of sAg antigen. The macrophages 
were first incubated with Fc block and subsequently, and stained with FITC 
conjugated hamster anti mouse CD80 diluted in FACS buffer. The stained cells were 
acquired on FACScan and populations of macrophages were analyzed using 
CELLQUEST software. The exclusion of debris and lymphocytes from cell 
suspension by suitable gating allowed analysis of only those scattering events having 
size consistency to that of macrophages. The analysis of mean fluorescence intensity 
(MFI) was performed on histograms in which the abscissa and ordinate denote log 
FITC fluorescence and relative cell count respectively. 
2.10. Flow cytometric detection ofROlby CM-H2DCFDA 
To measure the ROI we used cell- permeable redox sensitive dye CM- H2DCFDA, 
the non fluorescent reduced form converts to the fluorescent form upon oxidation 
allowing its detection by flow cytometry (Ha et al 1997, Kirkland and Franklin 2001, 
Royall and Ischiropoulos 1993). For this 10^  cells were incubated with sAg (10 ng/ml) 
for 24 hr at 37 °C and 10 nM H2DCFDA was added for 15 min at 37 °C and 5% CO2. 
A change in fluorescence was assessed with a FACS Calibur flow cytometer (Becton 
Dickinson, Franklin Lakes, N. J.). 
2.11. Assessment of delayed-type hypersensitivity (DTH) response 
DTH was determined as an index of cell mediated immunity elicited in the 
immunized animals. The response was evaluated by measuring the difference in the 
foot pad swelling after post 48 hr subcutaneous inoculation of various forms of sAg. 
The increase in footpad thickness of mice was measured in both footpads using a 
digital Vernier caliper. Percentage of increase in footpad thickness was calculated as 
follows: 
Percent increase in footpad thickness = 
Left footpad thickness - right foot pad thickness 
Right footpad thickness XlOO 
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Levels of cytokines viz. IFNy and IL-4 in mouse spleen homogenate were measured 
by using commercial ELISA kits following the manufacturer's instructions. Spleen 
homogenates were prepared by the method reported by Nakane et al (Nakane et al 
1992) with slight modification. Briefly, spleens were homogenized in ice cold PBS 
containing 1 % CHAPS with the help of tissue homogenizer. Homogenates were 
incubated in an ice bath for 1-2 hr at temperature below 0 °C and the insoluble matters 
were settled down. Supernatant were centrifuged at 2000xg for 20 min and the clear 
supematants were used for cytokines estimation by ELISA method. 
2.13. Determination ofIgG and its isotype litre by ELISA 
The level of anti-malarial antibody in blood of experimental animals was determined 
by using ELISA as described previously (Agrewala et al 1996, Agrewala et al 1998). 
sAg solution was coated on ELISA plate using 100 nl aliquot of stock solution (1 
mg/ml). The plate was incubated at 4 "C overnight and next morning washed three 
times with PBS tween-buffer. BSA (3 %) was added in each well and plate was 
incubated for 2 h at room temperature and washed three times with PBS-Tween. 
Subsequently, diluted serum sample (100 i^l) was added to each well and incubated 
for 2 h at room temperature. Plate was washed three times with PBS tween-buffer. 
Subsequently, horseradish-peroxidase-conjugated anti-immunoglobulin specific anti-
rat IgG was added to each well and incubated for 2 h. Plate was again washed three 
times with PBS tween buffer and then 100 nl of substrate solution 3 ,3 ,5 ,5 -
tetramethyl benzidine containing hydrogen peroxide was added to each well. Plate 
was incubated in darkness at room temperature for 15 min. The reaction was stopped 
by adding 50 \A of 2M H2SO4 to each well. The absorbance was measured at 450 nm 
using a microplate ELISA reader (Lab System Multiscan, Finland). Immune response 
was shown in terms of reciprocal antibody titre. 
2.14. Immunoblot analysis 
The Plasmodia! antigens were subjected to SDS- PAGE (10 %) analysis under 
standard conditions following published protocol (Laemmli 1970, Mishra et al 1994). 
For immunoblot analysis, the resolved proteins were electrophoretically transferred to 
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nitrocellulose membranes and the assays were performed according to the published 
procedure. Briefly, nitrocellulose strip was blocked ovemight in 100 mM tris buffered 
saline, pH 7.6 (TBS), containing 0.1 % tween 20. It was washed with 0.05 % T-20 in 
TBS (washing buffer) and incubated for the 90 min at 37 "C with the mouse sera 
(1:200 dilution). Further these strips were washed three times with TBS-T and 
incubated with a 1: 1000 dilution of HRP- conjugated goat anti-mouse 
immunoglobulin (Sigma Immunologicals, USA) for 90 min at 37 ''C. The strips were 
washed thrice, incubated with substrate (0.3 % DAB (Sigma) in PBS with 0.4 % 
H2O2) till development of color, and finally w?^hed thrice with distilled water. 
2.15. Statistical Analysis 
The data were analyzed by one- way analysis of variance (ANOVA) following 
Durmet's t test methods. The survival data was analyzed by Mann - Whitney Test. P< 
0.05 was considered statistically significant. 
3. Results: 
3.1. T-lymphocyte proliferation in response to immunization with niosome 
encapsulated sAg 
The niosome based sAg vaccine was evaluated for its potential to stimulate antigen 
specific T lymphocytes. The lymphocytes obtained from the animals immunized with 
niosomes entrapped sAg underwent significantly better proliferation compared with 
lymphocytes obtained from animals immunized with EPC-sAg or sAg emulsified with 
IFA. The T- lymphocyte proliferation was found to depend on dose of antigen. 
Maximum proliferation occurred when cells were stimulated with 10 \iglm\ antigen 
(data not shown). The response was significantly higher for nio-sAg (S.I.>7) as 
compared to EPC-sAg and IFA-sAg (S.I.<3, S.I.<2.5) respectively. Cells obtained 
from either free sAg immunized animals or the groups immunized with PBS or empty 
niosomes only (Sham niosomes with no sAg), failed to induce substantial T cell 
proliferation. 
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Figure 1: Spleenocytes Proliferation assay 
CD4^ T-cells were isolated from mice (n= 10) immunized with various fonn of sAg. 
The T-cells (2xl0^/well) were cultured with matching form of antigen viz. free sAg, 
EPC-sAg and nio-sAg pulsed macrophages (6xl0'*cells/well). After 72 h, [^H] -
thymidine was added in each well, and its incorporation was measured 16 h later by 
liquid scintillation spectroscopy. The stimulation index (S.I.) was calculated as mean 
cpm values of stimulated culture/mean cpm values of unstimulated culture. Control 
cultures containing cells obtained from either free sAg immunized animals or the 
groups immunized with PBS or fiisogenic lipids only (sham niosomes with no sAg / 
fice sAg), gave background levels of <2000 cpm of [H]-thymidine incorporation. 
[p value Saline Vs EPC Vs Nio-sAg < 0.001] 
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3.2. Niosome encapsulated sAg induces specific CD4^ and CDS* T-cell immunity in 
BALB/c mice 
There was a substantial increase in both CD4* (25.6 %) and CD8^ (30.45 %) T-cell 
populations upon immunization with the nio-sAg form of antigen. On the other hand, 
mice immunized with PC- sAg showed a relatively less increase in CD4^ T-cells 
(17.75 %) and CD8^ T-cells (10.05 %). IFA-sAg immunized animals showed only 
marginal increase in both T cell populations (CD4"' and CD8"^  13.53 % and 14.64 %). 
The unimmunized control animals have 12.53 % CD4* and 0.66 % CD8* T 
lymphocytes. 
3.3. Niosome encapsulated sAg upregulates CD80/86 molecules on antigen 
presenting cells 
The minimum requirements for activation of CD4^ T cells include presentation of 
processed antigen along with class II MHC molecules and its subsequent recognition 
by T-cell receptor of specific T cell. The activation of macrophages and dendritic cells 
should be accompanied with expression of the appropriate co stimulatory surface 
markers (CD80 and CD86) on their surface (Nickell et al 1993). The data of present 
study clearly revealed that nio-sAg induced higher expression of both CD80 and 
CD86 on the surface of antigen presenting cells. In contrast, macrophages isolated 
from animals vaccinated with EPC-sAg expressed relatively low levels of co-
stimulatory molecules. 
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Figure 2: (A- H): Percent population of CD4^ and CD8^ T cells in 
immunized and control mice 
The freshly isolated spleen cells from the immunized BALB/c mice, belonging to 
various groups were pooled and stained with FITC conjugated anti-CD8 (A) as well 
as anti-CD4 (B) monoclonal Abs (Sigma) before analyzing them by flow cytometry 
(BD Biosciences). 
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Figure 3: Effect of niosome mediated sAg delivery upon expression of 
costimulatory molecules (CD 80 and CD 86) 
Expression of co-stimulatory molecules (CD80 and CD86) on macrophages isolated 
from animals vaccinated with EPC-Ag and nio-sAg. The level of CD80 and CD 86 
was assed by flow cytometric analysis as described in material and methods. 
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3.4 Niosome induced ROS and reactive nitrogen species in the immunized animals 
The fluorescence intensity of oxidized dye was measured in PEC, which was 
incubated with reduced form of DCFDA dye (H2DCFDA) in presence of various 
vaccine formulations. Animals that were immunized with nio-sAg showed 
significantly higher fluorescence intensity as compared to other inmiunized groups. 
3.5. DTH responses 
DTH response is an indication of cell- mediated immunity that plays crucial role in 
elimination of intracellular pathogens. The immunized mice were evaluated for DTH 
response upon immunization with various forms of sAg. As shown in figure 5, sAg 
entrapped in niosomes induced strong DTH which was significantly higher (P< 0.01) 
than other group of animals immunized with sham niosome, free sAg, EPC liposomes 
or sAg emulsified with IFA respectively. 
3.6. Immunization with niosome- entrapped sAg enhances production of protective 
cytokines 
The animals immunized with nio-sAg induced significantly higher levels of both type 
I and type II cytokines. Immunization with niosomes based vaccine induced IFN-7 
(70.17pg/ml) and IL-4 (60.6 pg/ml) secretion of spleen cells of immunized mice. The 
animals immunized with EPC-sAg showed IFN-y (35.8 pg/ml) and IL-4 (30.22 
pg/ml) level. 
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Figure 4: Flow cytometric detection of Reactive oxygen species 
The level of ROI was determined using Flow cytometry. Mean fluorescence intensity 
(MFI) was measured after 15 min incubation of DCFDA with macrophages isolated 
from animals immunized with sAg enc^sulated in niosomes or in sAg- niosomes and 
other immunized groups (sAg emulsified with IF A,). Unimmunized animals were 
taken as a conrol. 
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Figure 5: DTH response in animals immunized with various sAg vaccine, 
DTH response in animals immunized with various sAg vaccine. The DTH response in 
animals vaccinated with various forms of antigen was determined by injecting 50 ^ ig 
of sAg in 50 ^l of vehicle (Saline, Sham niosome. Free sAg, IFA-sAg, EPC-sAg or 
nio-sAg) in left hind footpad of each mouse. An equal volume of saline was injected 
into the opposite foo^)ad. The thickness of footpad was measured by Vernier caliper 
and DTH was expressed as the absolute increase in footpad thickness at 24 hr post 
immunization, the time at which maximum reaction was observed. 
[p value Saline Vs EPC Vs Nio-sAg < 0.001] 
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Figure 6: Effect of immunization on the secretion of(lFN-y) cytokines 
Enhanced secretion of IFN-7 in animals immunized with niosome used sAg. IFN-y in 
sera of various groups of animals immunized with various preparations of vaccine 
was determined by sandwich ELISA. The data were mean of five mice per group ± 
S.D. and representative of three different experiments. 
Ip value Saline Vs EPC Vs YL-sAg < 0.001] 
Figure?: Effect of immunization on the secretion of(IL-4) cytokines 
The culture supematants from the wells were collected after 24 h for IL-4 assays. 
Cytokine levels were measured by sandwich ELISA. The levels of cytokines were 
calculated by use of standard curves that were plotted using recombinant cytokines 
Pharmingen and are expressed as picograms per milliliter. 
[p value Saline Vs EPC Vs YL-sAg < 0.001] 
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3.7. Antibody response 
We determined production of total antibody against various forms of P.yoelii sAg in 
the immunized animals. As shown in figure (8), sAg entrapped in niosome elicited a 
significantly high total IgG response after first booster as compared to EPC-sAg 
formulation. Immunization with sAg-IFA induced relatively less IgG response as 
compared to nio-sAg or EPC-sAg group. Analysis of IgG isotype in the sera of 
immunized mice showed highest level of IgGl in the mice immunized with nio-sAg 
as compared to EPC-sAg as well as IFA-sAg combination. Besides IgGl, nio-sAg 
induced production of substantial level of IgG2a isotype antibody as well. In contrast, 
EPC-sAg induced very less IgG2a antibody as compared to nio-sAg (p value nio- sAg 
Vs PC-sAg > 0.001). No significant rise in IgG2b level was observed when other 
forms of sAg antigen were used. 
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Figure 8. Induction of humoral immue response in animals immunized 
with various preparation ofsAg vaccine 
Induction of humoral immue response in animals immunized with various preparation 
of sAg vaccine. BALB/c mice were immunized with various forms of sAg and bled 
on seventh day of last booster to determine antigen specific total IgG in sera of 
various groups of animals by ELISA method. The data represents mean of five mice 
per group ± S.D. and representative of three individual experiments. 
[p value Saline Vs EPC Vs YL-sAg < 0.001] 
Figure 9: Effect of immunization upon IgG isotypes 
Development of antigen specific IgG isotypes in animals immunized with various 
types of malaria vaccine. Antigen specific antibody isotypes (IgGl and IgG2a) were 
determined in sera of various groups of immuninized animals. Sera (1:500 dilution) 
obtained from the control and experimental animals were analyzed for the presence of 
Ag-specific IgG isotype by ELISA method. The levels of the two major isotypes of 
the IgGs were expressed as absorbance (A492) of the colored complex developed in 
the immunosorbent assay. The values expressed are the mean of the absorbance of the 
sera of five individual animals ± S.D. 
[p value Saline Vs EPC Vs YL-sAg < 0.001] 
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Figure 10: Reactivity of the sera obtained from immunized animals with total eel: 
lysate of P. yoelii 
Immunoblot analysis of antibodies associated with immunization induced immunit)' 
to P. yoelii. The reactivity of sera obtained from mice previously immunized with 
niosome entrapped sAg (lane 1), EPC liposome entrapped sAg (lane 2) or sAg 
emulsified with Freund's adjuvant (lane 3) immunized mice with of P. yoelii blood 
stage antigen (10 |ig/lane) separated by SDS-PAGE on 4-17 % gradient gel. A normal 
unimmunized mice serum (lane 4) served as a negative control. 
1 1 8 -
Chapter 3B Potential ofniosome based vaccine 
against experimental murine malaria 
3.8 Potential ofniosome based sAg vaccine in imparting protection against P.yoelii 
infection in Balb/c mice: 
To compare the efficacy of various sAg based vaccines in conferring protection 
against parasite immunity, BALB/c mice were challenged with drug resistant isolate 
of P. yoelii (MDR) two weeks after last immunization. In a manner similar to control 
group (PBS only), mice immunized with free antigen, IFA-sAg or EPC-sAg suffered 
an abrupt increase in parasitemia levels with high mortality (Fig. 11 and 12). Mice 
immunized with nio-sAg followed less severe courses of infection with significantly 
lower parasitemia levels {P< 0.001 and P< 0.001, respectively) (Fig. 11). There was a 
delay of 2 to 3 days in attainment of peak parasitemia level in mice immtmized with 
antigen encapsulated in EPC liposomes, or IFA-sAg as compared to non-immunized 
mice. As shown in Fig. 11, mice immunized with PBS or sham niosomes developed a 
progressive infection. On day 6 post challenge with infection, parasitic burdens in all 
the control groups were found almost similar (2.7-3.9 %), while in the nio-sAg 
immunized animals, no parasitic load was detected. 
Further immunization with EPC-sAg resulted in partial protection 30 % on day 15, 
while 25 % protection was observed in IFA-sAg immunized group. Increased level of 
protection was achieved in the group of animals immunized with sAg in niosome on 
day 15 post challenge with infection (80.7 %). The results of the study indicate that 
nio-sAg was the best combination for conferring protection against blood-stage 
malaria in terms of high survival rate of the immunized animals. 
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Figure 11. Effect of immunizations with sAg in deferent adjuvants on 
Parasitaemia 
The effect of immunizations with various forms of sAg on parasitaemia of parasite 
exposed animals. The mice were challenged with 10^ parasitized RBCs of lethal 
Plasmodium yoelii i.p. at day 7 post final immunization. The percent parasitemia was 
determined by examining Geimsa stained thin blood smears of individual mice taken 
at 2-days interval are shown. 
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Figure 12: Effect ofimmimizations with sAg in d^erent adjuvants on 
survival ofBALB/c mice 
Prophylactic potential of niosomes in terms of survival rate of animals that were 
challenged with P. yoelii infection after immunization with various forms of sAg 
vaccine. Percent survival in the experimental animals was determined after 
immunization with sAg entrapped in niosomes provided better protection than both 
EPC liposomes-sAg as well as or IFA-sAg forms of vaccine. 
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4. Discussion: 
We evaluated niosome based vaccine for their potential to impart protection against 
blood stage P. yoelii infection in BALB/c mice. The data of present study suggested 
that the immune responses elicited by niosome based sAg are of Thl- type mainly. 
Interestingly, this class of T helper cells is of particular use in combating intracellular 
pathogens, which can be specificeilly eliminated by cell mediated immune arm of the 
immune system of the host. 
Various crude blood stage antigen immunization studies involving several Plasmodial 
sps have been conducted in the past with mixed results (Brown et al 1970, Desowitz 
1975, Hunter et al 1995, Kumar et al 1990, McColm et al 1982, Mitchell et al 1979, 
Murphy et al 1978, Playfair et al 1997, Playfair et al 1987, Reese et al 1978, Richards 
1966, Siddiqui 1977, Siddiqui et al 1978, Targett and Fulton 1965). We attempted to 
extend these studies considering it likely that soluble antigens encapsulated in 
niosomes would undergo different antigen processing requirements that in turn could 
influence the outcome of immune response. 
With increasing use of highly purified synthetic peptides in modem vaccinology, 
adjuvants are often required to enhance their immunogenicity. Indeed recent studies 
comparing niosomes and alum, (only adjuvant suggested for human) demonstrated 
that unlike Alum, niosome did not induce chronic granuloma formation at the 
injection site. Earlier studies have also demonstrated that the addition of non-ionic 
surfactants to liposomes greatly enhances adjuvanticity of the combination 
preparations (Zigterman et al 1987; Zigterman, Snippe et a/. 1988). 
In general, the ability of adjuvants to stimulate cells in the draining lymph node is 
more important in sustaining antibody production than the reactions occurring at the 
site of injection (Lascelles et al 1989). Therefore the ability of niosomes to be cleared 
rapidly from the site of injection and accumulate in the lymph node with the 
consequent lack of local reactions is not inconsistent with its activity as an 
immunological adjuvant. 
The results of the present study reveal that beside Th-1 mediated activation of CD8^ 
T lymphocytes, niosomes based immunization leads to the generation of CD4^ Th-2 
cells as well. This provides help to B- cells leading to production of antibodies, while 
~ 1 2 2 ~ 
Chapter 3B Potential ofniosome based vaccine 
against experimental murine malaria 
Th-1 cells successfully activate CTLs (Stevens et al 1988, Shaji et al 1998). The Th-
l/Th-2 shift is crucial for effective immunity and it is likely that many interlocking 
factors contribute to that decision (Bottomly 1998). The observed niosome mediated 
strong CTL generation, along with simultaneous induction of the CD4* T cell 
response in favor of Th-2 cytokines have been identified both during differentiation of 
Th cells and in terminally differentiated cells (Bottomly 1998). 
The present study has demonstrated that, following parenteral injection, niosomes act 
as potent adjuvants. It also establishes that niosomes with entrapped sAg induce 
strong antibody titres of a higher magnitude to that produced by the same dose of sAg 
entrapped in EPC liposomes and to that emulsified in IF A. Analysis of the sAg 
specific IgG subclasses promoted by nio- sAg and EPC- sAg, indicated that niosomes 
were better IgG2a stimulators than EPC. 
Antibody production of IgG2a by B cells has been shown to be dependent on the 
presence of the Thl associated cytokine IFN-y (Brewer and Alexander 1992; Snapper 
and Mond 1993), this data suggested that nio- sAg could preferentially promote 
expansion of the Thl subset of Tlymphocytes (Mosmann and Coffman 1989). 
The superior protective effect observed in the present study correlates well with the 
induction of early increase in IFN-y and IL-4, cytokines. The high level of IFN- y and 
IL-4 response in vaccinated mice correspond well with the increase in IgG2a and 
IgGl antibody production (Finkelman et al 1988, Snapper 1990). It seems that 
niosome mediated antigen delivery successfully activte macrophage. 
The protection studies demonstrated better survival rate in animals that were 
immunized with niosome encapsulated antigen. Almost 80 % animals survived on day 
20 post infection in comparison to 50 % survival of animals immunized with EPC 
liposomized antigen. Liposome based vaccine generally lead to the activation of 
humoral immune response, and thus eliminate only limited number of Plasmodia as 
their intracellular residence help in escaping antibody mediated killing, which 
ultimately d in recurrence of the infection and subsequent death of animal. The 
effectiveness of niosome may be explained on the premise that apart from generating 
humoral response, niosome cause antibody mediated killing of parasite harboring 
cells as well and successfully eliminate the pathogen from the host. The efficacy of 
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niosomes based vaccine against P. yoelii was further confirmed by remarkable 
suppression of parasite load in erythrocyte on day 5 post infection. Interestingly, 
further screening revealed that In fact, the animals vaccinated with nio- sAg were 
virtually free of any parasite load on day 15 post infection. 
Several vaccination strategies available today are able to induce humoral inmiunity 
mainly, with no or lesser degree of cell mediated immune responses. For many 
reasons, the development of new and more effective adjuvants is a key objective that 
eventually helps in resolution of infection before the full impact of new generation 
vaccines can be realized. In order to highlight features of niosome as potential 
adjuvant, we have performed some elaborated immunological studies. 
Finally, we can conclude that niosome based malaria vaccine may offer an efficient 
way of protecting animals from full blown malaria. Beside they also do not suffer 
from storage and transportation problem which is very much there with liposome 
based vaccine. 
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1. Introduction 
While anti-parasitic agents used in the treatment of infectious diseases prevent rapid 
multiplication and hamper vital physiological activities of the parasite, it is basically 
the immune system of the host that plays major role in complete 
suppression/elimination of the pathogens from host. In fact parasites weaken immune 
armory of as a strategy to establish themselves in the host. It can be speculated that 
activation/rejuvenation of the host immune system could be an effective means to 
successfully combat various infections. 
In spite of global efforts to develop an effective cure, malaria is still considered as one 
of the most prevalent and devastating disease worldwide, affecting about 300-500 
million people and claiming 1.5-2.7 million human lives annually. Further, about one 
third of the world human population lives in area that is infested with the disease in 
one or other form (Butler et al 1997). More alarmingly, the development of multiple 
drug resistant isolates of Plasmodium spp and the increased resistance of its vector, 
the Anopheles mosquito, to DDT underscore the importance of developing new 
chemotherapeutic means to hinder the spread of malaria. In this regard, it is always 
imperative to enhance anti-parasitic efficacy of already tested or existing 
antimicrobial compounds. For example chloroquine, the most potent antimalarial 
agent, has suffered a set back because of its non-effectiveness against drug resistant 
isolates of malaria parasite (Bjorkman and Phillips-Howard, 1990). One possible 
strategy to eliminate less susceptible isolates of Plasmodium spp. may rely on 
concomitant usage of antimalarial chloroquine in combination with some potent 
immunomodulators. 
Picroliv, a standardized fraction isolated from the ethanol extract of root and rhizome 
of Picrorhiza kurroa (Scrophulariaceae; veneral name kutki) contains iridoid 
glycosides, and is well known for its protective action against liver damage caused by 
various hepatotoxins (Rastogi et al 1996, Dwivedi et al 1992). The compound was 
also found to be effective to correct liver damage induced by Plasmodium berghei 
infection in Mastomys natalensis (Chander et al 1990, Puri et al 1992). It was also 
reported to possess strong immunostimulant activity and showed significant 
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protection against challenge with Leishmania donovani promastigotes in experimental 
golden hamsters (Puri et al 1992). 
In general, picroliv has been shown to provoke monocytes and macrophages for their 
natural killer activity against microbes (Puri et al 1992). In the present study, we 
performed elaborated studies to evaluate immunomodulatory effect of picroliv in 
model animals to establish its practical suitability in treatment of infectious diseases. 
We have also evaluated potential of combination therapy involving picroliv and 
chloroquine to combat less susceptible isolates of Plasmodium yoelii in model 
animals. 
2. Materials and Methods 
2.1. Chemicals 
Chloroquine di phosphate was purchased from the Sigma Chemical Company St 
Louis Mo,USA. Picroliv was isolated according to the protocol of Dwivedi et al. 
(Dwivedi et al 1991). Picrorhiza kurroa grows abundantly in Himalayan and sub 
Himalayan regions at the height above the sea level 3300- 3400 m. Roots and 
rhizomes of the plant were collected during autumn (August-September), dried, 
powered and finally extracted with alcohol by cold percolation. The extract was 
evaporated in vacuo below 50° C. The extracts were dissolved in methanol: water 
(1:1) and further washed with chloroform. Chloroform phase was discarded, while 
aqueous methanolic phase was further extracted with ethyl acetate and butanol. Both 
the ethyl acetate soluble as well as butanol soluble fractions were combined and 
evaporated to dryness in vacuo to get picroliv. As revealed by HPLC and TLC , 
picroliv contained about 60 % of Kutkoside and Picroside in the ratio of 1:1.5, the 
remaining 40 % being a mixture of iridoid as well as cucurbitacin glycosides and 
some still unidentified substances. 
2.2. Animals and parasites 
In bred female BALB/c mice (8-10 weak old), of 18± 2 gm weight, were obtained 
from the institute s Animal House Facility. The Plasmodium yoelii nigeriensis MDR 
(Multi drug resistant) strain was obtained from Division of Parasitolgy, Central Drug 
Research Institute Lucknow. The techniques used for bleeding, injection, as well as 
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sacrifice of animals were strictly perfonned following mandates approved by the 
Animal Ethics Committee (Committee for the purpose of control and supervision of 
experiments on Animals, Govt, of India). 
The parasitized erythrocytes were obtained from the blood of highly infected mice 
(average, parasitemia 38 %). The suspension was diluted in 0.9 % sodium chloride to 
get the stock of 5x10^ parasitized red blood cells per ml. Animals were inoculated 
intraperitoneally with 1x10^ parasitized erythrocytes in 0.2 ml of normal saline. The 
immunomodulatory activity of picroliv was determined by trying various dosage 
regimen as well as inraiunization schedule. 
2.3. Immunization 
Our pilot studies suggest that pretreatment with picroliv for 14 consecutive days 
before immunization (at a dose of Img/kg body weight) elicited effective immune 
response. To assess its inamuno-modulatory potential, animals were pretreated with 
picroliv before immunization with model antigen. The picroliv pretreated animals 
(Img/kg body weight) were subsequently immunized with free OVA or OVA 
emulsified with IFA (100 fxg antigen /animal). Control animals (no picroliv treatment) 
received saline only. On day 7 post immunization, the T-cells were isolated from the 
spleen of immunized animals using published procedure as standardized in our lab 
(Agrewala et al 1996). The splenic tissue was macerated and erythrocytes were lysed . 
with the hemolytic Gey's solution (3 ml per spleen) by incubating the cell suspension 
for 10 minutes on ice. The macrophages were removed by panning method, while B 
cells were eliminated by incubating the non-adherent cells with nylon wool (Ix 5cm 
column) as described elsewhere (Agrewala et al 1996). The cells eluted fix)m the 
column, were incubated with cocktail of anti-Mac3, anti-I Ad and anti IgM Ab at 40 
for 45 min. The cells were washed and then treated with baby rabbit complement for 
30 min at 37 °C. Finally, the cells were again washed with RPMI-1640 and used as an 
enriched source of T- cell population. 
2.4. Macrophages 
The BALB/c mice were inoculated with 2- 3 ml of thioglycollate. Peritoneal exudates 
cells (PEC) were isolated by peritoneal lavage four days later. The cells were washed 
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with cold HBSS. The macrophages were obtained, by incubating the cell suspension 
for Ih at 37 "C on plastic Petri dishes followed by several washing with cold HBSS. 
2.5. T-cell proliferation Assay 
The T-cell proliferation assay was performed following published procedure as 
standardized in our lab (Agrewala et al 1996). Briefly, T- cells (2x 10''/well) obtained 
from spleens of various groups of mice were cultured in 96 well plate (triplicate 
wells). The cells were incubated with macrophages (6xl0Vwell) followed by 
exposure with increasing doses (0.001-100 |ig/ml) of ovalbumin. The macrophages 
were treated with Mitomycin C (50 ng/ml). The cultures were further incubated for 72 
h at 37 °C / 7% C02. The cells were pulsed with 1.0 nCi [^ H] - thymidine for 16 h 
before harvesting by automatic cell harvester (Skatron. Tranby. Norway). The [ H]-
thymidine incorporation was measured by standard liquid scintillation counting 
method. The results were expressed as mean cpm of triplicate cultures. 
2.6. Determination of Antigen Specific IgG Isotypes by ELISA 
The production of OVA specific antibodies was measured in the sera of immunized 
groups of mice as described elsewhere (Agrewala et al 1996). The animals were 
injected with two doses of free antigen, (100 ng/ animal) on days 0 and 7. The 
animals were subsequently bled on day 7 post last immunization, to monitor presence 
of antigen specefic antibodies. Ninety six-well microtier plates (Costar, Boston.MA. 
USA) were coated overnight with 50 ^1 of antigen (25 |ig/ml) in carbonate-
bicarbonate buffer (0.05 M, pH 9.6) at 4 °C. The antigen coated plate was blocked 
with 3% skimmed milk and then incubated with log 2 dilutions of test and sera of the 
immunized animals. The reaction was allowed to proceed at 37 °C for two hours. The 
micro-titer plates were washed and 50 |j,l biotinylated goat anti-mouse IgGl and 
IgG2a ABS were added. After usual steps of washings, 50 |il of streptavidin-HRP was 
added in each well and the plates were incubated at 37 °C for 1 hr. The plates were 
washed again before adding 50 \i\ of orthrophenylene diamine dihydrochloride (OPD 
0.2M HCl) and were finally incubated at 37 °C for 20 min. The reaction was 
terminated by the addition of 50 |al of 7 % H2SO4. The absorbance of the colored 
complex was read at 495nm with microplate reader (Eurogenetics, Torino, Italy). 
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Antibody titers were expressed as the absorbance of the colored complex determined 
for different serum samples at 1:4000 dilutions. 
2.7. Effect ofpicroUv treatment on efficacy of chloroquine against Plasmodium 
yoelii infection 
The efficacy of picroliv was determined by evaluating its potential to suppress drug 
resistant Plasmodium yoelii infection in mouse model. The animals were pretreated 
with picroliv for 14 days before challenging them with infection. The potential of 
combination therapy was assessed on the basis of survival rate and parasitic load in 
red blood cells of infected mice. In pilot study, various doses of chloroquine (i. p.) 
were tried to achieve best dosage regimen for treatment of infected BALB/c mice. 
Finally, a suboptimal dose of 8mg/kg body weight of chloroquine was selected for 
evaluating the efficacy of picroliv - CHQ combination. 
The infected animals were divided into following four groups. Each group consisted 
of 10 animals. 
Group:! Saline (No drug treatment) 
Group:!! picroliv treatment 
Group:!!! chloroquine treatment 
Group: IV treatment with chloroquine in picroliv pretreated animals 
* Chloroquine (i.p.) Img/kg body weight was administered for three consecutive days 
post P.yoelii infection. 
2.8. Statistics 
The data were analyzed by one- way analysis of variance (ANOVA) following 
Dunnet,s t test methods. The survival data was amalyzed by Mann Whitney Test. P< 
0.05 was considered statistically significant. 
3. Results: 
3.1. Picroliv augments proliferation of OVA- specific T- cells in BALB/c mice 
The immunomodulatory potential of picroliv was assesed by immunizing picroliv 
pretreated animals with model antigen OVA. The picroliv pretreatment induced 
significantly higher T-cell proliferation in comparison to the animals that were not 
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pretreated with picroliv. T-cell responsiveness to antigen was observed in a dose 
dependent manner. The stimulation index (S.I.) value obtained in animals pretreated 
with picroliv prior to their exposure with OVA (Picroliv- OVA- IF A) was around 
5.87± 0.6154, while control animals that were not pretreated with picroliv could 
induce only 1.85± 0.563 S.I. in the inmiunized mice (Fig 1). The PBS treated animals 
did not induce any T-cell proliferation. 
3.2. Picroliv treatment increases the secretion oflgGla isotype of antibodies 
The level of OVA-specific total IgG present in the sera of immunized as well as 
control animals was assessed by ELISA. Antibody titers were estimated as the O.D. of 
0.2 above the control wells. The administration of antigen in picroliv (p<0.001) 
pretreated animals elicited strong immunological response in terms of antibody 
production, while immunization of animals that were not pretreated with picroliv 
could induce moderate level of antibodies. We also determined isotypes of antibody 
generated upon administration of picroliv prior to immunization with antigen. The 
control animals immunized with saline or free OVA could not induce any detectable 
level of IgG-isotypes. Interestingly, significant increase in ratio of IgG2a/IgGl type of 
antibodies was detected in the sera of animals that were primed with picroliv. While 
low levels of IgGl and IgG2a isotypes were found in control animals that were not 
pretreated with picroliv (p<0.001). (Fig 2 & 3). 
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Figure 1: Effect ofpicroliv treatment on proliferation ofCD4^ T-cells in Balb/c 
Antigen administration in picroliv pretreatment augmented the proliferation of OVA-
specific T-cells. T-cells (2x10'') were isolated from the groups of five animals 
immunized with various formulation of OVA and cultured with OVA pulsed 
macrophages (6x10'' cells/well). After 72h, ^[H]- thymidine was added, and its 
incorporation was measured 16h later by liquid scintillation spectroscopy. The 
stimulation index (S.I.) was calculated as mean cpm values of stimulated 
culture/mean cpm values of unstimulated culture. Control cultures containing cells 
obtained from either free OVA immunized animals or the animals immunized with 
PBS, gave background levels of <2000cpm of ^ [H]-thymidine incorporation. The data 
represents mean S.I.± SD of three determinations. 
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Figure 2: Increased humoral response in immunized mice that were pretreated with 
picroliv 
Antibody levels obtained in sera of BALB/c mice immunized with ovalbumin 
pretreated with Picroliv. The level of OVA- specific total IgG present in the sera of all 
immunized as well as control animals was assessed by ELISA. Results are expressed 
as mean of antibody titre of five mice in each group ± SD. There was a robust 
increase in total IgG levels among animals immunized with picroliv- OVA- IFA than 
the animals immunized without treatment ofpicroliv. 
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Figure 3: £jQ e^c/ of picroliv pretreatment on induction of IgG isotype response 
against OVA in Balb/c mice 
IgG isotype responses in various groups of animals immunized with ovalbumin, 
ovalbumin emulsified with IFA with or without treatment of picroliv. Sera obtained 
from normal and experimental animals were analyzed for the presence of ovalbumin -
specific IgG isotype by ELISA method as described in Materials and Methods. The 
level of IgG isotype were expressed as absorbance (A495) of the colored complex 
developed in the immunosorbant assay. 
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Figure 4: The effect of Picroliv pretreatment on survival of animals. 
The animals were challenged with 10^ parasitized RBC of the lethal Plasmodium 
yoelii followed by treatment with chloroquine.. Percent survival of the treated animals 
was determined in various experimental animal groups. Day 8, p< 0.001 Picroliv Vs 
Chloroquine Vs Pic-CHQ; Day 10, p<0.001 Picroliv Vs Chloroquine Vs Pic- CHQ; 
Day 14, P<0.001 Chloroquine Vs Pic- CHQ. 
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Figure 5: Effect of Picroliv pretreatment of P.yoelu infection on blood parasitic 
load 
Groups of BALB/c mice (n = 5) were administered with 8mg/kg dose of chloroquine 
and picroliv (Img/kg for 14 days prior to infection) or free chloroquine at the same 
dose, free picroliv. Control animals (n= 5) were given PBS only. Animals were 
challenged with 10^  P.yoelii (MDR) parasitized erythrocytes. Parasitemia was 
estimated by preparing thin blood smears, stamed with Giemsa strain. Day 8, P< 
0.001 Picroliv Vs Chloroquine and Pic- CHQ; Day 10, P< 0.001 Chloroquine Vs Pic-
CHQ; Day 16, P< 0.001 Chloroqume Vs Pic- CHQ. 
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3.3. Effect of co-administration ofPicroliv in combination with chloroquine against 
drug resistant isolate of P. yoelii in Balb/c mice 
We also evaluated effect of picroliv pretreatment on efficacy of chloroquine against 
drug resistant Plasmodium yoelii infection in BALB/c mice. The treatment with 
8mg/kg dose of chloroquine alone could not completely suppress resistant isolates of 
Plasmodium yoelii. The animals treated with chloroquine alone (same dose) died by 
day 12 only (Fig 4). Treatment with same dose in animals that were pretreated with 
picroliv (Img/kg), ensued in 100% survival up to day 16 post infection.The parasitic 
burden in treated animals was monitored after three day to exposure to infection by 
preparing blood smears of infected animals. Interestingly there was no parasitized 
RBC in case of picroliv treated animals till 8* post infection, while in the group 
treated with free chloroquine there was significantly higher parasite load (15.8%, 
p<0.001) on 8"' day post infection. The parasitic load shot up to 56.12% on day 12. In 
contrast, in the group treated with picroliv and chloroquine combination, the parasite 
load was 1.9% (p<0.001) on \2^^ day post infection (Fig 5). 
4. Discussion: 
In spite of tremendous advancement in the field of malaria parasitology, the exact 
mechanism regarding mode of action of chloroquine -s not well understood. Most of 
the antimalarial drugs including chloroquine enter into infected red blood cell and 
reach to digestive vacuole of parasite by simple diffusion. As parasite resides inside 
erythrocyte, the effective concentration of drug reaching to cytosol of the erythrocyte 
play regulatory role in killing of the parasite. In order to cope up with drug on 
slaught, the parasite propels drug molecules outside the cell thus preventing 
attainment of minimum effective drug concentration inside the cells (Krogstad et al 
1987). This is a regular trend for development of drug resistant isolates of 
Plasmodium sps. There is at least 40 times higher'dx'Ug efflux in CHQ-resistant 
parasites as compared to CHQ- sensitive isolates (Plowe 2005). 
In general, it is pathogen specific host immune components that play active role in 
elimination of pathogen, while the usage of chemotherapeutic agents does not allow 
multiplication and growth of the parasite. The development of full blown malaria 
suggests non effectiveness of parasite specific antibodies and T-cells develop by the 
~ 136 ~ 
Chapter 4 Immunomodulator effect ofpicroliv and its 
potential in treatment against resistant 
Plasmodium yoelii (MDR) infection in mice 
host during course of establishment of infection. This intum suggest that use of 
immunomodulator picroliv in combination with CHQ could be a useful choice in 
revoking immune system of the host ensuing in successful elimination of pathogen. 
The immunomodulatory role of picroliv was established by its potential to induce 
humoral (antibody production) as well as cell mediated immunity (T cell 
proliferation) in the host. As evident from data of the present study pretreatment with 
picroliv helps in induction of strong immune response in the animals upon their 
exposure to OVA. Interestingly, picroliv was found to help in induction of IgG2a 
isotype of antibody. This indirectly suggests that the immunomodulator helps in 
skewing of immune response in favor of Thl subtype of T- helper cells. We and 
others have earlier shown that IgG2a subtypes of antibodies are of great importance in 
containing P.yoelii infection in model animals (Sharad et al 2006). Picroliv educate 
immune cells to help in production of IgG2a type of the antibodies against P.yoelii 
antigens that are released by lysis of parasite. Beside the antibodies also inhibit 
released parasite for attacking fresh erythrocytes. 
The data of the present study support our hypothesis and demonstrate that 
combination of CHQ with picroliv is successful in treating Plasmodium infection in 
mice. In general, blood- induced P. yoelii infection in Balb/c mice led to fulminant 
infection that peaks up to 60 % parasitemia in 6 days. If not treated with drug the 
infected animals die within 5 to 8 days of the infection. This offers very convenient 
and effective mean for determining antimalarial efficacy of drug candidates as well as 
novel formulations of existing drugs. 
Evidences suggest that acute malaria infection supresses immune response via 
autocoids (Agarwal et al 2002, Kubata et al 1998). For eaxmple, during infection with 
Plasmodium sps parasite, there is down regulation in circulating T- cells, as revealed 
by lymphoproliferative response and cytokine release by peripheral mononuclear cells 
when stimulated by malaria antigens (Riley 1988). The data of the present study 
advocates above fact, as picroliv mediated replenishment of type I cytokines helps in 
elimination of parasite. Further, picroliv seems to help in development of specific 
antibodies against parasite antigens. The developed antibodies play crucial role in 
containing the infection. 
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Incidentally, immunity to erythrocyte stages of the P. yoelii relies on activation of 
CD4^ T cells, B- cells as well as type I cytokine and IFN- gamma as well(Bums et al 
1997, Pamela et al 1999, Zhong et al 2003). The immune cells are claimed to be 
involved in both humoral as well as cell mediated protective immunity (Langhome et 
al 1990, Hunter et al 1995, Melancon-Kaplan et al 1992). Earlier investigations have 
suggested that protection against blood stage malaria is complex and requires both 
Th2 and Thl cellular responses (Langhome et al 2002, Blomberg et al 1999, Mohan 
and Stevenson 1998, Suss and Pink 1992). Further, the protection studies suggest that 
by begiiming of the second week after infection the surviving animals develop a very 
effective cellular immune response that contributes significantly to control the 
infection (Salmon et al 1990). 
Chloroquine in general causes nausea, stomach upset, cramps, loss of apetite etc, 
while its high doses or long term usage causes irreversible retinal damage and blood 
dyscrasias including agranulocytosis, aplastic neutropenia or thrombocytopenia. 
Moreover the drug accumulates in liver and leads to many malfunctions in the body 
(Yam and Kwok 2006, Savarino et al 2003, Savarino et al 2006, Sotelo et al 2006). 
The effectiveness of the dosage regimen used in the present study suggests that 
antiparasitic drugs could be made effective at low concentration when used in 
combination of immunomodulator picroliv. This opens new vistas in malaria 
chemoprophylactic strategies and result of present study also indicate that picroliv per 
se has more or less no antimalarial activity; however it indirectly causes suppression 
of infection when used in combination with CHQ. Infact it synergistically potentiates 
antimalarial activity of CHQ. A suboptimal dose of chloroquine (8 mg/kg) was 
sufficient to inhibit oi Plasmodium yoelii MDR strain. We have recently reported that 
in case of visceral leismaniasis picroliv successfully suppresses infection when used 
in combination with miltefosine an antileishmanial drug, in Hamesters (Mittal et al 
1998, Gupta e/a 2005). 
The concept of using combination therapy involving potential immunomodulator and 
an effective antimicrobial agent is not new. The muramyl dipeptide as well as PGG 
glucan have been shown to help in activation of host immune sysXtm (Reeta et al 
1985, Tziananabos and Cisnevos 1996). The former has been successfully exploited 
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against fungal infection while PGG glucan was found to enhance efficacy of 
antibiotics against drug resistant bacteria (Reeta et at 1985, Tziananabos and 
Cisnevos 1996). We also demonstrated that co administration of immunomodulator 
tuftsin in combination with chemotherapy could be an effective strategy in supression 
of fungal, bacterial and protozaoa pathogens (Arif et al 2007, Khan et al 2006, Khan 
and Owais 2005). 
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